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Abstract 
 
Background: Since the 1960’s, a world-wide system of spontaneous adverse drug 
reaction (ADR) reporting has provided a centralised means for monitoring post-
marketing drug safety. However, under-reporting to this system remains a major 
problem. In addition, whether consumers should participate is controversial and 
largely unexplored.  
 
Aim: This study investigated whether the intervention of a pharmacist-operated 
telephone helpline and/or an educational workshop could increase the number, quality 
and breadth of ADRs reported to the Australian Adverse Drug Reaction Advisory 
Committee (ADRAC) by consumers and health professionals (HPs) and how the 
results of each group would compare.  
 
Method: Two independent studies were conducted. In the HP study, 381 doctors, 
nurses, pharmacists, dentists and complementary medicine (CM) practitioners were 
recruited and randomly assigned to one of four intervention groups: 1) access to the 
ADR Reporting Hotline; 2) small-group workshop on ADR reporting; 3) access to the 
Hotline AND the workshop or 4) no intervention (controls). The number of ADRAC 
reports submitted by participants in the two years prior to the study (1999-2000) and 
during the study (2001-2002) was compared. 
 
In the consumer study, a pharmacist-operated 1300 telephone helpline was established 
through which ADRs could be reported or enquired about. Marketing of the service 
was limited to the state of Queensland, and after 22 months, call data were audited.  
  
ix 
Results: The HP hotline received 108 calls over the study period, mostly from 
pharmacists (61%) and doctors (29.6%). Average call duration was 21.3 minutes. 
Fifty-two ADRAC reports were generated, resulting in a signal to noise ratio (SNR) 
for the hotline of 48.1% or 1:1. A further 52 reports were independently submitted by 
participants to ADRAC, giving a total of 104 reports for the study, 19% of which 
were serious. Data analysis confirmed that ADR reporting increased significantly 
(p<0.05) in all intervention groups, to three to four times pre-study rates whereas 
reporting in the control group fell slightly. 
 
In contrast, the consumer helpline received 972 calls throughout the study period, 
with television and radio being the most effective forms of marketing. At 24.3 
minutes, average call duration was not dissimilar from HP calls. Callers were 
predominantly female (79.5%) and middle aged (49.4% aged 51-70 years); 84.6% 
called regarding themselves and the remaining 15.4% calling on behalf of a 
significant, most frequently a spouse, parent or child. Of the 750 potential adverse 
drug events, only 13% were assessed by the helpline as being not medication-related. 
A total of 336 ADRAC reports were submitted, giving a SNR of 34.5% or 1:2.  
 
Consumers reported a broad range of symptoms associated with a wide range of 
therapeutic drug classes. The novelty of consumer ADRAC reports was demonstrated 
by 13.4% being associated with CMs, 2% concerning recently marketed drugs and 
15.6% of reactions not listed in the medicine’s product information. Training and 
protocols ensured that ADRAC reports submitted by helpline pharmacists were of 
consistently high quality, 62% of which were probable or certain, and 13.1% serious 
(involving hospitalisation). 
x 
 
Conclusions: ADR reporting by HPs improved marginally with education and 
assistance to reduce the burden of reporting. The number, breadth and quality of 
ADRs reported by consumers via a pharmacist-operated helpline demonstrated that 
consumers can make a positive contribution to pharmacovigilance, which 
complements existing HP ADR reporting systems.  
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2 
1. Introduction 
Medicines are the most frequently used health care intervention. Australia is fortunate 
to have a comprehensive National Medicines Policy to ensure that consumers have 
ready access to affordable medicines of acceptable quality, safety and efficacy. One of 
the central objectives of Australia’s National Medicine Policy is Quality Use of 
Medicines (QUM). (1) 
 
Safety is one of the four pillars of QUM. Many health professionals have faith that 
appropriate dosing of medicines for their registered indications will result in safe use. 
Unfortunately, due to the limitations of pre-marketing clinical trials, there are many 
aspects of drug safety that cannot be known until a drug is widely used in a broad 
range of medically complex patients. Rare adverse drug reactions (ADRs) such as 
aplastic anaemia or hepatitis may not emerge until the drug has been taken by tens of 
thousands of patients. In addition, previously unknown adverse events may not occur 
until very young, elderly, or very ill patients with concomitant diseases and medicines 
use the drug, as these patients are often excluded from clinical trials. 
 
For these reasons, clinicians must be alert to the chance of new adverse drug events. A 
system for reporting spontaneous adverse drug reaction (ADRs) has operated 
worldwide since the 1960’s to provide a centralized means for monitoring drug safety 
post-marketing. However under-reporting to this system by health professionals and 
drug manufacturers is a major problem, severely limits its efficacy. Methods that may 
improve HP ADR reporting have been keenly sought for many years. However, 
strategies for improving post-marketing pharmacovigilance have also included 
training non-medical reporters such as pharmacists, nurse and consumers for the task. 
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Whilst studies have previously explored the contribution non-medical professionals 
can make to ADR reporting, whether consumers should be invited to participate in 
spontaneous ADR reporting schemes is controversial and largely unexplored.  
 
The ADR study is essentially a tale of two studies aimed at increasing the frequency, 
quality and breadth of ADR reporting by a range of HPs and consumers, and 
ultimately to comparing the results. Both studies relied on the intervention of a 
pharmacist-operated telephone helpline to report ADRs, but the HP study also 
involved an educational intervention. This thesis describes our findings. 
 
 
 
 
 
4 
 
 
 
CHAPTER TWO 
 
 
Pharmacovigilance 
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2. Introduction 
Pharmacovigilance is the science of collecting, monitoring, researching, assessing and 
evaluating information from healthcare providers and patients on the adverse effects 
of medicines, biological products, herbals and traditional medicines, with a view to 
identifying new information about drug-related hazards, and ultimately preventing 
harm to patients. (2)  
 
2.1 Terminology: ‘Drug’ versus ‘Medicine’ 
Pharmacists tend to prefer the word ‘medicine’ to the word ‘drug’ when describing 
chemical substances used with therapeutic intent.  To some extent this term is also 
preferred as it avoids the negative connotation of the word ‘drug’, which encompasses 
chemical substances used for recreational purposes and deliberate abuse.  
 
In the pharmacovigilance literature, however, the terms ‘drug’ and ‘medicine’ tend to 
be used interchangeably, despite not being synonymous. Moreover, in the Adverse 
Drug Reaction (ADR) and Adverse Drug Event (ADE) literature the term ‘drug’ tends 
to be used by convention instead of the word medicine. Therefore, throughout this 
thesis ‘drug’ will be the preferred term.  
 
2.2 What is an Adverse Drug Reaction? 
In 1970, the World Health Organisation established a definition for an ADR as:  
“……any response to a drug which is noxious, unintended and occurs at doses 
used in man for prophylaxis, diagnosis or therapy of disease or modification 
of physiological function.” (3) 
 
This definition has served the pharmacovigilance community well for over 30 years to 
indicate that an ADR is generally an unwanted effect that occurs during appropriate 
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and proper use of medicines. (4) However, that definition has also been found by 
some authors to be lacking the patient’s perspective and the importance of the ADRs 
is the impact on future drug therapy. Therefore, to address this perceived deficiency, 
Edwards and Aronson proposed an alternative definition of an ADR, as follows:  
“……an appreciably harmful or unpleasant reaction resulting from the use of 
a medicinal product, which predicts hazard for future administration and 
warrants prevention or specific treatment, alteration of the dosage regimen or 
withdrawal of the product”. (5) 
 
ADRs are often subdivided into six categories (5, 6), with accompanying mnemonics. 
• Type A (augmented): Predictable, dose dependent. Caused by augmentation 
or exaggeration of the known pharmacology of the drug 
• Type B (bizarre): Unpredictable, not dose dependent. Unrelated to the known 
pharmacology of the drug. Often immunologically mediated. 
• Type C (chronic): Dose and time dependent.  
• Type D (delayed): Time dependent only.  
• Type E (exit): Withdrawal reactions. 
• Type F (failure): Unexpected failure of therapy. Often from drug interactions. 
 
2.3 What is the difference between an Adverse Drug Event and an Adverse Drug 
Reaction? 
ADE is an umbrella term to describe any adverse experience that occurs during the 
use of a pharmaceutical product that may or may not have a causal relationship with 
the drug. (5) ADEs may be divided into two broad types: ADRs and Medication 
Errors (MEs). Technically speaking, ADRs occur “spontaneously” during safe and 
appropriate use of a medicine, whereas MEs arise out of flawed human intervention, 
including poisoning and therapeutic failure and other problems due to human error 
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along the medication continuum, from manufacture, distribution, prescribing, 
dispensing, to storage and administration. MEs can also be subdivided into two types 
i.e. those that lead to injury and those called “near misses” where the error occurs but 
injury does not ensue. (7). Of course, ADRs and MEs can occur simultaneously, 
particularly when one leads to the other. For example, a prescribing error can lead to a 
patient taking the wrong drug, which subsequently causes an adverse reaction.  
  
 
 
 
 
Figure 1: ADEs encompass both ADRs and Medication Errors 
 
2.4 ADRs: a major public health problem 
Estimates for the incidence of ADRs vary depending on the setting, the definition 
used for an ADR (whether medication error is included or not) and method of 
detection used. Despite these issues, it is clear that ADRs are a major public health 
problem worldwide in terms of morbidity, mortality and cost. In the United States, for 
example, ADRs have been estimated to be the fourth to sixth leading cause of 
mortality, ranking higher than pneumonia or diabetes. (8, 9) In 1999, Roughead (10) 
estimated that in Australia 80,000 medication-related hospitalisations occur each year, 
costing the nation at least $350 million annually.  
Adverse 
Drug 
Reaction 
Medication 
Errors 
8 
 
ADRs have been well studied in the hospital environment, with reported rates ranging 
from 0.3% to as high as 11%. (11),(9), (12) For geriatric patients (older than 75 years) 
studies have found that up to 30% hospital admissions are medication-related.(13)  
 
The cost of these admissions is not insignificant. Dartnell’s survey of admissions to 
the Royal Melbourne Hospital in November 1994, estimated that 5.7% were drug-
related, costing the hospital an estimated $3.5million annually. (14) Recent studies 
suggest that in Australia between 2-4% of hospital admissions per year 
(approximately 140,000) are medication-related, accounting for more admissions than 
for asthma and heart failure combined. (13), (15) 
 
Similar results are found overseas. In the Netherlands, a meta-analysis of 68 
observational studies calculated that 4.9% of all hospital admissions were ADR-
related. (16) In the United Kingdom (UK), a prospective analysis of 18,820 patients 
found that 6.5% of admissions were medication-related, 80% of which were directly 
due to an ADR. The projected annual cost of these admissions to the NHS was £466 
million. (17). Other studies have raised the issue that ADRs impose further burdens on 
health care by occurring during hospitalisation, prolonging length of stay and 
increasing hospitalisation costs. (17-20) 
 
ADRs also pose a considerable public health burden in the community setting. White 
(8), has claimed that significant ADRs occur in 2.6% to 41% of ambulatory care 
patients. However, this is a much more difficult area to evaluate due to a lack of well-
designed studies. (4) One Australian study has found that up to 400,000 GP 
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encounters per year (out of 100 million in total) related to adverse drug events. (15) In 
the US, a nationwide survey of office-based physician visits by ambulatory patients, 
found that over 2.01 million visits were solely attributed to medication-related 
morbidity. (21) It has been suggested that the public health impact of ADRs in the 
community has been under-estimated simply because they do not result in hospital 
admission. (22) 
 
2.5 ADRs are preventable 
The key issue is that ADR-induced morbidity and mortality is not inevitable. As a 
great number of ADRs are predictable and therefore preventable. Methods for 
assessing ADR preventability vary, with some studies using implicit criteria while 
others use independent assessment by an expert review panel. Definitely or possibly 
preventable hospital admissions caused by ADRS usually include those caused by 
non-compliance, predictable ADRs (Type A), prescribing errors, contraindicated 
medication and known drug allergies. (12, 14, 23) 
 
The Quality in Australian Health Care Study (24) estimated that 43% of adverse drug 
events were predictable and potentially preventable. Similarly, an Australian study of 
ADRs in oncology patients demonstrated that 48% of ADRs were preventable. In 
their meta-analysis of drug-related hospital admissions in the US, Winterstein et al 
reported a median preventability rate of 59%. (25) The high level of reported 
avoidability suggests that much can and should be done to reduce the burden of ADRs 
on public health. 
 
ADRs are preventable if their eventuality can be foreseen. However, there are many 
situations in which drug safety issues cannot be foreseen. This is particularly so for 
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new medicines in the immediate post-marketing period, where experience of safety 
and efficacy is limited to use in clinical trials.  
 
2.6 New drugs are a special problem 
During pre-marketing clinical trials it is customary for only 1500-2000 subjects to 
have been exposed to the test medicine. (4), (26, 27) With this level of patient 
exposure, only the most common ADRs will have been detected. Rare and type B 
ADRs, especially those with an incidence of less than 1 in 500, are unlikely to have 
been identified. In addition, patients participating in clinical trials are often highly 
selected and therefore not necessarily representative of the wider population that 
ultimately require the drug. (27) 
 
Therefore, the side effect profile of newly marketed medicines is not entirely 
understood when it is first made available. The true safety profile only emerges over 
time and as the drug is used within a broad range of patients in medically complex 
situations.  The term pharmacovigilance describes the process by which such 
information about drug safety and tolerability is discovered, communicated and 
assimilated into Quality Use of Medicines. 
 
2.7 Pharmacovigilance and preventing ADRs  
Pharmacovigilance is the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects and other drug-related problems. 
Pharmacovigilance data is derived from many sources, most conspicuously via 
published case reports in the medical literature and spontaneous ADR reporting to 
national pharmacovigilance centres. Other sources of drug safety data include post-
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marketing clinical and epidemiological studies, morbidity and mortality databases and 
prescription event monitoring schemes.(28) While the primary concern of 
pharmacovigilance is to alert the world to possible new safety hazards, it is also 
concerned with enhancing the quality of medical therapy and preventing ADRs with 
new information about benefit, harm, effectiveness and risk of medicines and rational 
use of medicines for patients. (2) 
 
2.8 Spontaneous ADR reporting 
One of the most widely used forms of pharmacovigilance is spontaneous ADR 
reporting (SAR). The concept of SAR was initially developed in the 1960’s 
subsequent to the thalidomide tragedy. In 1968, ten countries operating national 
pharmacovigilance services, including Australia, decided to collaborate under the 
auspices of the World Health Organisation (WHO) and launched the WHO Pilot 
Research Project for International Drug Monitoring. (29) In 1971, a resolution of the 
twentieth World Health Assembly laid the foundation for the WHO International 
Drug Monitoring Programme (IDMP). (30) 
 
Today, pharmacovigilance agencies in 72 countries collect, process and evaluate case 
reports of suspected ADRs submitted by health professionals (HPs). Information from 
these reports is passed back to HPs but is also submitted to the WHO’s central data 
processing agency, the Uppsala Monitoring Centre (UMC) in Sweden, for inclusion in 
their international database. Each year, the UMC receives 150,000 - 200,000 
individual case reports of reactions suspected to be drug-induced. (29) The aim of 
pooling this data via the WHO is to collectively detect drug-induced injury as early as 
possible and ultimately prevent serious and extensive injury to consumers. (31) 
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In some countries, such as Sweden, France, Canada and the UK, ADR reporting 
services are decentralised to a network of regional monitoring centres (RMCs) 
situated strategically in specific localities to promote ADR reporting, as well as 
collect and triage ADRs before they are sent to the central agency. Some RMCs are 
based within hospitals or universities, whilst others also act as Poisons or Drug 
Information Centres. An important advantage of RMCs is that good communication 
and personal relationships may be established between the centre and the local 
reporting professionals. However, it has been said that RMCs are costly due to the 
number of staff needed, and unless reports are fed directly into the central database, 
can result in delays in the flow of information to the central monitoring agency. (32) 
 
In Australia, the Adverse Drug Reaction Advisory Committee (ADRAC), an expert 
subcommittee within the Therapeutic Goods Administration, oversees SAR. Despite 
Australia being one of the smaller member countries of the IDMP, it is ranked fourth 
highest in terms of the number of ADR reports submitted each year to the UMC, with 
the second highest reporting rate per capita, second only to New Zealand.  
 
Tables 1 shows the top ten contributors to the WHO database, measured as the total 
number of reports received since each country joined the collaboration, to March 
2002. Table 2 shows the top countries in terms of the number of reports submitted per 
million inhabitants per year (average 1996-2000). (33) 
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Table 1: No. of reports received by the WHO-UMC from countries since joining 
Country No. reports Start year 
United States  1,314 525 1968 
United Kingdom    391,868 1968 
Germany   160,648 1968 
Australia   146,116 1968 
Canada   136,192 1986 
Sweden     77,058 1968 
Spain    71,993 1984 
Netherlands   48, 472 1968 
Denmark   44,196 1968 
 
Table 2: Number of reports to the WHO-UMC per year, per million inhabitants 
Country No. reports /million inhabitants 
New Zealand 740.7 
Australia 479.7 
United States 416.1 
Sweden 312.0 
United Kingdom 310.8 
Netherlands 305.7 
Ireland 274.1 
Denmark 220.8 
Switzerland 170.4 
France 163.8 
 
Through the expert guidance of ADRAC, Australian pharmacovigilance has been the 
first to detect several important ADR signals (32, 34) including:  
 
• Glucomannan-induced oesophageal obstruction 
• Urinary incontinence associated with prazosin 
• Cystitis associated with Tiapofenic acid 
• Amoxycillin-clavulanic acid-induced hepatitis 
• Flucloxacillin-induced hepatitis 
• Liver dysfunction with Kombucha tea 
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2.9 Strengths of the SAR system 
While the past achievements of SAR are important, it is critical to acknowledge the 
various strengths and weaknesses of this system as summarised in Table 3, as SAR is 
only one of many pharmacovigilance activities used by drug regulatory authorities 
throughout the world. 
Table 3: Strengths and weaknesses of SAR 
Strengths 
 
Weaknesses 
Simple 
 
Variable quality of reports 
Comprehensive 
 
Unable to provide incidence rates 
Detects rare events 
 
Reports open to misinterpretation 
Relatively inexpensive 
 
Under-reporting 
 
The simplicity of the SAR process is probably its greatest strength, as it places 
minimal demands on busy HPs and diminishes the delay between an ADR’s 
occurrence and being reported. Indeed, Wiholm has shown that a range of rare 
adverse events on the UMC database was reported via SAR up to six months before 
they were published in the medical literature. (32) 
 
The comprehensive coverage of medicines and patients is strength of SAR. Unlike 
clinical trials, where paediatric and elderly patients are usually excluded, an SAR 
system accepts reports relating to all patients regardless of age or disease state. 
Similarly, SAR places no limits on the medicines involved, and all drugs can be 
reported on at all stages of their life cycle, as soon as they are in use. For this reason, 
SAR is probably a most effective pharmacovigilance tool for highlighting problems 
with new drugs.  
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Campbell (35) has shown that via SAR, ADRs have been reported for two-thirds of all 
new drugs. In contrast, structured post-marketing studies for new drugs usually fail to 
find ADRS clearly attributable to the drug being studied, as the sample required to 
detect unusual reactions is so large.  
 
SAR is well configured to detect rare events, such as liver failure or aplastic anaemia, 
where the expected background incidence is in the range of a few cases per million 
people annually. (36) For example, in order to detect an ADR with an incidence of 1 
in 2000, it would be necessary to collect data from 6,000 patients. (37) For an ADR 
with an incidence of one to two in 10 000, two groups of 306,000 patients would be 
required. (38) 
 
Finally, compared with other pharmacovigilance activities, an SAR system is 
relatively inexpensive to operate compared with active post-marketing surveillance 
systems, as it only requires an investment in staff, training, office space and basic 
technical equipment such computers and telephony. (32)  
 
2.10 Weaknesses of SAR 
Limitations of SAR are typical of those seen with passive or voluntary reporting 
systems of any kind. (36) Information submitted in ADR case reports are frequently 
incomplete, of poor quality and have the potential to be false, unfounded and biased. 
For these reasons, SAR has often been criticised for its potential to generate 
unwarranted or inappropriate concerns about drugs. (31) (32) 
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Due to the subjective nature of the information carried in an ADR report, processing 
and analysis thereof can be subject to bias and misinterpretation. When well-known 
drug safety commentator Charles Medawar (39) published his examination of ADR 
reports provided by users of paroxetine compared with ADR reports submitted by 
HPs, he claimed that the Yellow Card SAR system in the UK is chaotic and 
misconceived. He based this statement on his conclusion that  
 “…miscoding and flawed analysis of yellow cards has led to under-estimation 
of the risk of suicidal behaviour and impeded the recognition of what appears 
to be a close relationship between suicidal behaviour and changes in drug 
concentration.”  
 
Another disadvantage of the SAR system is that it can generate signals of suspected 
ADRs, but cannot provide an indication of the frequency of the reaction and thus the 
true level of risk. This is because the true number of cases is invariably under-reported 
and the denominator (i.e. the total number of patients exposed to the drug) is always 
unknown. (4, 36) Because of this limitation, it has been said that ADR reports are 
primarily useful for hypothesis generating rather than hypothesis testing. (40, 41) 
 
Unfortunately, it is rarely possible to use spontaneous reports to establish a causal 
connection between an adverse event and a drug, unless there is at least one case 
report with a positive rechallenge and other cases that do not have confounding drugs 
or diseases. A reasonable argument could also be made if there is a cluster of exposed 
cases, where the background incidence of the adverse event is close to zero and there 
are no confounding factors. (32) 
 
For all the above reasons, critics have said that at best an SAR scheme provides an 
incomplete case series of ADEs and at worst, a biased case series, without any 
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information on the size or characteristics of the population exposed to the drug. (39) 
This issue is worsened by the persistent problem of ADR under-reporting by HPs, 
which is a major limitation of the utility of an SAR system.  
 
2.11 The problem of ADR under-reporting 
Currently, ADR under-reporting rates by HPs are estimated to range from 62-99%. 
(36, 42, 43) Similarly, it has been estimated that no more than 10% of serious ADRs 
and 2-4% of non-serious ADRs are reported by HPs to SAR systems. (44-47) 
Comparing the number of ADR-related hospital admissions and general practitioner 
(GP) consultations with the number of ADR reports received by national 
pharmacovigilance centres, suggests that overall ADR reporting rates are likely to be 
close to 1%.(39) A recent survey in Sweden of specific ADR-induced hospital 
admissions found that only 14% of the specific and serious ADRs investigated had 
been reported to the Swedish ADR registry. (48) 
 
The problem of under-reporting may in part be attributed to the fact that only a small 
proportion of HPs ever become involved in pharmacovigilance. In a 1986 review of 
Canadian ADR reporting, Lortie (49) stated that  80% of ADR reports were sent in to 
the Canadian pharmacovigilance centre by only 7% of doctors. In the UK, a 
comprehensive survey of the first 20 years of the Yellow Card scheme found that 16% 
of doctors had ever sent in a Yellow card, and that 7.4% of all doctors sent in 80% of 
all reports.(50)  
 
In the same year, Inman (44) reported that, on average, one yellow card was submitted 
per doctor every four years. A recent survey of ADR reporting over a 21 month period 
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in the Merseyside region of the UK found that one in eight doctors eligible to report 
ADRs had actually sent in Yellow cards.(51) When pharmacists first started 
contributing to ADR reporting in the UK in 1997, it was found that 2.5% of all reports 
had been submitted by five individual hospital pharmacists based in the West 
Midlands.(52) 
 
Health professionals have given many reasons for hesitating to report suspected 
ADRs. In the mid-1970s, Inman identified seven major reasons for under-reporting, 
subsequently dubbed “Inman’s Seven Deadly Sins” (44) as follows: 
 
1. Complacency, encouraged by one-sided drug promotions and the belief that 
only safe drugs are allowed on the market; 
2. Fear of possible litigation or attracting attention to their prescribing practises 
by health departments; 
3. Guilt for having administered the treatment which may have harmed the 
patient; 
4. Ambition to personally collect and publish a series of cases; 
5. Ignorance of the reporting system i.e. what reactions to report and how to 
report; 
6. Hesitancy to report mere suspicions, trivial or well-known ADRs; 
7. Indifference on the part of an individual doctor to his/her role as a clinical 
investigator who should contribute to the general advancement of medical 
knowledge.  
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Recent surveys of HP attitudes towards ADR reporting have shown that lack of time, 
being unsure of how to report, and unavailability of reporting cards have become 
the most frequently cited deterrents of ADR reporting. (53-55) (56-58) Clearly, there 
are many reasonable and practical obstacles to ADR reporting by HPs. 
 
2.12 Conclusion 
ADRs are a common and serious cause of morbidity and mortality, and preventable in 
approximately 50% of cases. In addition to human costs, ADRs place a major 
economic burden on society in terms of hospitalisations and other forms of healthcare. 
As the great majority of ADRS are predictable, the sooner drug-related problems are 
identified the sooner they can be prevented. Pre-marketing trials generally do not have 
sufficient power to detect important ADRs, so post-marketing surveillance of new 
drugs is required to detect new and unpredictable reactions. Despite its limitations, 
SAR is a simple, comprehensive and cost-effective method of pharmacovigilance 
especially for new drugs, but its success is limited by under-reporting. The following 
chapter will discuss ADR reporting by HPs, and methods by which researchers have 
sought to improve reporting. 
20 
 
 
 
CHAPTER THREE 
 
 
ADR Reporting by 
Health Professionals 
 
21 
3. ADR reporting by Health Professionals. 
3.1 Introduction 
SAR plays a vital role in identifying new, rare and serious adverse drug events that 
arise in the post-marketing period. However, as ADRs continue to be a leading cause 
of morbidity and mortality especially with recently marketed drugs, (59) the 
weaknesses and limitations of the SAR system are often highlighted and demands to 
improve ADR reporting are increasingly being expressed. (29, 60)  
 
3.2 Recalls of new drugs  
In recent years, serious ADRS in the post-marketing period have been linked with 
prompting worldwide recalls of new drugs. Mibefradil, troglitazone, cerivastatin and 
rofecoxib are but a few examples of medicines that have been withdrawn from the 
worldwide market just a few years after they were approved, prompting concerns that 
pre-marketing safety testing has become too lenient and post-marketing surveillance 
ineffective. (59, 61) It has been claimed that inadequate ADR reporting by HPs has 
contributed to delayed detection of new drug toxicity, prolonging patient exposure at a 
time when the drug’s true safety profile is not fully understood (59, 62)  
 
The problem is that patient exposure to new drugs can be extensive. Recent 
developments in the commercialisation and marketing of pharmaceutical products via 
the Internet, electronic media, so-called “bone fide current affairs” and direct-to-
consumer advertising, create strong demand for new drugs, both by physicians and 
consumers who have faith that medication, prescribed correctly for labelled 
indications, will be safe. (63)  
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By the time it was withdrawn on October 1 2004, an estimated 80 million people 
worldwide had taken rofecoxib (64) during which time between 88,000 and 140,000 
excess cases of serious coronary heart disease probably occurred in the USA 
alone.(65) The US national estimate of the case-fatality rate was 44%, which suggests 
that many of the excess cases attributable to rofecoxib use were fatal. (64) It is 
estimated that nearly 20 million patients in the US took at least one of the five drugs 
withdrawn from the market between September 1997 and September 1998. Seven 
drugs marketed since 1993 and subsequently withdrawn have been causally linked 
with at least 1002 deaths in the US alone. (59)  
 
Obviously the morbidity and mortality associated with new drugs also needs to be 
addressed from the drug approval perspective and the quality of data provided or 
withheld by pharmaceutical companies. (63, 66) (41). Nevertheless improved post-
marketing surveillance may prevent some of the human injury caused by the new 
drugs, by generating signals more quickly and alerting HPs to the risks. Given that 
this was the original goal for the WHO Programme for International Drug Monitoring 
when it was established 30 years ago, it behoves HPs to explore means by which 
ADR reporting could be enhanced.  
 
3.3 Current ADR reporting practises 
When the IDMP was first established it was generally accepted that only physicians 
and coroners would report ADRs, as they alone would have access to the necessary 
details of medical therapy, laboratory testing and the impact of an ADR on patient 
status. However, from the beginning of the programme several countries have invited 
reports from non-medical professionals, including pharmacists, dentists and nurses, 
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Australia being one. (67) Today, the trend in most IDMP countries is to place no 
limits of who can report, in order to cast as wide a net as possible for receiving ADR 
reports. (68) In general, nurses, dentists and complementary health care practitioners 
submit very few reports. (32) 
 
In Australia, Canada, France and the UK physicians and pharmacists are by far the 
most frequent contributors to SAR, the vast majority of reports being submitted by 
hospital-based professionals. In Germany, Italy and the US the vast majority of ADR 
reporting is contributed by the pharmaceutical industry. Indeed, in the US, physicians, 
pharmacists and consumers only submit approximately 9% of all reports to the FDA, 
as the majority of reports are submitted by pharmaceutical industry, which has a legal 
obligation to reports ADRs. (69) In at least 25 countries, including the EU and Japan 
it is obligatory for pharmaceutical companies to submit all ADR reports that come to 
their attention. In at least 10 countries, including France, Sweden and Norway, 
doctors and dentists are required by law to report ADRs. (32) 
 
Regarding pharmacists’ contribution specifically, in Sweden pharmacists are not 
permitted to contribute to the ADR reporting scheme. In a 1999 survey, many 
countries such as Denmark, Iceland, Indonesia and Vietnam stated they would 
welcome reports from pharmacists but simply do not receive them. (70) In contrast, 
pharmacists in the Netherlands submit 40% of all ADR reports and their overall role 
in pharmacovigilance is substantial. (30) Even though pharmacists have only been 
invited to join the ADR reporting scheme in the UK since 1997, their contribution 
already exceeds 10% of all reports. (71) In Canada and the US many reports from 
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pharmacists come via hospital pharmacies that operate ADR surveillance systems that 
report ADRs on behalf of all hospital staff. (30)   
 
3.4 What motivates HPs to report ADRs? 
Reporting of ADRs by HPs should be seen as an essential task. When Biriell (72) put 
to doctors an open-ended question asking why they report ADRs, the following were 
given as their main reasons, in order of frequency: 
• Motivation to contribute to medical knowledge; 
• Reaction previously unknown to the reporter; 
• Reaction to new drug; 
• All significant reactions should be reported; 
• Known association between drug and reaction; 
• Severity of the reaction. 
 
Hospital pharmacists were asked what motivated them to report ADRs in two British 
surveys. Sweis and Wong (73) found that 88% of pharmacists  were likely to report 
serious, rare or ‘Black Triangle’ drug-associated ADRs, and if they were confident of 
recognising the ADR. They therefore suggested that hospitals should have written 
policies on SAR, and that ADR reporting training should be offered regularly offered. 
In the same study, 51% of pharmacists said they were less likely to report if they were 
too busy, but that active support from medical staff would encourage them to report.  
 
Green et al (74) found that 50% of British hospital pharmacists surveyed felt ADR 
reporting should be mandatory as it was a professional obligation. They also 
expressed that absence of a fee was not a deterrent to reporting ADRs, however, the 
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time taken to complete forms and lack of specific training were stated to be major 
deterrents. 
 
In Backstrom’s Swedish study (75) piloting the value of SAR by nurses, their prime 
motivators for reporting were the unexpectedness of the reaction (78%), the severity 
of the reaction (62%) and certainty that the observed symptoms were due to an ADR 
(56%). Half of the nurse reporters stated that they had difficulty reporting on 
suspicion alone, and that training had been essential in their reporting at all. However 
93% of the nurses surveyed afterwards declared they were prepared to continue 
reporting ADRs after completion of the study. 
 
3.5 Strategies to improve ADR reporting 
 Much has been done over the last thirty years to identify and develop a range of 
strategies to overcome barriers perceived by HPs that prevent ADR reporting. No 
single activity has been shown to achieve a sustained increase in the quantity or 
quality of ADR reports and it is generally agreed that repeated and regular 
interventions are required to maintain interest in the ADR reporting system. (76) 
Some of the more effective and relevant strategies will now be discussed. 
 
3.5.1 Improving access to ADR reporting forms 
In Australia, copies of ADR reporting forms are readily available on the Internet, 
inside the front cover of every PBS book and sent to every doctor and pharmacist with 
their quarterly copy of Australian Prescriber. However, health professionals 
perennially complain that unavailability of reporting forms is a significant obstacle to 
ADR reporting. (56) 
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It stands to reason that increasing reporting form availability should be a simple and 
effective strategy for increasing ADR reporting. However, it has been shown that 
without reminders and personal prompting, this strategy has a limited and temporary 
effect. (77) 
 
Original studies conducted in the UK in the 1970’s were encouraging when it seemed 
that insertion of yellow ADR reporting cards in every NHS prescription pad was 
followed by a significant increase in ADR reporting by doctors. (78) However, it was 
later found that reporting rates gradually declined despite continuing availability of 
reporting forms. Insertion of the yellow card in the British National Formulary (BNF) 
in the 1980’s resulted in little improvement in ADR reporting as the percentage of 
ADRs reported remained unchanged at 6.3%, of which only 6.5% involved newer 
drugs. (77) 
 
An Irish study examined the effect of increasing availability of ADR reporting forms 
on reporting rates by hospital doctors. (76) Postal and telephone surveys firstly 
established baseline levels of ADR reporting. Then the research team placed yellow 
cards inside patient’s medical charts, sent them by mail to prescribers’ offices and 
clinics, and placed them in all wards, outpatient clinics and treatment areas in the 
hospital.  Prescribers were also prompted about ADR reporting with reminder 
circulars and direct contact regarding the availability and use of the yellow cards. 
 
Initially a five-fold increase in ADR reporting was recorded. When the verbal 
reminding intervention was withdrawn after 3 months, ADR reporting fell by half, 
despite continuing availability of reporting cards. Six months after the discontinuation 
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of yellow card insertion into patients’ charts, the number of ADR reports from the 
hospital returned to baseline levels. The authors concluded that increasing yellow card 
availability alone does not significantly increase reporting, and that more fundamental 
constraints prevent an ADR “reporting culture” amongst doctors. 
 
A study based at the Catalan Centre for Pharmacovigilance in Barcelona, (79) looked 
at the effect of increasing the availability of ADR reporting forms and providing an 
adverse drug reaction bulletin (ADRB) on physicians’ ADR reporting rates over 13 
years. No intervention was recorded from 1982-1985. From January 1983-October 
1995, the ADRB was sent to physicians homes monthly or bi-monthly. From 1991-
1994, a yellow card was included in all prescription pads of the Catalan health 
Service.  
 
Prior to the study, the mean SAR rate was 34.4 received per month (SD 14.1, n =106 
months) but during the years the ADRB was mailed out, the mean monthly rate 
increased on average to 46.1 reports per month. In the period yellow cards were 
included in prescription pads, the mean monthly reporting rate increased to 53.9 (SD 
14.4, n=48 months).  The authors concluded that inserting a report form in 
prescription pads was a cost-effective means by which ADR reporting could be 
increased, and should be encouraged.  
 
Although the ADRB was also an effective intervention, it was a costly and labour-
intensive task to produce with ultimately less of an impact on ADR reporting.  A 
significant aspect of this study is the long-term persistence of the increase in reporting 
over 13 years. However, a limitation is that there was no control group with whom 
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comparisons could be made. The fact that ADRBs were sent to homes also may have 
limited the impact of the bulletin on workplace behaviour. These studies show that 
ready availability of reporting forms has a positive effect on ADR reporting rates, but 
the benefits may be short-lived without accompanying education campaigns. 
 
3.5.2 Facilitation of reporting processes (eg. computer links) 
The advent of the Internet and the World Wide Web has resolved many of the 
abovementioned problems with ADR form availability.  In many countries, ADR 
reporting forms are now readily available on the Internet in an electronic format, 
accompanied by instructions, educational packages and copies of regular information 
bulletins. Moreover, ADR reporting can be performed electronically via the Internet, 
thus making the whole process more convenient and user-friendly for time-poor HPs.  
 
Argentina was the first country to set up ADR reporting by email, which linked 
hospital-based regional monitoring centres to their national regulatory authority. (29) 
In the UK AEGIS [ADROIT (Adverse Drug Reaction Online Information Tracking) 
Electronically Generated Information Service] was introduced in 1993 to facilitate 
electronic exchange of information between the pharmaceutical industry and the 
MCA (now MHRA). Collaboration with the prescribing software suppliers has lead to 
the development of an electronic yellow card system for GPs in the UK. (80) 
 
Web-based ADR reporting was initiated by the TGA in Australia in January 2003, but 
the effectiveness and acceptability of this form of ADR reporting has yet to be 
established. (81)  
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Finally, it seems that every major pharmacovigilance agency offers a telephone 
helpline as a mode of contact. However, an extensive literature search of Medline, 
Embase, Medscape, IPA and bibliographies of key references, failed to retrieve 
studies systematically evaluating the impact of a telephone helpline on ADR reporting 
by HPs.  
 
3.5.3 Educating HPs about ADR reporting 
Ignorance was one of the “seven deadly sins” postulated by Inman as a reason for not 
reporting ADRs. Indeed, lack of knowledge continues to be cited by clinicians as a 
major reason for not contributing to the ADR reporting system. (57) ADR-based 
training and group meetings are among the most common suggestions made by HPs to 
improve ADR reporting (73) Belton has argued that if pharmacovigilance were more 
extensively incorporated into medical training at all levels, doctors could develop an 
ADR reporting ‘culture’. (54) 
 
In the UK a recent report from the National Audit Office (NAO) (82) has recognised 
that under-reporting of ADRs by doctors stems from a lack of training at an 
undergraduate level, by stating that: 
 “……whilst medical students receive technical tuition on potential for 
adverse reactions and interactions with medicines, their undergraduate 
education does not cover arrangements in place for licensing and monitoring 
medicines or a discussion of the role of the regulatory agency”.  
 
The NAO has therefore recommended increased links between medical students and 
the Medicines and Healthcare Products Regulatory Agency (MHRA). A report from 
the House of Commons has argued for greater involvement of the MHRA with 
specialist physician training as well. (83) 
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Literature is scant on the teaching of ADR reporting to undergraduate HPs. There is, 
however, one survey (84) of pharmacy and medical schools in the UK which showed 
that the Yellow Card scheme is included in the vast majority of undergraduate 
programmes. However, the knowledge gained by students was assessed in only 79% 
of pharmacy courses and 57% of medical courses. More importantly, only 43% of 
pharmacy and medical schools provided students with a guide to reporting ADRs, and 
50% did not provide written materials from the CSM at all. The authors suggested that 
mere inclusion in the course is insufficient and opportunities exist for the UK 
regulatory authorities to make a greater contribution to undergraduate programmes, by 
providing written material (e.g. ADR reporting information packs) and expert 
speakers to lend weight to the curriculum.  
 
The Rhode Island Adverse Drug Reaction Reporting Project conducted by Scott et al 
(85) showed that educational programs aimed at practising physicians improved the 
number and quality of ADR reports submitted. Rhode Island physicians were 
surveyed before and two years after interventions of direct mailing of ADRBs and 
educational presentations were provided. After 2 years, there was a more than 17-fold 
increase in reports submitted from Rhode Island HPs compared with the national 
yearly average before the project. The number of severe ADR reports also increased 
significantly during the study period, however similar increases did not occur 
nationally. Significant gains in knowledge and positive attitudes toward the ADR 
reporting system also occurred.  
 
Schlienger et al (86) demonstrated that ‘academic detailing’ by hospital pharmacists 
during ward rounds increased reporting of ADEs by doctors and nurses. This Swiss 
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study was conducted as a prospective, comparative, crossover study, where ADE 
reporting by two medical teams was compared for the 12 months when the ADE 
pharmacist joined their team for 12 months, and the 12 months he was absent and they 
served as the control team. Study results showed that, over the 24 months, teams with 
an ADE pharmacist reported 224 ADEs compared with 25 reports from control teams. 
Of the 224 ADEs, physicians reported 37%, nursing staff reported 14%, 39% were 
gathered during ward rounds and 10% were found during chart review post-discharge. 
In the control group 64% of ADEs were reported by physicians, and 34% by nurses.  
 
In the teams with a pharmacist, 6% of ADEs were type B but in control teams 40% 
were type B. The authors commented that without a pharmacist, clinicians were more 
likely to report “visible” type B reaction such as skin rashes, and less likely to report 
obscure type A ADEs that require knowledge of the drugs’ pharmacology. The 
researchers concluded that the ADE reporting increased 9-fold during the study as a 
result of the pharmacist providing ADE education and awareness to medical team that 
increased their confidence to report.(86) 
 
A study conducted in the UK (87) to analyse the effect of training on hospital 
pharmacist ADR reporting found that problem-based learning costing £57 per 
pharmacist (in 1999) lead to an increase in reporting. After four teaching sessions, the 
pharmacists themselves began to have their own meetings at no extra cost, and six 
months later ADR reporting was still higher than at baseline. The authors claimed that 
this type of teaching would be a cost-effective addition to post-registration pharmacy 
training.  
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3.5.4 Incentives for reporting 
It has been suggested that an incentive system might alter the priority balance of busy 
HPS in favour of ADR reporting. One option is to offer financial incentives to HPs or 
their employers. One Irish study has tested the influence of providing a small fee to 
doctors on ADR reporting. (88) 
 
Junior hospital doctors were offered three Irish punts (equivalent to about US$4.50 or 
AU$6.30 at 1990 conversion rates) if they completed yellow card reporting forms. Of 
the 40 doctors that reported, 32 said that the fee was an incentive to report. Collection 
of the reports for six weeks showed a dramatic (almost 50-fold) increase in reporting. 
In the survey, 48% of doctors reported ADRs, compared with 10% at baseline. A 
random audit confirmed the ADRS in over 90% of cases. Unfortunately after the 
study was completed and the payments stopped, the number of reports fell 
dramatically. 
 
The latter study showed that a financial incentive, albeit quite a small fee, could have 
a meaningful affect on ADR reporting, however it is possible that the fee served more 
as a reminder than an incentive. (89) It is unknown whether a fee would influence 
reporting positively long term. (88) In addition, providing payment to HPs is bound 
by several practical, legal and ethical limitations. For example, who would provide the 
fee? Government regulatory authorities are unlikely to do so as limited funding 
already restricts their current activities.  
 
Pharmaceutical companies may have some economic reasons to participate in an 
incentive scheme as they bear significant costs from adverse reactions, and increased 
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SAR may prevent them. However, it is unlikely that manufacturers would want to 
encourage ADR reporting on products they wish to portray as safe and in the current 
political and ethical climate, greater distance between drug regulatory authorities, 
prescribers and pharmaceutical companies is preferred. (63) 
 
To whom should the fee be paid? Even though doctors have stated that a financial 
incentive would motivate them to report ADRs, Green’s survey (74) showed that 
hospital pharmacists were not dissuaded from ADR reporting by the absence of a fee. 
Is there a risk that doctors would be paid but not other HPs, such as pharmacists? 
Such discrimination between professions could create unforeseen problems with the 
SAR system. Should the fee be paid to employees or employers? A fee paid directly 
to HPs may create a perverse incentive to report ADRs, and increase the chances of 
submitting ADRs supported by tenuous evidence. Conversely, a fee paid to employers 
may put pressure on employees to report more ADRs than they normally would, in the 
interests of continued employment. (89) 
 
Another incentive is to make ADR reporting mandatory. As mentioned earlier, in at 
least ten countries including Sweden, France, and Norway physicians and dentists are 
legally bound to report serious suspected ADRs to their regulatory authority. 
However, there is no evidence that enforcing ADR reporting by law increases either 
the quality or quantity of ADRs reported. (39) 
 
3.5.5 Encouragement of reporting by pharmacists 
Pharmacists’ involvement in ADR reporting varies from country to country.  As 
mentioned in section 2.2, the Netherlands, Canada and Australia have involved 
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pharmacists in ADR reporting since the IDMP began, the number of reports submitted 
by pharmacists is substantial and these reports are generally highly valued.(30) In 
France, Italy and Spain ADR reporting by pharmacists is mandatory. In contrast, 
Nordic countries (Sweden, Finland and Norway) do not permit pharmacists to report 
directly to national reporting system. (30, 81)  
 
Nevertheless, pharmacists are recognised as playing an important role in medication 
safety (90) and because of their proximity to medication-related issues, have unique 
opportunities for identifying and reporting ADRs. (71) In attitudinal surveys, 
pharmacists have expressed enthusiasm to report ADRs, and acceptance that it is their 
professional duty to do so. (73, 74, 91) Greater involvement of pharmacists in ADR 
reporting has therefore been cited as a method for improving ADR reporting around 
the world. (2, 29, 30, 71)  
 
Pilot studies, particularly in the hospital setting, have shown that pharmacist-
involvement significantly increases ADR reporting both in number and quality. (86, 
87, 92, 93) For example, US-based pharmacists who actively interviewed 
approximately 200 outpatients attending a Veterans hospital, discovered 46% more 
ADRs than had been identified previously by their health providers (doctors and 
nurses), and nearly half of the ADRs required a medication change.  (94)  
 
It wasn’t until 1997 that UK pharmacists were given authorisation to participate in 
ADR reporting. (52) Initially only hospital pharmacists were invited into the scheme, 
in a bid to address flagging reporting rates by physicians. The addition of hospital 
pharmacists to the reporter pool lead to an overall increase in the number of good 
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quality reports of serious ADRs, and prompted extension of the scheme to include 
community pharmacists as well, in 1999. (71)  
 
Pharmacists working in a community setting are in a unique position to be involved in 
monitoring and reporting ADRs associated with non-prescription and complementary 
medicines. (95) Indeed, this was one of the primary reasons the MHRA in the UK 
chose to eventually include community pharmacists in ADR reporting. 
 
The argument against ADR reporting by pharmacists is that their clinical knowledge 
is limited, and insufficient data would be provided for quality ADR reports. (30) 
Although this may be true for pharmacists who work as dispensing technicians, many 
pharmacists today are trained to work in non-dispensing roles such as drug 
information, medication management and pharmaceutical care. It has been shown that 
such pharmacists can contribute significantly to ADR reporting, and in some ways 
address the problem of under-reporting by other HPs. (30) 
 
3.5.6 Encouragement of reporting by nurses 
Data provided by ADRAC demonstrates that hospital staff (doctors and pharmacists), 
drug companies and general practitioners provide the lion’s share of ADR reports. 
However a wide range of health professionals, including dentists, nurses, and 
complementary health practitioners, are permitted to contribute to post-marketing 
pharmacovigilance as a multidisciplinary approach has been shown to increase ADR 
reporting. (96, 97) Currently, few reports from non-medical and non-pharmacy 
professionals are received by ADR reporting agencies. (81) However studies have 
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shown that, with education and support, nurses can make a significant contribution to 
ADR reporting.(98)   
 
Backstrom et al (75) conducted a study of 117 nurses working in a hospital geriatric 
department. Over a 12-month period, education was offered to the nurses consisting 
of 24 comprehensive lectures about drugs and ADRs, ADR reporting and special 
aspects of ADRs in the elderly. After the 18-month trial period a total of 22 ADR 
reports were submitted by these nurses, compared with 21 ADRs from the 50 other 
geriatric units in Sweden combined. Although all 117 nurses recruited into the study 
were allowed to report ADRs, only the 10 nurses who had attended education sessions 
did so.   
 
Morrison-Griffiths (51, 99) has published two studies demonstrating the value of 
nurse ADR reporting, however the 2003 study is interesting as it compared ADR 
reporting by nurses and doctors simultaneously.  In that UK-based study, a total of 
763 practice, psychiatric and specialist nurses were recruited into the study, all of 
whom attended a one hour teaching session on ADR reporting and were give an 
information pack to take away.  
 
Over the 12-month study period, nurses submitted more ADRs (137 out of 177 = 
77%) that satisfied submission criteria and were judged appropriate than doctors (676 
out of 984 = 69%), which was a statistically significant difference (p<0.02). One 
report was received for every seven eligible nurses, compared with one report for 
every eight doctors. Serious reactions were described in 36% of nurses ADR reports, 
compared with 41% of doctors’ reports, and 97% of nurse ADRs were classified as 
possible or probable compared with 98% of doctors’ ADRs. The researchers 
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concluded that nurses were capable of recognising and reporting ADRs and the 
quality of nurse reporting was similar to doctors’, which suggests that nurses certainly 
can play a valuable part in pharmacovigilance.  
 
3.5.6 Recognition of reports with thankyou letters and feedback to reporters 
Generally speaking, good communication between HPs and their local 
pharmacovigilance centre is essential to promote ADR reporting. Essentially, this 
entails feedback on individual ADR reports and regular clinical publications or 
newsletters from the centre.  Ralph Edwards, medical director of the WHO 
Collaboration Centre for the IDMP in Sweden, is often quoted in the literature as 
saying “…… It is a truism that feedback and reporter involvement leads to improved 
ADR reporting”. (29, 32)  
 
Thank you letters can be a simple yet effective ADR reporting incentive. The Rhode 
Island Project in the late 1980’s included with their process for streamlined ADR 
reporting, a feedback form (a new concept at the time) to all reporters, which led to 
increased ADR reporting by physicians in number and quality. (85) When the 
intervention ceased, ADR reporting fell back to pre-study levels. (100) In Morrison-
Griffiths’ study of nurse ADR reporting, letters of acknowledgement were sent to all 
nurse reporters, as well as any extra information about their reports as requested. (51) 
 
In Australia, ADRAC sends pre-printed thank you notes to all ADR reporters as 
acknowledgment of receipt, and a signed thank you letter to reporters whose serious 
ADRs are selected for discussion by the committee at their next meeting. This is in 
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addition to their quarterly ADRAC bulletin, which is sent to every registered Doctor, 
dentists and pharmacist in Australia. 
 
3.6 Conclusion 
There continues to be a need to overcome the problem of under-reporting by HPs. A 
controversial and rarely trialled intervention is to permit consumers to report ADRs. 
Advantages and disadvantages of this approach will be discussed in the next chapter. 
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4. Consumer ADR reporting 
4.1 Introduction 
ADR monitoring agencies such as ADRAC in Australia, receive many thousands of 
suspected ADR reports per year, almost exclusively from HPs and medicine 
manufacturers. However, reports from end-users of medicines, i.e. consumers are, as a 
rule, not encouraged. With reference to ADR reporting, the term consumer is used in 
preference to patient in this document, because the term ‘consumer’ refers not only to 
the patient taking the drug, but also their partner, carer, friends and family members 
who may be closely involved with the care and management of the patient and may 
witness and justifiably report ADRs. 
 
4.2 Consumers and pharmacovigilance 
Consumer lobby groups have claimed that the problem of under-reporting by HPs 
could partly be overcome by permitting consumers to report their own ADRs. (69) 
Others have said that the first-hand nature of reports from consumers, and the 
patient’s motivation to report their own ADRs quickly, would enhance the impact and 
timeliness of ADR reporting. (101)  
 
In recent times, pharmacovigilance activities have been criticised for excluding the 
consumer voice from ADR reporting. Critics such as Medawar and Herxheimer claim 
that, without consumer input, the data collected by ADR agencies “ ……cannot stand 
alone as a true representation of drug tolerability.” (39) Much has been written about 
the need to improve current systems of pharmacovigilance, especially post-marketing 
surveillance of new drugs. Introducing consumer ADR reporting (CAR) has been 
theorised as a means by which this could be achieved. 
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In addition to the very practical arguments in favour of CAR, there are a range of 
philosophical reasons that support the concept. (43) These reasons are expressed are 
in terms of: 
1) Consumer rights and empowerment: - Health consumers have the 
fundamental right to express themselves, to be listened to, the right to 
information and to participate in decision-making (informed consent), which 
empowers and educates consumers to help themselves. 
2) Safe and effective use of medicines: - Consumers have unique perspectives 
and experiences with medicines that may be crucial to advancing knowledge 
of what constitutes safe and effective use of medicines.  
3) A more accountable health system: - Service providers who seek client input 
always benefit with improved processes and outcomes.  
Despite the strong support for CAR, to date no research has demonstrated that 
extending current ADR reporting to include reports from consumers will in fact 
increase the size and speed of signal generation (69). Moreover, there are concerns 
that consumer-derived reports will lack detail and only be weakly associated with 
medicines and thus “……may only serve to overwhelm an already-stretched system 
with a great deal of noise”. (27) 
 
4.3 Models for CAR reporting  
Studies examining the value of CAR emerged in the literature in the 1980’s.  In most 
of the studies to date, CAR reports have been elicited by means of prescription event 
monitoring.  This is pro-active model of ADR reporting whereby consumer of specific 
prescription medicines are recruited, usually at the point of medicine collection i.e. 
their pharmacy. Patients are provided with an invitation to report ADEs or ADRs via a 
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questionnaire attached to their medication or telephone interviews for which they just 
give their consent. (102) (103-105) 
 
Fisher and Solovitz published studies in 1987 (103, 105) in which they concluded that 
a greater number of ADRs reported by patients could provide a promising 
complement to existing HP-based reporting systems.  Their methodology involved 
patients being provided with a leaflet from the pharmacy that invited them to report 
any “new or unusual symptoms” (including beneficial effects) in the following two 
weeks via a toll-free helpline, answered by a research assistant (not a pharmacist). 
Only patients prescribed an oral antibiotic or tricyclic antidepressant were included. A 
control group of patients on the same range of medicines were not requested to self-
report, but were interviewed by the researchers two weeks later.  
 
Analysis of patient responses in both groups showed that patients attributed ADR-
related symptoms to the target drugs correctly 69% of the time, and attributed non-
ADR symptoms accurately 57% of the time. The researchers concluded that patients 
were able to discriminate ADRs from other types of symptoms to a significant degree, 
and thus were able to contribute useful data to ADR reporting systems.  
 
In the UK, Campbell and Howie (35) conducted a survey in which patients were 
invited to report possible ADRs to their GP by means of a leaflet issued by 
community pharmacies. They focused on patients prescribed “black triangle” 
medicines, which are drugs the UK Committee on Safety of Medicines (CSM) closely 
monitoring. They found that the number of ADRs reported to GPs doubled, however, 
the number of Yellow Cards submitted to the UK pharmacovigilance scheme did not 
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increase.  The authors concluded that patients ADR reports can be a valuable alert to 
potential drug safety issues, but the value is lost if these alerts do not result in a formal 
report to the CSM.  
 
Mitchell et al (106) published an Australian study in the same year, aimed at assessing 
consumer ability to identify and report potential ADRs. Community pharmacists 
distributed forms to patients prescribed amoxycillin or trimethoprim-
sulphamethoxazole on which the patients were to report either suspected ADRs or any 
adverse event experienced during treatment. All participants were followed-up with a 
detailed telephone interview to assess reliability of written responses. Patients’ 
perceptions of symptom causality were compared with a panel of experts.  
 
As the study response rate was high (77%) the authors concluded that consumers were 
keen to report ADRs.  Overall, responses were reliable and consistent, and patients 
were generally capable of discriminating between adverse drug effects and other 
complaints.  However, the researchers were concerned by the lack of agreement 
between patients and the expert panel in assessing causality especially of serious 
events, and concluded that ADR reports from patients may be poor in quality, and 
“……unlikely to contribute much to our knowledge of the effects of new drugs”. (106) 
Nevertheless, they recommended that a large-scale trial of event reporting by patients 
was justified.  Extensive review of the literature failed to provide evidence that this 
kind of trial has been undertaken. 
 
The model of CAR used by Egberts et al (107) was the Dutch national drug 
information centre for consumers. ADR reporting was derived from a retrospective 
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analysis of calls made to the centre from specific patient groups or about specific 
drugs.  
 
Another method used to access specific patient groups was that used by 
Jarernsiripornkul et al (108) wherein hospitalised patients who had been prescribed 
specific types of medicines over a fixed period were invited to report ADEs. The 
researchers issued these patients with a body system-based questionnaire including a 
“checklist” to ensure thorough consideration of all possible adverse drug events 
during their admission.  
 
It has been stated that the above methods to elicit ADR reports from consumers, using 
questionnaires or drug information services, is not the same as spontaneous ADR 
reporting via a pharmacovigilance centre, which is the model most frequently put 
forward for CAR. (69) This is because SAR has been identified as the most cost 
effective method for widespread ADR reporting within the community. 
 
4.4 Benefits of CAR 
4.4.1 Address under-reporting by HPs 
Jarernsiripornkul et al (108) conducted a study, suggesting that patient ADR reporting 
may capture post-marketing data not currently being reported by HPs. The purpose of 
their study was to test a questionnaire method for collecting patient ADR reports, with 
a focus on nine new “black triangle” drugs (four antidepressants, three anti-epileptics 
and two analgesics). The questionnaire was posted to 2307 patients who had been 
prescribed one of the nine medicines, asking them to identify any possible 
medication-induced symptom experienced over the previous year. Thereafter, a 
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random sample of these patients’ medical records was examined to compare which, if 
any, of these potential ADRs had been recorded in their notes. 
 
Results showed that participants were keen to report ADRs. From a 40.1% response 
rate a median of six symptoms was reported (range 0-71). At least one symptom was 
reported by 88.6% of respondents and 48.5% reported fewer than 5 symptoms. The 
researchers classified 71% of these symptoms as being probably or possibly related to 
the drugs studied, and concluded that consumers ability to identify drug-induced 
effects were acceptable.  
 
Disclosure to the doctor of some or all of these symptoms was poor, in that only 
54.2% of patients claimed to have done this, but documentation by doctors was worse. 
Only 22.6% of the 716 symptoms reported by the patients taking venlafaxine and 
tramadol were documented in their patient notes and only 23 reports were received by 
the CSM of adverse events relating to these two drugs in the study period from 
participating practices. 
 
These results suggested that CAR via a questionnaire could result in improved post-
marketing surveillance of new drugs, because consumers were keen to report potential 
drug-related symptoms, almost half of which had not been reported to their doctor, 
and very few of which were reported formally by their doctor.  
   
4.4.2 Consumer’s unique perspective can detect novel ADRs 
In his paper on consumer-reported ADRs to paroxetine, Charles Medawar (39) stated 
that  
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“…… Patients can report, in their own words, essential information which 
professional reporters can never be expected to provide. They can elucidate 
the real dimensions of an ADR in the context of personal and social life. And 
patients can report things that patients may be scared to talk about e.g. effects 
on driving, feeling like they were going mad.”  
 
The finding in the Jarernsiripornkul study (108) that almost half of potential ADRs 
reported by patients on a questionnaire had not been reported to GPs, supports this 
statement. In addition, the first-hand consumer perspective on ADRs is probably no 
more important than in paediatrics, where the parent is often better placed than the 
doctor and the patient to detect and report adverse drug effects. For example, Hughes 
et al (109) conducted a prospective study of midazolam withdrawal in critically ill 
children where it was the parents who detected the abnormal behaviour in two of the 
young patients.  
 
A Norwegian study (110) of the frequency and characteristics of ADEs in hospitalised 
children, found parents fulfilled a useful complementary role to medical staff in 
detecting and reporting the ADEs. Of the 579 children treated with drugs, 28% 
experienced ADEs. Most ADEs were found by screening patient records, however 
14% of the events were reported by parents and were related to effects on the central 
nervous system (CNS). The authors concluded that CNS reactions may be more 
common than expected in children and therefore observations by parents are 
important when investigating such reactions.  
 
4.4.3 Consumer reports cover a broader range of medicines and organ systems  
There are important differences in the type and nature of ADR reports submitted by 
consumers and HPs, which support the theory that CAR would be complementary to 
existing ADR reporting by HPs. 
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In 1994, Mitchell et al (111) found that HPs tended to report “serious” symptoms of 
critical body systems such as liver, blood and skin whereas consumers more often 
reported common, symptomatic complaints, particularly of the lower urinary tract and 
the central nervous system. In addition, consumers can reports on situations about 
which HPs are not informed, such as the use of over-the-counter, supermarket and 
complementary medicines. These remedies are usually self-prescribed and their use 
often not disclosed to HPs. (112) Consumers are also better placed than HPs to report 
on adverse events arising from non-compliance, drug misuse or treatment by multiple 
doctors. (67)  
 
4.4.4 Consumer ADRs generate possible signals earlier than HPs.  
Evidence from the field indicates that direct consumer reporting can result in an 
earlier accumulation of signals, some of which will point validly to new and hitherto 
overlooked reactions. (113) 
 
A study from the Netherlands by Egberts et al (107) compared reporting of ADRs 
associated with paroxetine by patients via a pharmacy helpline with traditional ADR 
reporting by doctors. On average, they found that patients’ reports were documented 
seven months earlier than doctors. Nine new ADRs to paroxetine were identified in 
the study period (2000-2), but in all cases patients reported their symptoms earlier 
than health professionals. Table 4 summarises the results of this study, showing the 
ADRs discovered, the number of days after marketing when a consumer reported the 
ADR, and the number of days before an HP reported the ADR. The mean difference 
in time to reporting per reaction was 273 days (range: 89-458). 
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Table 4: ADRs and the delay before reporting by patients and HPs  
ADR Days after marketing 
first reported by patients 
First reported by a 
health professional 
Rigours 390 578 
Bleeding disorders 396 1025 
Hypertension 432 1192 
Mydriasis 597 660 
Taste disturbance 635 827 
Apathy 943 1124 
Flushing 967 110 
Menstrual disorders 971 1162 
Rash 1102 1125 
  
4.4.5 Consumers can provide a more personal and detailed account of the ADR 
Patients can provide a more vivid, detailed and complete account of an adverse event 
than a HP, since it is the consumer who experiences the ADR and lives with the 
consequences. (43) In addition, the impact of an ADR from the patient’s perspective 
contributes to the evaluation of its seriousness, as this largely influences whether the 
patient continues with the medicine or not. (27) In addition, seemingly minor ADRs 
such as somnolence, gastrointestinal dysfunction and blurred vision may not be 
reported by HPs who tend to report only serious events. (67) However, if the 
symptoms have a real and distressing impact on the patient’s quality of life, they are 
likely to be reported by consumers instead. (113) 
 
4.5 Arguments against CAR  
4.5.1 Inability to correctly attribute adverse effects 
The most frequently cited objection to consumer ADR reporting is that consumers 
lack the necessary pharmacological knowledge to differentiate between drug-induced 
and disease-induced symptoms. It has been assumed therefore that the probability of 
consumer-reported ADRs actually being medication-related would be low, would 
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contribute few signals and would simply represent background noise. This has been 
referred to in the literature as a “low signal-to-noise ratio”. (47) 
 
At least five studies to date have explored how well consumers attribute their 
symptoms to medication. In their 1988 study, Mitchell et al (106) compared patient- 
reported ADRs on questionnaires with telephone interviews and found the reports to 
be reliable (observed agreement with the same statements posed in each = 85%, kappa 
= 0.56) and valid (sensitivity = 54%, specificity = 94%). Reports were further 
compared with assessments made by an expert panel, and it was concluded that 
patients were generally capable of discriminating between adverse drug effects and 
other symptoms; however they were more conservative than experts in attributing 
serious events to their medicines.  
 
Solovitz et al (103) used a similar method to Mitchell’s group inviting consumers to 
report ADRs during treatment with an oral antibiotic or tricyclic antidepressant. They 
found that patients attributed symptoms to the target drug correctly 69% of the time, 
and accurately attributed non-ADR symptoms 57% of the time. They concluded that 
patients were able to discriminate ADRs from other types of symptoms to a 
significant degree. As the reports submitted in writing were found to closely match 
those that were reported on by interview, consumer ADR reports were also judged to 
be valid.  
 
Mannesse et al (114) assessed older patients’ performance in recognising the presence 
or absence of an ADR on admission to hospital, and found that in 79% of cases the 
patients’ opinion of whether their symptoms were drug- or disease-induced agreed 
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with the medical team’s opinion (95% CI: 70.2-86.6). Patients performed slightly less 
well, however, when assessing symptoms due to severe ADRs, as the presence of 
these was only recognised by 14 of 21 patients. The authors concluded that older 
patients should be asked whether they are experiencing side effects from their 
medicines, “…….because they are often correct in recognising them”. (114) 
 
In the study by Jarernsiripornkul (108), the researchers and an independent specialist 
pharmacist classified most symptoms (71%) as being probably or possibly related to 
the drugs studied, which also supports the theory that patients are reasonably capable 
of identifying drug-induced symptoms. 
 
Interestingly, while negative opinions have been expressed about patients’ ability to 
discriminate effectively between symptoms attributable either to drugs or diseases, 
there are similar concerns with health professionals’ ability to do so. (115, 116) 
Although no studies have been published to specifically assess HPs ability to 
differentiate between drug- and disease-induced symptoms, the absence of ADR 
reporting guidelines to assist HPs is a concern (108).  This is because currently 
available definitions and criteria only categorise ADRs into levels of probability, and 
do not guide the HP through the complex array of variables involved in an ADR.  
Medawar and Herxheimer (39) have used their experience comparing patient and 
doctor reports of ADRs associated with paroxetine to argue that consumers not only 
have the right to report ADRs directly, but also that in some ways, the quality of 
professional ADR reporting is inferior to that provided by patients. 
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4.5.2 Consumers have limited access to ADR information 
Critics of CAR often point out that, although consumers may want to report ADRs, 
they may not be able to provide the necessary information for ADR documentation.  
For example, there are situations where patients do not know with which medicines 
they have been treated or at what dosage. This is especially so in hospitals and nursing 
homes, where carers give medicines, or where patients may be unconscious or too 
sick to heed their medicines. Identification of medicines can be difficult from a 
laypersons’ perspective especially where one medicine carries many different brand 
names or in countries where labelling requirements are not enforced. (47) 
 
Knowing exactly when a medicine was commenced and ceased is often elusive to 
consumers, being a detail usually left to doctors to record. Indeed, consumers who to 
take a passive approach to their health may have little or no knowledge of their 
medicines, as they prefer to relinquish that responsibility to their doctor or pharmacist. 
(117) Finally, results of pathology tests and diagnostic procedures, sometimes pivotal 
in assessing ADR causality, are not usually given to consumers.  
 
4.5.3 CAR is dependent on awareness and networking  
It has been recognised by authors on CAR that a high level of publicity and consumer 
support must be generated on a regular basis for a CAR scheme to function 
effectively. This task is made somewhat more difficult by the fact that CAR services 
have never existed before and consumer awareness has to be built from a zero base. 
Consumers have little insight that they can and should play a role in monitoring drug 
safety.  Therefore, publicity is required not only to inform the general public that the 
service exists, but also educate them on its purpose, function and contact details. 
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High-level publicity may serve to educate health professionals on this new service, as 
well as put them at ease at the emerging role of the consumer in monitoring drug 
safety. 
 
At the Kilen conference in 2000, it was suggested that any CAR scheme should be 
independent from government and industry, in order for data gathering and 
interpretation to be free from commercial bias and influence. (43) However, in the 
interests of streamlining the system, it is generally agreed that consumer ADRs should 
be submitted in the standardised manner to an existing pharmacovigilance centre, 
such as ADRAC.  Moreover, the CAR system cannot stand alone. Its value will 
depend on enlisting the support of a wide range of health-related organisations and 
professional bodies.  
 
4.6 International developments in CAR 
In September 2000, the Swedish Consumer Institute for Medicines and Health, Kilen, 
hosted the “First International Conference on Consumer Reports on Medicines”, 
where CAR was discussed as a key strategy for improving pharmacovigilance. 
Aspects of how a consumer-driven ADR reporting system could practically work 
were discussed, as well as the detailed arguments for and against CAR.  
 
4.6.1 In Australia 
In 1992, the Pharmaceutical Health and Rational Use of Medicines (PHARM) 
committee recommended that: 
“ ……consumers be encouraged through an education program to report 
adverse drug reactions”, as such an activity had been recognised as 
“highlighting safety issues which make a difference to people taking 
medicines.” (118)  
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In 1995, the Australian Pharmaceutical Advisory Council (APAC) established a 
working party to discuss the issues involved in consumer reporting of adverse drug 
events (CRADE), and this issue remained on the APAC agenda until 1999 when a 
proposal was formulated to fund a pilot study for CRADE.  Coincidently, the Mater 
Pharmacy Services Education and Information Unit (EIU) had developed an ADR 
study proposal, which was submitted to PHARM for funding in 1999 and resulted in 
the ADR project from 2000 to 2002.   
 
APAC developed a proposal for the development of a national system for consumer 
reporting of adverse drug events in 2002, which was supported by the Australian 
Council for Safety and Quality in Health Care in association with the National 
Prescribing Service (NPS)(119). This led to the establishment of a national CRADE 
pilot project, called the Adverse Medicine Event (AME) line, operated by the Mater 
Pharmacy Services EIU, which will complete its survey of Australian CAR from a 
national perspective in May 2005. 
 
For several years ADRAC has had a policy to welcome ADR reports from members 
of the general public, but has not actively encouraged them to report. As a result, an 
average of 300 ADR reports is submitted directly from consumers each year.  This 
forms part of an average total of 10,000 reports received by ADRAC per year. (120) 
  
There is only one other agency in Australia that collects ADE reports on behalf of 
consumers, that being the Australian Patient Safety Foundation (APSF). Since the 
early 1990s the APSF has been operating the Australian Incident Monitoring System 
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(AIMS). Prior to 2003, this database was available for public access via the Internet 
and consumers could submit reports of ADEs online. However, AIMS has recently 
become a subscription-only product and is no longer freely accessible to consumers.  
At any rate, AIMS has not been thought of as a significant repository of ADRs from 
consumers, as only 20% of the reports concerned medication and only 4% of these 
were about adverse events. (118) 
 
4.6.2 In the United States 
Medwatch, the FDA’s Safety Information and Adverse Event Reporting Program, 
offers patients scope to directly report ADRs, especially via the Internet. (121) The 
FDA encourages consumers to download an ADR reporting form and have it 
completed by their doctor. However, they explain that consumers may also file a 
report on their own if they prefer not to involve a HP or if their HP refuses to report 
the problem.  
 
As it is mandatory for the pharmaceutical industry in the US to report all ADRs to the 
FDA, a small proportion of consumer-derived ADRs that reach the FDA are 
submitted via pharmaceutical companies. (69) 
 
4.6.3 In Canada 
The Canadian pharmacovigilance community has been one of the first to accept 
consumers into their official ADR reporting systems. Since August 2001, members of 
the general public have been invited to directly report ADRs to the Canadian Adverse 
Drug Reaction Monitoring Program via a toll-free telephone helpline, by fax, through 
their website (122) or through a newly created consumer-oriented centre for 
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pharmacovigilance called Pharmawatch. (123)  The general public is also at liberty to 
interrogate the Canadian Adverse Drug Reaction Information System (CADRIS) via 
the Health Canada website. (124) 
 
4.6.4 In the Netherlands  
Egberts et al (107, 125) have been responsible for publishing some of the seminal 
work in CAR based on findings from the Dutch Telephone Medicines Information 
Service (DTMIS) that has been operating since 1990 under the auspices of the Royal 
Dutch Association for the Advancement of Pharmacy. In his groundbreaking paper 
comparing ADR-related question from the DTMIS and Lareb, the Netherlands 
Pharmacovigilance Centre, Egberts showed that consumers called about a different 
cluster of medicines from HPs and the age-group calling was also markedly different. 
The DTMIS data showed that consumers could potentially provide post-marketing 
drug safety information that is additional and complementary to that provided by HPs. 
Egberts theorised that this data, combined with the ADR information acquired 
through Lareb, allowed the two services to identify ADR signals sooner. (125) 
 
The faculty of Pharmacy of the University of Utrecht published a paper in 2003 which 
discussed which specific facilities and services in the Netherlands were considering 
accepting ADR reports from patients and how these facilities would have to be altered 
to do so (69). In addition, two Dutch hospitals conducted research into patients as 
information sources regarding possible ADEs, showing promising results. (67) 
 
In April 2003, Lareb began operating an official arm of their service to accept ADR 
reports directly from consumers, via a telephone helpline or the Internet.(126) Results 
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from the first year of this service have recently been published in Dutch. (127). 
During the first year of operation, April 1st 2003 to 31 March 2004, patients submitted 
276 reports.  
 
 The reports usually contained sufficient information and more frequently referred to 
serious ADRs than reports received from HPs. As previously experienced on the 
DTMIS, there was a tendency for consumers to report ADRs associated with 
psychotherapeutic agents, notably antidepressants. The authors stated that, based on 
these encouraging results, Lareb has decided to continue operating their ADR 
reporting station for patients. (127) 
 
4.6.5  In the UK 
Several pilot projects for patient reporting of ADRs are already underway in the UK. 
This has occurred as a result of an independent review of The Committee on Safety of 
Medicines (CSM) Yellow Card Scheme, published in May 2004, which recommended 
that, in addition to health professionals, patients and carers should be able to report 
their experience of ADRs directly to the Medicines and Healthcare Products 
Regulatory Agency (MHRA).(128) 
 
A working group comprised of patient and consumer group, academic, pharmacist and 
medical representatives met for the first time in September 2004 to further this 
concept. Although still in the process of designing the best systems to enable patients 
to send reports of the suspected ADR experiences, they expect to have final systems 
in place by 2006. In the meantime, consumers have been welcomed to submit ADR 
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reports via the Yellow Card Scheme website by filling in an electronic Yellow Card 
or paper-based Patient Yellow Card report forms. (129) 
 
4.6.6  On the Internet  
The Internet is well populated with websites that provide patients with an opportunity 
to communicate adverse experiences with medicines. (130, 131) Apart from 
demonstrating that consumers need to share this information, and for it to be heard 
and understood, it also illustrates that consumers are a rich source of information. (69) 
However, it is evident that distinguishing between valuable data and unreliable 
complaining remains a real problem. (132)  
 
4.7 Conclusion 
Evidence suggests that CAR can give a more detailed, first-hand account of ADEs, 
are submitted more quickly than HPs, and cover a broader range of drugs, such as 
non-prescription and complementary medicines and therefore serve as a useful 
adjunct to existing HP-based reporting. Therefore, consumer ADR reports help to 
bridge the knowledge gaps evident in the current HP ADR reporting systems.  
 
ADRs have a significant impact on public health in Australia and internationally. SAR 
provides a means by which ADRs can be detected and prevented, but under-reporting 
limits the effectiveness of this system. Despite some promising preliminary studies, 
there is no definitive research into improving the rate and breadth of ADR reporting in 
this country. In addition, few studies have examined the practical contribution 
consumers make to ADR reporting or compared it with HP reporting.  
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The ADR project aimed to address these issues by examining the effect of education 
and/or a telephone helpline to improve ADR reporting by a range of HPs. In addition, 
consumers were provided with an opportunity to report ADRs via a pharmacist-
operated telephone helpline.  This facilitated a comparison between consumers’ 
contribution to pharmacovigilance and that made by HPs. 
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5. Methodology 
5.1 Introduction  
The ADR project was a two-year study aimed at increasing the frequency, quality and 
breadth of ADR reporting by consumers and health professionals. The project was 
divided into two independent studies.  
 
The first study involved health professionals (HPs), who were given access to a 
telephone helpline titled the “ADR hotline”, an educational workshop on ADR 
reporting or both, and it was determined whether these interventions increased the 
number, quality and breadth of ADRs submitted by HPs to the Adverse Drug 
Reaction Advisory Committee (ADRAC).  
 
In the consumer arm of the project, the impact of a telephone helpline called the “Side 
Effect Reporting Line” to generate, capture and examine ADR reports from members 
of the general public was investigated and the value of these reports to existing 
pharmacovigilance systems was reviewed.  Finally, elements of consumer and HP 
ADR reporting were compared. 
 
Preparations for the ADR project as a whole, such as ethics approval, staffing, tool 
development and data handling procedures are outlined below. However, the aims, 
objectives and methods of the two studies within the project were significantly 
different, so these have been outlined separately.  
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5.2 Ethical considerations 
The protocol for the ADR project was submitted to the Mater Public Hospitals’ 
Research Ethics Committee in May 2000 and approval was granted on 13th June 2000 
(Appendix 1).  In August 2000 permission was also obtained from St Luke’s Nursing 
Service’s Ethics Committee for their staff to participate in the HP arm of the study as 
control subjects   
 
5.3 Staff training and tools for call handling procedures 
The ADR project was based in the Education and Information Unit (EIU) of Mater 
Pharmacy Services, Mater Misericordiae Health Services, South Brisbane. A total of 
six pharmacists from the Mater EIU were trained and available to take calls on either 
the HP or consumer hotlines. During operational hours, a total of 1.5 full-time 
equivalents were rostered to the hotlines.  
 
The introduction of the two new ADR reporting helplines into the existing network of 
helplines already operated by Mater Pharmacy Services required some modification 
of existing workflow practices. Flow charts and guidelines were developed by the 
project officer (the D Clin Pharm candidate) to ensure calls were handled uniformly. 
These were provided to all ADR study pharmacists in a training manual, which also 
included pertinent newspaper clippings, journal articles regarding ADR issues in the 
popular press, and ADRAC’s latest list of Drugs of Current Interest (DOCI).  These 
tools proved to be of great value to staff, as well as forming an integral part of the 
educational material offered to consumers and HPs in their ADR lectures and 
workshops. (Appendices 3-8)  
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Training tools included in the manuals included: 
 How to handle a consumer ADR call (Appendix 2); 
 How to diagnose an ADR (Appendix 3); 
 A guide to description of rashes (Appendix 4); 
 Definitions of minor, moderate and major impact on QOL (Appendix 5); 
 Definitions of serious ADRs (Appendix 6); 
 Definitions of uncertain, possible, probable and certain ADRs (Appendix 7); 
 Criteria for reporting to ADRAC (Appendix 8). 
 
5.4 Call handling and streamlining  
Triage pharmacists asked every caller to express whether, in their opinion, their call 
actually related to an adverse drug event (ADE) or not (no ADE). Then the triaging 
pharmacist assessed, based on the information given, whether they agreed with the 
caller or not. The guideline entitled “How to handle a consumer call” (Appendix 2) 
further assisted pharmacists to handle calls from consumers in a confident and 
structured manner, and promoted uniform call handling by all team members. As 
outlined in Figure 2, the pharmacist was prompted to determine, early in the call, 
whether the query related to an actual adverse drug event, and if it did, whether the 
ADE was an ADR only, an ADR from a drug interaction, a drug-induced birth defect 
or a medication error.  If there was no ADE, then the call involved a general or side 
effect enquiry, and if not, the call was referred to another service. 
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Figure 2. Flow Chart of Call Handling 
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Of the eight ADE perceptions, four combinations were possible, and these were 
reduced to two decisions, as shown in Table 5. This approach was called “the ADE 
collaborative decision matrix”, and significantly improved communications between 
operator and caller, as well as helping the pharmacist direct the caller to the next 
action. Calls that resulted in No ADE were terminated at that point with either 
education, reassurance, the offer to send drug information, or referral to a more 
appropriate service. Calls relating to an ADE were further triaged by the operator 
considered for potential adverse drug reactions (ADRs).  
 
Table 5: ADE Collaborative Decision Matrix 
Combin-
ations 
Consumer 
perception 
Helpline 
perception 
Collaborative 
Decision 
 
Action 
1 No ADE No ADE No ADE Educate, reassure or 
refer 
2 ADE No ADE   
 
3 No ADE ADE ADE 
(Include possible 
ADRs) 
Continue call 
 
4 ADE ADE   
 
 
The role of call triage pharmacists was to ascertain relevant details pertaining to the 
patient’s complaint, the suspected drugs, the patient’s medical history and the time 
correlation with the adverse event. Pharmacists assigned causality to drug-related 
concerns with calls falling into one of four categories, as outlined in Table 6.  
 
Triage pharmacists assigned the ADE classification system during the call, as a 
temporary categorisation. In contrast, the classification in Table 6 was assigned after 
each call was concluded, to reflect the final categorisation once all data pertaining to 
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the case were gathered. This explains why the similarity between classifications. 
General and side effect enquiries represented largely non-ADE calls, while ADRs not 
for and for ADRAC largely represented ADEs.  
Table 6: Four Enquiry Types 
Enquiry type Description 
 
General questions Drug interactions, use in pregnancy, prescription costs 
 
ADR questions General safety issues e.g. I’ve started a new medicine. 
What could be the potential side effects? 
ADRs- not for ADRAC Possible drug-induced event, not satisfying reporting 
criteria. 
ADRs for ADRAC Possible drug-induced event- reportable to ADRAC 
 
  
 
5.5 Data collection forms 
A data-collection form that captured both qualitative and quantitative data was 
developed to guide the pharmacists in handling calls as well as to document call 
details and statistics. The same form was used regardless of whether the caller was a 
consumer or HP.  A prototype data collection form initially had the appearance of a 
modified (blue) ADRAC form, but was piloted and modified based on operator 
feedback to the final version provided in Appendix 9.  
 
5.6 Data collation  
A purpose-built ACCESS ™ database was used for data collation and evaluation. 
Individual pharmacists were responsible for entering details from their data collection 
forms into the database, at the conclusion of every call. The data points gathered on 
the database are outlined in Table 7. 
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Table 7: Data points collected from ADR helpline calls. 
ADR data collection form 
 
Call details Date 
Sequential number (“Stompy”) 
Pharmacist operator initials 
Mode of contact (phone/fax/email/post) 
Call duration 
Caller demographics Caller Age (years) 
Caller gender (M/F) 
Caller profession (consumer/HP/carer) 
Call for Self / Other 
Source of telephone helpline number 
Patient 
demographics 
Patient Age (years) 
Patient gender (M/F) 
Relationship to caller- self, partner, child, parent, friend, other family, 
client/patient 
Complaint Primary complaint (including no complaint) 
Time of onset 
Information sources already consulted 
Drugs involved Main suspected drug 
Other drugs taken 
Adverse event Comparative perception of adverse drug event (ADE) involvement: 
• No ADE/ No ADE 
• No ADE/ ADE 
• ADE/ ADE 
• ADE/ No ADE  
Type of call General question 
Side effect question 
ADR not for ADRAC 
ADR for ADRAC 
ADR type: ADR only/ drug interaction/ birth defect 
ADR characteristics Probability: certain/ probable/ possible/ unlikely 
Novelty: in PI>5%, in PI 1-5%, In PI <1%, not in PI, CAM, new drug, 
ADRAC drug of current interest (DOCI) 
Predictability: type A/ type B 
Treatment required: Hospitalisation. Visit DR. visit pharmacist/ self- 
treatment/ no treatment  
Did patient cease drug? Yes/ no 
Has patient recovered? Yes/no 
Was drug re-challenged? Yes/no 
QOL impact- Major/ Moderate/ minor 
ADR report Report sent to ADRAC? Yes/no 
Follow-up required? Yes/no 
Send Information Yes/No/ details 
Comments 
 
 
5.7 Data analysis  
Standard descriptive statistics (frequencies, means, standard deviations) were 
generated for continuous data values. Comparisons within and between groups were 
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made using the Student t-test and significance value set at p<0.05. Statistical analyses 
were conducted using Microsoft EXCEL™ and manual calculations using standard 
statistical formulae.  
 
5.8 Reporting to ADRAC 
In association with ADRAC, the project team developed criteria to guide pharmacists 
as to which drug-related complaints were appropriate to report to ADRAC (Appendix 
8).  These same criteria were used in assessing the quality of ADR reports submitted 
to ADRAC. 
 
All ADRs submitted to ADRAC were documented on a modified version of the ‘blue 
card’ approved by ADRAC (Appendix 10). The modifications permitted description 
of the ADR, a greater number of drugs to be included, and specific details of how 
ADR study criteria were met for each report. Health professionals in the study were 
not obligated to use the ADR reporting service and were encouraged to submit their 
own ADRAC forms if they wished.  
 
5.9 Liaison with ADRAC 
Throughout the project, the candidate was in close contact with members of ADRAC 
in relation to a number of aspects: 
 Approval of data collection and reporting forms; 
 Provision of harmonised ADR terminology –the World Health Organisation 
Adverse Reaction Terminology (WHOART) dictionary; 
 Legal and ethical considerations; 
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 Approval of the health professional study consent form by ADRAC lawyers and 
comment by ADRAC staff; 
 Determination of means by which ADRAC reports submitted by the ADR 
research project were to be quarantined from other reports generated by staff of 
the Mater Hospitals, South Brisbane;  
 Handling media issues, including when ADRAC was in the media; 
 Defining ADRs appropriately e.g. statin-induced myopathy; 
 Optimising documentation of suspected ADRs associated with complementary 
medicines; 
 
In addition, the candidate was invited to attend the 30 March 2001 ADRAC meeting 
in Sydney as an observer, and to update the Committee on the progress of the ADR 
project.  
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6. HP study methodology 
6.1 Aims and Objectives  
The primary aim of the HP study was to measure how three interventions would 
impact on the frequency of ADR reporting by participating HPs. Secondary aims were 
• to promote high quality ADR reporting by HPs by ensuring that ADRAC 
reports submitted met the minimum ADRAC criteria.  
• to increase the breadth of ADR reporting by recruiting participants from a 
broad range of health professionals, nurses, dentists and naturopaths, in the 
project. 
 
6.2 Hypotheses  
In conducting this study, four hypotheses were tested, as follows: 
 
Ho1: An educational intervention will increase ADR reporting from baseline levels. 
Ho2: Access to a pharmacist-operated, ADR hotline will increase adverse drug 
reaction reporting from baseline levels. 
Ho3: A combination of both interventions (education on adverse drug reaction 
reporting and access to an ADR hotline) will increase ADR reporting from 
baseline levels. 
Ho4:  Compared with a control group, all three interventions will increase ADR 
reporting. 
 
6.3 Study design 
In the HP study, doctors, nurses, pharmacists, dentists and complementary medicine 
(CM) practitioners were recruited and randomly assigned to one of four intervention 
groups:  
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Group 1: Hotline group 
Group 2: Workshop group; 
Group 3: Hotline plus Workshop group; and 
Group 4: Control group (no intervention). 
 
The number of ADRAC reports submitted by participants in the two years prior to the 
study (1999-2000) and during the study (2001-2002) was compared. In addition, 
meeting the minimum criteria for reports submitted to ADRAC and the range of drugs 
involved in those reports were used as an indicator of the quality and breadth of ADRs 
reported to ADRAC.  
 
6.3.1 Recruitment and informed consent  
HPs for the hotline-only arm of the study were invited to participate at a variety of 
professional education and speaking engagements presented by the candidate. HPs 
were recruited into the workshop arms of the study (Groups 2 and 3) whilst attending 
ADR seminars presented by the candidate.  
 
An invitation to participate and the informed consent document (Appendix 11) were 
issued to all attendees at the presentations and those who wished to participate 
responded by signing and returning the consent form. HPs consented to the candidate 
having access to their ADR reporting records held in the ADRAC archives for the 
period from January 1999 to December 2002.  Recruits were then randomly assigned 
to be in the hotline only, workshop only or workshop plus hotline groups.  They were 
then provided with marketing materials for the ADR study and a project identification 
number. 
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Other recruitment strategies were necessary to attract HPs to the workshops. These 
included: 
 Small group workshops held in GP surgeries or their homes within the greater 
Brisbane area; 
 Invitation of medical practitioners to attend pharmacy workshops in eight rural 
locations including Bundaberg, Mackay and Cairns; 
 A mail-out to a range of HP organisations calling for expressions of interest to 
participate in the study; 
 St Vincent’s Nursing Service (Brisbane). 
The latter group agree to participate in the active arms of the project in return for 
medication-related education in regional centres such as Toowoomba, Bundaberg, and 
the Gold Coast. 
 
Subjects for the control arm of the study were recruited by way of a letter inviting 
them to participate, which explained the nature of the study and that other than 
providing consent to access their ADRAC reporting data for the specified period, no 
further participation was required (Appendix 12). 
 
Control group letters were sent to all doctors practising within the Brisbane Inner 
South Division of General Practice, all Queensland members of the Pharmaceutical 
Society of Australia and employees of St Luke’s Nursing Service. 
 
6.3.2 Groups with ADR Hotline access  
Groups 1 and 3 were given access to the “ADR Hotline” where case details could be 
provided and, for those cases meeting ADRAC criteria, a report would be sent to 
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ADRAC on their behalf.  Hotline hours of operation were 9.00am to 5.00pm Monday 
to Friday, except public holidays. The telephone number was (07) 3840 8404, a local 
number because only Queensland-based HPs were using the number. In addition to 
telephone access, the service was also available via email, fax or mail.  
 
Only HPs with a valid project identification number were entitled to use the hotline 
for advice or reporting to ADRAC. When HPs not enrolled in the study contacted the 
service, it was policy that they should not be rejected, but their activity kept to a 
minimum and any ADRs generated would be excluded from study results.  
 
An information pack about the ADR Reporting Hotline was sent as a reminder to 
participants in the Hotline arms of the study, immediately after recruitment, and 12 
months into the study. This pack contained:  
 a poster about the hotline outlining how it works, telephone number and hours of 
operation (Appendix 13) ; 
 stickers with the hotline number to adhere to or near their telephone 
 a page entitled “ADR Hotline – Guidelines and Frequently asked questions” 
(Appendix 14); and 
 a blue ADRAC card. 
 
6.3.3 Groups participating in workshops 
Groups 2 and 3 participated in a workshop, which consisted of an interactive, 90-
minute case-based presentation on ADRs entitled “Pharmacovigilance and YOU”. 
Elements for the workshop were selected from feedback obtained from previously 
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piloting the workshop with a general practitioner focus group. Their suggestions 
included: 
 Case examples incorporating recognition of the potential ADR in the patient to 
completion of all required documentation, including a blue ADRAC card; 
 What to report and what not to report; 
 How ADRAC assigns causality; 
 What happens to the ADR report after it is submitted to ADRAC; 
 How the data is used to improve QUM. 
 
Workshop participants completed a multi-choice questionnaire at the beginning and 
end of the seminar. The purpose of assessment was to evaluate the extent to which 
new knowledge was acquired. In addition, participants completed a survey to measure 
their satisfaction with the workshop, its applicability and quality.  
 
6.4 Sample size calculation  
A power calculation was prepared by the candidate and confirmed by epidemiologist 
Dr Joanne Aitken. It determined that, with a type I error of 0.05 and power (1-beta) 
value of 0.8, the number needed for each group was 64. Therefore a minimum of 256 
participants was required for the study to have sufficient power to show statistical 
significance. For ease of calculation and to allow for at least 10% dropout rate, the 
study aimed to recruit a total of 400 HP participants, with 100 (minimum of 85) 
participants in each group.  
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6.5 Outcome measures  
The primary measure for assessing the impact of the interventions in this study was 
the change in the number of ADRAC reports submitted by each participant before and 
during the study.  The number of reports submitted by each participant over the period 
of 1999-2002 were obtained from the ADRAC archives, and were divided into two 
discreet time periods: 
 January 1999 to December 2000, defined as PRE-STUDY, and  
 January 2001 to November 2002, defined as DURING STUDY; 
 
Irrespective of their study group allocation, HPs could still report their own ADRs 
directly to ADRAC, if they so desired.  
 
6.6 Statistical analysis 
The effect of each intervention on ADR reporting was measured by comparing the 
number of ADRAC reports submitted by each group prior to and during the study. 
The comparative results for each individual cohort were made using a paired t-test 
(two-tailed) and the difference between results was deemed significant if the p value 
was < 0.5. Comparisons between intervention cohorts and the control group were 
made using an unpaired t-test (two-tailed) and the difference also deemed significant 
if the p value was < 0.5.  
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7. Consumer Study Methodology 
7.1 Aims and objectives 
The overall aims of the consumer ADR reporting (CAR) study were to give 
consumers an opportunity to contribute to post-marketing pharmacovigilance via a 
pharmacist-operated telephone helpline, and to evaluate their contribution in terms of 
frequency, quality and breadth.  
 
Secondary aims were to compare elements of CAR with ADR reporting by HPs, 
including their frequency, signal-to-noise ratio, the breadth, novelty and seriousness 
of ADRs reported.  
 
7.2 Study Design  
A pharmacist-operated 1300 telephone helpline named the Side Effect Reporting 
(SER) Line was established through which ADRs could be reported or enquired about 
by consumers. The SER Line could be accessed from anywhere in the state of 
Queensland on 1300 134 237 for the cost of a local call. Calls from mobile phones 
were charged at STD rates. Hours of operation were 9am - 5pm Monday to Friday, 
except public holidays.   
 
Details from consumer calls were collected on the same form used in the HP study, 
which captured both qualitative and quantitative data.  Data points collected were 
therefore the same as those outlined in Table 7. Individual pharmacists were 
responsible for entering details from their data collection forms into the purpose-built 
ACCESS ™ database at the conclusion of every call.  
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The geographical coverage of the SER Line was theoretically Australia-wide. 
However, funding limited marketing activities to the state of Queensland, as 
represented in Figure 3.  
 
 
©The State of Queensland (Queensland Health) 2005 
Figure 3.The State of Queensland, Australia (Brisbane) 
 
7.3 Marketing 
Widespread and frequent marketing was sourced, including opportunities to lecture, 
television, radio and newspaper publicity to ensure effective utilisation of the helpline 
by the members of the public.  As the project funding did not allow for any structured 
advertising such as printed brochures or listing in Australian telephone directories, 
service awareness was generated from the range of ad hoc marketing activities as 
listed in Appendix 15. 
 
Television was a particularly important referral source for the SER Line , which was 
officially launched to consumers on Channel 9’s local current affairs show Brisbane 
EXTRA and Channel 7’s Evening News. Subsequently, details of the SER Line and its 
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operation were circulated to consumers on a flyer (Appendix 16) handed out at over 
30 talks given by the project officer to consumer organisations and self-help groups.  
These flyers were also faxed to over 50 consumer support groups throughout 
Queensland.  Articles about the SER Line subsequently appeared in many of their 
newsletters. Many consumers were directed to the SER via these newsletters or by 
either the support group’s own helpline. Government departments responsible for 
health-related matters were also sent SER Line publicity material, including the 
Queensland Health switchboard, Public Health services and the Health Rights 
Commission.  
 
Some national coverage of the SER Line was serendipitously achieved through an 
article written by the project officer, published in Choice magazine (Appendix 17).  A 
small article on the helpline was made in the Readers’ Digest. Active publicity for the 
SER Line ceased in mid-2002.  
 
7.4 Data analysis 
Twenty-two months after the SER Line was launched, call data were audited. 
Standard descriptive statistics (frequencies, means, standard deviations) were 
generated for continuous data values.  Consumer and HP ADR reporting were 
compared in terms of their nature and frequency.  
 
7.5 Selection of subjects 
All adult consumers, over the age of 15 years were eligible to contact the SER Line if 
they wished to ask questions regarding safety aspects of their medications, or they 
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wished to report a suspected adverse medicine event. However, callers that were 
excluded from the study were: 
 children; 
 hoax calls; 
 wrong numbers; 
 health professionals with an ADR to report, who were referred to the HP arm of 
the study;  
 health professionals with a general question,  who were referred to the NPS 
Therapeutic Advice and Information Service; and   
 poisoning enquiries were referred to the Poisons Information Centre. 
 
7.6 Patient consent 
Patient consent to be included in the study was not explicitly sought, as it was implicit 
in their choice to call the service.  However, when it was decided to submit a report to 
ADRAC, consent was often verbally sought so that the consumer understood why so 
many questions had to be asked or why the service may have had to call them back at 
a later date. In all SER Line publicity it was clearly communicated that the service 
was part of a pilot study of consumer ADR reporting and de-identified results from 
calls would be used for research.  
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8. HP Study Results 
 
8.1 Recruitment 
Recruitment of sufficient HPs into the study proved to be an onerous task. Over a 
period of twelve months, 65 workshops or lectures were presented which resulted in a 
total of 381 HP study participants recruited, as outlined in Table 8.  
 
Table 8: HP participants for ADR study by profession and cohort 
Profession Group 1 
Hotline 
only 
Group 2 
Workshop 
only 
Group 3 
Hotline and 
workshop 
Group 4 
Controls 
TOTAL 
Doctors 
 
33 17 28 35 113 
Pharmacists 
 
34 34 32 46 146 
Nurses/CMPs/ 
Dentists 
24 38 43 17 122 
 
Totals 91 89 103 98 381 
 
The time taken to complete recruitment for each profession was general practitioners 
and specialists- 12 months; nurses - 10 months; pharmacists - 7 months; dentists and 
CAM practitioners - 6 months.  
 
Only two naturopaths were ultimately recruited to the study, as it proved difficult to 
find a professional group of CAM practitioners (CMPs) willing to be involved. The 
only group interested were the team of naturopaths operating the information hotline 
for Golden Glow products. However, after the ADR workshop was conducted for 7 
naturopaths at their head office, they all declined to participate in the study, based on 
their legal counsel. 
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8.1.1 Satisfaction with workshops 
The 192 potential participants for Groups 2 and 3 attended an ADR workshop. In total 
eight ADR workshops were conducted, four for doctors and four for pharmacists, 
whether they were recruited or not.  External evaluation of the pharmacist workshops 
was conducted independently by the Pharmaceutical Society of Australia, Queensland 
Branch to assess their satisfaction with the presentation, the quality of the material 
and the applicability of the subject matter to pharmacy practice. The majority of 
attendees expressed that the subject matter, relevance to pharmacy practice and value 
to the individual were good or very good in 98%, 94.9% and 98.8% respectively. 
(Appendix 18)   
 
 
8.4 Description of calls to the ADR Hotline 
 
8.4.1 Number of calls  
A total of 108 contacts were made by HPs on the ADR Hotline over the study period, 
the majority from pharmacists (61.1%) and doctors (29.5%). There were no contacts 
from dentists. Although the majority of study participants used the telephone to report 
ADRs, a small percentage communicated by mail, email and fax, largely by 
pharmacists. (Table 9)   
 
Ten HPs not enrolled in the study used the ADR Hotline based on a recommendation 
from a colleague. These comprised 3 doctors, 3 pharmacists, and 4 nurses. Their ADR 
data are not included in the results for statistical analysis.  
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Table 9: HP Mode of contact 
No. of ADR hotline contacts 
Mode of 
contact 
Specialist GP PHC Nurse CMP TOTAL % 
Phone 7 25 62 7 2 103 
  
95.4% 
Post - - 2 1 - 3 2.8 
 
Email - - 1 - - 1 0.9 
 
Fax - - 1 - - 1 0.9 
 
7 25 66 8 2  
TOTAL 32 
(29.6%) 
66 
(61.1%)
10 
(9.3%) 
108 
 
100% 
 
 
8.4.2 Call duration  
As outlined in Table 9, calls from all HPs were, on average, 21.3 minutes (+/- 12.8) in 
duration.  However, duration differed based on the nature of the call and the 
profession of the callers.  General enquiries were of shorter duration (12.2 min) than 
enquiries involving ADRs (17.4 min). Calls resulting in ADRs for ADRAC took the 
longest, being of 31.1 minutes duration.   
Table 10: Call duration 
Average call duration (minutes) Type of Call 
Specialist GP PHC Nurse CMP  All HPs 
General enquiry  
 13.3 17.0 10.0 10.5 10.0 12.2 
Side effect 
enquiry - 9.7 23.0 19.5 - 17.4 
ADR - not for 
ADRAC 40.0 16.0 17.9 - - 24.6 
ADR - for 
ADRAC 27.0 17.7 22.0 24.8 64.0 31.1 
 
Average 
 (+/- SD)  
 
 
26.8 
 
15.1 18.2 18.3 37.0 21.3 +/- 12.8 
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Calls from GP’s generally took less time than calls from other HPs, but the data 
regarding call duration with medical specialists and CAM practitioners are likely to be 
skewed due to the low number of these HPs participating in the study. ADRs reported 
to ADRAC by nurses (24.8 minutes) and pharmacists (22 minutes) took considerably 
longer on the phone than with GPs (17.7 minutes).  However CMPs and medical 
specialists took longest at 37 and 26.8 minutes respectively. 
 
8.4.3 HP Caller Location 
ADR Hotline callers were located by their postcode. For ease of interpretation, these 
have been collated into the 34 Queensland Health districts (Table 11). Callers were 
predominantly from South-East Queensland, with 48.8% from the Brisbane 
metropolitan area. These results parallel the distribution of the project’s awareness 
campaign. 
 
Table 11: HP caller location 
No. of calls to ADR hotline  HP caller location  
Doctor PHC Nurses CMP TOTAL % 
Brisbane South  5 17 2 1 25 23.1 
Brisbane North  12 2 2 1 17 15.7 
Bayside 8 5 - - 13 12.0 
Gold Coast 2 9 1 - 12 11.1 
Mackay - 11 - - 11 10.1 
Redcliffe-Cab’ture - 7 - - 7 6.5 
Sunshine Coast 1 4 1 - 6 5.6 
Cairns 1 4   5 4.8 
Logan-Beaudesert 1 2 - - 3 2.8 
West Moreton - 2 - - 2 1.9 
Toowoomba - 1 1 - 2 1.9 
South Burnett - - 1 - 1 0.9 
Townsville 1 - - - 1 0.9 
Northern Downs 1 - - - 1 0.9 
Innisfail - 1 - - 1 0.9 
Banana - 1 - - 1 0.9 
TOTAL 32 66 8 2 108 100% 
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8.4.4 Source of ADR Hotline number / service awareness 
Table 12 describes from where participants accessed the telephone number for the 
ADR Hotline. The majority of HPs obtained the number from involvement in the 
study.  Electronic or print media did not significantly influence access to the ADR 
Hotline. Four HPs obtained the hotline number via word of mouth, but as these HPs 
were not official study participants, their ADRs were not included in statistical 
calculations.  
 
Table 12: Source of ADR Hotline Number 
No. of calls to ADR hotline  Source of ADR 
HOTLINE No. Doctor PHC Nurses CAM TOTAL % 
ADR study 26 49 4 1 80 74.1 
Unknown 3 4 1 0 8 6.8 
Word of mouth 3 3 1 1 8 5.9 
TV 1 1 2 0 4 3.3 
Prev. call (new) 1 2 0 0 3 2.4 
Radio 1 0 0 0 1 0.9 
Other HP 0 1 0 0 1 0.9 
Qld Health 1 0 0 0 1 0.8 
Dr/Ph’cist 1 0 0 0 1 0.8 
Support Service 0 0 1 0 1 0.7 
TOTAL 37 60 9 2 108 100% 
 
8.5 HP Caller Profile 
 
8.5.1 Gender of HP  
Table 13 shows the gender distribution of HPs who called the ADR hotline. More 
female than male HPs participated in the study (1.8:1) as per Table 14, so it was not 
surprising that more female HPs called the ADR Hotline (1.6:1).  However, this 
gender imbalance was strongly influenced by the dominance of females in the nursing 
cohort. A sub-analysis of solely doctor and pharmacist participants however, still 
showed a bias towards female callers.  
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Table 13: Gender distribution of HPs 
Enrolled Calls  
Female Male Female Male 
Doctor 50 63 21 11 
Pharmacist 88 58 36 30 
Nurse/other 105 17 9 1 
TOTAL 243 138 66 42 
Ratio F: M 1.8:1 1.6:1 
 
 
8.5.2 Age of Caller HP 
Grouping caller age into decades showed that three quarters (74.1%) of service uptake 
was by HPs, with a mean age of 41.4 years. The prevalence of callers in this age range 
was reflected across professions. 
Table 14: Age of HP caller (by profession) 
Age (years) of 
HP caller 
Doctor PHC Nurse / 
 other 
TOTAL % 
21-30 yrs - 9 1 10   9.3 
31-40 yrs 18 30 2 50 46.3 
41-50 yrs 12 15 3 30 27.8 
51-60 yrs - 10 3 13 12.0 
61-70 yrs 1 2 1 4   3.7 
71-80 yrs 1 - - 1   0.9 
TOTAL (yrs) 32 66 10 108 100% 
Mean (+/- SD) 41.4 (+/- 10.1) years  
 
 
8.5.3 Call for self or other 
The majority (92.6%) of HP callers contacted the ADR Hotline on behalf of a client 
or patient. The remaining 8 calls (7.4%) were personal enquiries (Table 15).  
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Table 15: HP Call for Self or Other 
 No. of calls  
Call for Specialist GP PHC Nurse CAM TOTAL % 
Self 
 
- 2 3 2 1 8   7.4 
Client 
 
7 23 63 6 1 100 92.6 
TOTAL 7 32 66 8 2 108 100% 
 
8.6 Patient gender and age  
One hundred of the 108 calls from HPs were regarding a patient, in a gender ratio of 
2.5:1 female to male. Table 16 highlights a broad patient age distribution, with a trend 
towards patients in 40 years and older.  Only pharmacists reported ADRs in the age 
groups 0-20years of age. 
 
Table 16: Age of patient in HP call 
Age of 
patient 
(yrs)   
Specialist Doctor PHC Nurse/ 
other 
TOTAL % 
0-10 yrs - - 3 - 3 3 
11-20 yrs - - 2 - 2 2 
21-30 yrs 3 2 7 - 12 12 
31-40 yrs 2 5 5 1 13 13 
41-50 yrs - 8 8 - 16 16 
51-60 yrs 1 1 15 1 19 19 
61-70 yrs 1 6 8 2 17 17 
71-80 yrs - 1 11 - 12 12 
81-90 yrs - - 2 1 3 3 
Unknown - - 2 1 3 3 
TOTAL 7 23 63 6 100 100% 
 
 
8.7 Call classification and signal-to-noise ratio 
Table 17 outlines the frequency with which each of the four call types occurred. These 
types were further sub-classified by caller profession. Approximately one fifth of all 
calls from HPs related to enquiries of a general nature (12.1%) or to medication side 
89 
effects (7.4%) and did not involve an ADE. The remaining 87 calls (80.5%) consisted 
of ADRs not for ADRAC (32.4%) and ADRs for ADRAC (48.1%) respectively.  The 
majority (80%) of ADRs not for ADRAC came from pharmacists, and the main 
reason for this was insufficient information provided to meet minimum ADRAC 
reporting criteria.  
 
Given that the ADR Hotline submitted 52 reports to ADRAC from 108 calls, this 
represents a signal-to-noise ratio for the ADR hotline of approximately 1:1 or 1 in 2. 
Table 17: HP enquiry type 
 No. of calls to ADR Hotline 
Type of Call Specialist GP PHC Nurse CAM Total % 
 
General 
enquiry  
3 2 5 2 1 13 12.1 
Side effect 
enquiry 
- 3 3 2 - 8 7.4 
ADR - not for 
ADRAC 
2 5 28 - - 35 32.4 
ADR - for 
ADRAC 
2 15 30 4 1 52 48.1 
Total 
 
7 25 66 8 2 108 100% 
 
 
8.8 Primary complaint 
 
The symptom or adverse event prompting the HPs’ concern was documented as the 
primary complaint. Table 18 lists the primary complaints in all HP calls. Where HPs 
rang with a general or side effect question, “no complaint” was documented as the 
primary complaint.  These data suggest (and it was our observation during the study), 
that specialists and GP’s tended to report diagnoses more than symptoms whereas 
non-medical HPs (pharmacists and nurses) tended to report both symptoms more than 
diagnoses, as the primary complaint. 
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Table 18: Primary complaint in all calls 
Specialists Doctors Pharmacists Nurses/other 
Aplastic 
anaemia 
Malaena 
Myopathy 
Speech 
Disorder 
 
 
     
Agitation 
Alopecia 
Bleeding time incr’d
Face Oedema 
Fatigue 
Haemorrhoids 
Headache 
Hepatic Dysfunction 
Hypocalcaemia 
Hypotension 
Manic Reaction 
Menopausal 
Symptoms 
Mucosal Ulceration 
(2) 
Myopathy 
Nausea 
Oedema 
Rash Erythematous 
Urticaria 
Vascular Disorder 
 
Muscle Contractions 
Nausea 
Nystagmus 
Porphyria 
Rash (9) 
Saliva Altered 
Sexual Dysfunction  
Somnolence 
Tachycardia (2) 
Ther. Response incr’d 
(2) 
Ther. Response decr’d 
Tinnitus (2) 
Tremor 
Vomiting 
Xerophthalmia 
 
 
Bronchospasm 
Constipation 
Diarrhoea 
Gynaecomastia 
Ther.response decr’d 
Weight Increase 
 
 
 
 
8.9 ADRs for ADRAC  
The ADR Hotline submitted 52 reports to ADRAC, derived from 48.1% of the 108 
contacts from HPs, which represents a signal to noise ratio for the ADR hotline 
service is approximately 1:1 or 1 in 2. However, a further 52 reports were submitted 
to ADRAC by study participants independently, giving a total of 104 ADRAC reports 
submitted during the study, as outlined in Table 19.  As only limited details of the 
independently submitted reports were accessible by the candidate, and these reports 
were not submitted via the ADR hotline, only selected analyses of their content could 
be performed.  
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Table 19: Number of ADRAC reports submitted by each profession 
Profession  
 
Specialist
 
GP 
 
PHC 
 
Nurse
 
CMP
 
 
Hotline 
 
 
Non-
hotline  
 
TOTAL  
 
No. of 
ADRAC 
reports 
 
2 
 
 
15 
 
30 
 
 
4 
 
1 
 
 
52 
 
 
52 
 
 
104  
 
 
8.10 Drugs in HP ADRAC reports 
 
Calls from HPs related to a wide range of drugs (Appendix 19). In contrast the drugs 
frequently resulting in ADR report to ADRAC, across professions were buproprion, 
celecoxib, rofecoxib, tramadol, paroxetine and atorvastatin. The top ten drugs are 
listed in Table 20.  
 
Table 20: Top 10 Drugs in ADR’s to ADRAC 
Drug Name Specialist GP Pharmacist Nurse CAM 
Practitioner 
Number 
of Calls
Bupropion  1 6   7 
Celecoxib  1 4   5 
Rofecoxib 1  3   4 
Tramadol   1   3 
Atorvastatin  2 1   3 
Paroxetine   1   3 
Venlafaxine   2 1  2 
Zolpidem   1   2 
Alendronate   1   2 
Herbal  2    2 
 
 
8.11 Probability of the reported ADR  
 
The probability of the total 104 ADRs for ADRAC reports is detailed in Table 21, 
across professions. It should be noted that causality in the non-hotline ADRs was 
assigned by ADRAC itself.  Only a small number (5.8%) of ADRAC reports from 
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HPs could be classified as certain, and these were equally distributed across all 
professions. However 44.2% of the reports held a strong enough association with the 
event to be classified as probable. Almost 50% of all ADRAC reports, again equally 
distributed across HPs, could only be classified as possible.  
 
Table 21: ADR Probability – hotline and non-hotline ADRAC reports 
No. of ADRAC reports  
Specialist GP PHC Nurse CMP
 
Hotline 
ADRs 
Non-
hotline 
ADRs 
Total No. 
(%) ADRs 
Certain 1 1 1 0 - 3 6 9  
(8.6%) 
 
Probable 0 6 15 2 - 23 21 44  
(42.3%)  
 
Possible 1 8 14 2 1 26 25 51  
(49.1%)  
 
TOTAL 2 15 30 4 1 52 52 104 (100%) 
 
 
 
8.12 Novelty of ADRAC reports 
 
Table 22 shows that ADRs reported by HPs carried a moderate degree of novelty (i.e. 
not in PI, new drug, CAM or DOCI). Although 9.6% of the ADRs reported to the 
Hotline were based on symptoms documented in the PI greater than 5%, 19.2% of 
symptoms not mentioned in the PI, 13.5% were reports regarding new drugs and 
13.5% were associated with CAMs. These data suggest that novelty of the perceived 
adverse reaction was a strong motivator for reporting of the potential ADR.  
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Table 22: Novelty of ADRAC reports 
 No. of ADRAC reports 
Novelty  
 
Specialist GP PHC Nurse CMP No. of 
ADRAC 
reports 
% 
in PI > 5% 
 
-  2 2 1 - 5   9.6 
in PI < 5% 
 
1 5 14 2 1 23 44.2 
NOT in PI 
 
1 3 5 1 - 10 19.2 
CAM 
 
-  4 3   -  7 13.5 
NEW Drug 
 
-  1 6   -  7 13.5 
D.O.C.I. 
 
-  -  -  -  -  0 - 
TOTAL 2 15 30 4 1 52 100% 
 
 
8.13 Impact on QOL (n=52) 
 
Three-quarters (73.1%) of ADRC reports had a major or moderate impact on QOL, as 
defined in Appendix 5 (Table 23). 
 
Table 23: Impact of ADR on QOL 
 No. of ADRAC reports 
Impact of QOL Specialist GP PHC Nurse CMP No. of 
Calls 
% 
Major 1 3 9 - - 13 25.0 
Moderate 1 8 13 3 - 25 48.1 
Minor - 4 8 1 1 14 26.9 
TOTAL 2 15 30 4 1 52 100% 
 
 
8.14 ADR treatment intervention  
 
According to the study protocol, only the primary treatment intervention option could 
be documented for each ADR. Table 24 shows that a treatment intervention was 
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required for the majority (86.6%) of ADRAC report from HPs. These included a visit 
to hospital (19.2%) or to the doctor (69.3%). However, no ADRAC reports involving 
hospitalisation were received from specialist doctors, nurses or CAM practitioners. 
 
Table 24: ADR treatment intervention 
 No. of ADRAC reports 
Treatment Specialist GP PHC Nurse CMP  TOTAL % 
Hospital,  
life threatening 
- -  1 - -  1   1.9 
Hospital, not life 
threatening 
 - 3 6  - -  9 17.3 
Visit Doctor 2 11 18 4 1 36 69.3 
Visit Pharmacy  - -  5  - -  5   9.6 
Visit CAM practitioner  - -  -   - -  - - 
Self treatment  - -  -   - -  - - 
No treatment  - 1 -   - -  1   1.9 
TOTAL 2 15 30 4 1 52 100%
 
 
8.15 ADR Predictability- type A or B  
The category of predictability was included to determine whether HPs were more 
likely to report ADRs expected from the known pharmacology of the drug (type A) 
than those unrelated to the known pharmacology of the drug (type B). The data 
presented in Table 25 suggest that type B effects (e.g. atypical reactions or rashes) 
were slightly more likely than type A effects to be reported by HPs.  
 
Table 25: ADR Predictability 
 No of ADRC reports 
Predictability Specialist GP Ph’cist Nurse CAM No.  
of Calls 
% 
Type A 
 
1 6 12 2 -  21 41% 
Type B 
 
1 9 18 2 1 31 59% 
TOTAL 2 15 30 4 1 52 100% 
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8.16 Serious ADRs  
For the purpose of this analysis, the seriousness of an ADR was determined by the 
significance of the complaint and the level of medical intervention required to manage 
the complaint e.g. hospitalisation. ADRAC employs a slightly more broad definition 
of a “serious ADR”, which is described in Appendix 22. Table 26 outlines the 21 
serious ADRAC reports defined by either the candidate and/or ADRAC as serious. 
Only one of the serious ADRs was classified as certain, with six rated as probable. 
The remaining reports were rated as possible. In contrast, most of these potential 
ADRs were novel.  
 
Table 26: Serious ADRs to ADRAC reported by HPs  
Drug Complaint(s) Serious? + 
outcome 
Novelty ADRAC 
Causality
Alendronate/Celebrex 
 
Thrombocytopenia YES- 
Hospitalised 
<1% Possible 
Augmentin Duo Forte Elevated LFTs 
 
YES. Dr visit.  1-5% Probable 
Black cohosh/ 
Evening primrose oil 
Uterine haemorrhage YES: 
Hospitalised, 
hysteroscopy  
CAM Possible 
Carbimazole Myopathy/rhabdomyoly
sis with CPK elevation 
YES- drug 
ceased 
<1% Probable 
Celecoxib 
 
Gastric bleed and 
malaena 
YES. 
Endoscopy 
1-5% Probable 
Cephalexin Hepatitis (+intercurrent 
EBV infection) 
YES- 
hospitalised 
<1% Possible 
Cetirizine (Zyrtec) Headache, agitation, 
nightmares in 10 y.o. 
girl 
YES- child. 1% Probable 
Citalopram 
(Talohexal) 
Therapeutic inefficacy YES:  Doctor 
ceased drug 
In PI 
<1% 
Possible 
Diane 35 ED Vulval atrophy YES: DR. Rx 
testosterone 
Not in 
PI 
Possible 
Dicloxacillin 
 
Cholestatic hepatitis YES- visit 
DR. 
<1% Probable 
Fluvastatin  Syncope, asthenia, 
severe abdominal pain 
YES. 
Hospitalised. 
Not in 
PI 
Certain 
Interferon alpha2B & 
ribavirin (Rebetron 
Hypothyroidism YES. DR 
visits, Rx 
<1% Possible 
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Combination) thyroxine 
Metformin & 
Clomiphene 
 
Multiple foetal 
abnormalities 
YES, 
Pregnancy 
Termination 
Birth 
defect 
Possible 
Naltrexone (Revia) Erythema, pruritis, facial 
oedema, flushing, 
headache 
 
YES (patient 
was 
undergoing 
rapid opiate 
detox under 
GA).  
Not in 
PI 
Possible 
Omeprazole/ 
cisapride 
 
Chest pain. 
(Interaction?) 
YES- 
hospitalised. 
<1% Probable 
Rofecoxib 
 
Bilateral leg oedema YES- drug 
ceased` 
1-5% Possible 
Rofecoxib Severe bullous rash YES-RX 
prednisone 
<1% Possible 
Tramadol Seizures YES In PI Probable 
 
 
 
8.17 Results of interventions on ADR reporting 
Members of the four study groups submitted 104 reports to ADRAC during the study 
period. This compares with 43 reports submitted by participating HPs prior to the 
study. Statistical comparisons are provided in Tables 27 and 28 respectively. 
 
 
8.17.1 Comparison of each group before and after intervention 
Table 27 shows the ADR reporting rates by HPS in each intervention group, prior to 
the study (PRE-STUDY) and during the study (STUDY).  The increase in reporting 
frequency was statistically significant for Group 1 and Group 2 (p<0.05), however, 
the results from Group 3 (hotline plus workshop), failed to reach statistical 
significance.   
 
Review of the raw data highlighted that a single health professional (a general 
practitioner) in Group 3 had submitted eleven reports to ADRAC (out of a total of 20 
97 
reports for his group) in the period prior to the study but only 7 (out of 38) during the 
study. It was felt that this HPs disproportionate contribution to ADR reporting in both 
reporting period was misrepresenting the result for the 103 HPs in his group. 
Therefore, the paired t-test was recalculated removing this outlier, and the final results 
were statistically significant at p<0.026, showing that in fact the remainder of Group 
3’s ADR reporting did increase over the study period. 
 
Therefore, the statistically significant increase in ADR reporting from baseline, 
demonstrated by each group, proved the first three of the four null hypotheses 
originally proposed in section 6.2. Importantly, the frequency of ADR reporting for 
the control group did not change significantly over the study period. 
 
Table 27: ADR reporting in each HP group, prior to and during the study 
No. of ADRAC reports Group No. in 
Group PRE-
STUDY 
STUDY 
Significance* 
 
Group 1:  
Hotline 
91 9 38 p < 0.001 
 
Group 2: 
Workshop 
89 3 14 p <0.02 
 
Group 3 
Hotline & 
Workshop 
 
Without 
outlier # 
 
103 
 
 
 
102 
20 
 
 
 
9 
38 
 
 
 
31 
p < 0.1 
 
 
 
p <0.026 
 
Controls 98 11 8 NS 
 
Not in study 
 
- - 5  N/A 
TOTAL 
 
381 43 104 - 
* Paired t-test (2 tailed) 
# Outlier was one GP participant who reported submitted made a disproportionately 
large number of ADR reports compared with other participants. 
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8.17.2 Comparison of each group with controls 
Table 28 compares ADR reporting by each intervention group with the control group, 
and demonstrates that all three interventions produced a statistically significant 
increase in the frequency of ADR reporting (p<0.05) compared with controls, which 
proves the fourth null hypothesis proposed in section 6.2. 
 
Table 28: ADR reporting by each group compared with control group 
Groups  Number 
in Group  
ADRAC reports 
during study 
Significance* 
 
91 
 
38 Group 1 (Hotline) 
versus 
Group 4 (Control) 98 
 
8 
p < 0.02 
 
89 
 
14 Group 2 (W’shop) 
versus 
Group 4 (Control) 98 
 
8 
p < 0.05 
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38 Group 3 (Hotline 
plus Workshop) 
versus 
Group 4 (Control) 
98 8 
p < 0.01 
 
*Unpaired t test (2 tailed) 
 
8.17.3 Quality of ADR reporting. 
An audit of the HP reports submitted to ADRAC confirmed that: 
 100% of the reports submitted via the ADR hotline to ADRAC met minimum 
ADRAC criteria; 
 Reporting by the Hotline and individual health professionals occurred consistently 
over the 22-month study period, not clustered early in the intervention;  
 Drugs involved in submitted ADRAC reports were from a broad range of 
therapeutic groups including over-the-counter and complementary medicines. 
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9. Discussion 
9.1 Introduction 
Under-reporting of ADRs by HPs is a widespread problem that limits the 
effectiveness of post-marketing pharmacovigilance. HPs have complained that poor 
availability of reporting forms, limited time and lack of ADR education prevents them 
from reporting. This study was designed to offer access to education and /or to a 
telephone helpline service for reporting ADRs to investigate whether such 
interventions overcome these obstacles and improve ADR reporting by HPs. In 
addition, a broad range of HPs was invited to participate in the study to explore 
contribution to pharmacovigilance made by non-medical HPs and whether this could 
partly address the problem of under-reporting. In the following chapter, a discussion 
of the HP ADR reporting project results will be presented. 
 
9.2 Recruitment and study design 
Recruitment of HPs into this study proved to be a difficult and time-consuming task, 
largely due to resistance from medical practitioners, who claimed a range of business 
and time and enthusiasm barriers to involvement. Interestingly, these barriers largely 
parallelled the reasons given by doctors in the literature for not reporting of ADRs 
(44), so perhaps the candidate should have anticipated this resistance. 
 
In contrast, it took less time to recruit pharmacists, nurses and dentists who were more 
willing and enthusiastic to participate in the study. This response is consistent with 
other ADR reporting studies, especially in countries where pharmacists and nurses are 
not traditionally invited to report ADRs. (52, 71, 75) 
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It was disappointing that only two CAM practitioners were willing to enrol in this 
study, and somewhat alarming that their employer’s legal counsel was of the opinion 
that ADRs were the domain of their QA department rather than a public health issue.  
 
A possible limitation of these study results could be that the recruitment strategy used 
to enlist HPs may have been prone to a self-selection bias. As HPs essentially 
volunteered to participate after attending an education event or receiving a letter, 
those sufficiently motivated to participate were also likely to be those more motivated 
to report ADRs. However, given that this self-selection method was used for all four 
arms of the study, it can be assumed that whatever self-selection bias existed would 
have been equally distributed in all four arms, and thus should not have prejudiced the 
results.  
 
 
9.3 Demographics  
 
The ADR hotline was popular with pharmacists (61.1%) and doctors (29%), mostly 
located in Southeast Queensland and calling on behalf of clients. The majority of HPs 
using the hotline were female and aged in their 30’s and 40’s which is consistent with 
the gender and age profile of callers to both consumer-oriented and HP helplines in 
other studies (125, 133) (134-137) This gender bias is also consistent with females as 
primary carers, as females seek health information more frequently than males on 
behalf of significant others (i.e. family and friends)(138, 139).   
 
9.4 Responses by different professions  
Over the two-year study period, 103 calls were received on the ADR hotline, 
including 10 from non-participating HPs.  Although the professions of medicine, 
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pharmacy and nursing were equally represented in the study,  two-thirds (61%) of 
calls were made by pharmacists, and one third (29.6%) by doctors (GPs and 
specialists combined).  The majority of calls resulted in ADRs for ADRAC, submitted 
mostly by pharmacists (57%), followed by GPs. (29%), which is in contrast to 
ADRAC data that states 30% of ADR reports are submitted by pharmacists and the 
remainder by physicians. (30, 120, 140) 
  
The reluctance by nurses to use the ADR hotline service (only 7.4% of calls) is in 
contrast to attitudes stated in the literature by nurses wishing to participate in ADR 
reporting. (27, 51, 98, 99) This hesitation could be similar to that reported by 
Backstrom et al (75) in their study of hospital-based nurses reporting ADRs.  A total 
of 22 ADR reports were submitted after the 18-month trial period. Although all 117 
nurses recruited into the study were allowed to report ADRs, only the 10 nurses who 
had attended education sessions did so.  Surveyed after the study, 46% of the nurses 
stated that they were loathe to report ADRs if they were unsure whether the observed 
symptoms were due to an ADR, and 50% stated they had difficulty reporting ADRs 
based on suspicion alone.  
 
More importantly, the education offered to the nurses in Backstrom’s study consisted 
of 24 comprehensive lectures over a 12-month period, about drugs and ADRs, ADR 
reporting and special aspects of ADRs in the elderly. In contrast, in our study the 
education offered to nurses was one lecture only, with follow-up information and 
support only offered to nurses in the ADR hotline groups (1 and 3). These details 
suggest that only a small percentage of nurses or those who have received intensive 
education are likely to contribute to ADR reporting. Of course, this does not detract 
from the stated benefits of a multidisciplinary approach to ADR reporting. (97) (96) 
103 
However, it does suggest that different professions require varying levels of coaching 
and support for ADR reporting, an issue has not been extensively examined in the 
literature. 
 
9.5 Call duration  
The average duration of calls from HPs was 21.3 minutes, but varied from 12.2 to 
37.1 minutes, depending on the question type and profession of the caller. General 
and non-ADR side effect enquiries were shorter than those involving ADRs, probably 
because less background information and clinical detail would have been required.  
We found that calls with GPs were relatively short (average 15.1minutes) because 
GPs were already somewhat familiar with ADR reporting, usually pressed for time 
and frequently came to the phone with the necessary details ready.  
 
On the other hand, we found ADRs reported by nurses and pharmacists took longer on 
the phone because considerable time was spent clarifying the clinical picture. Indeed, 
many of the “ADRs not for ADRAC” failed reporting criteria because many of the 
pharmacists who called did not have the necessary clinical information at the ready.  
 
Calls from medical specialists and CMPs were lengthy (26.8 and 37 minutes in 
duration, respectively) and both professions required some coaching regarding the 
details required. Clearly, the low number of calls limits the generalisability of these 
results, as only seven calls were received from these two professions combined. 
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9.6 Call type  
Even though half  (48.1%) of all calls resulted in an ADR for ADRAC, essentially one 
in five calls involved a general or side effect enquiry, where no ADR had occurred. 
This is an important finding as it highlights that HPs have an expressed need for drug 
information and support in addition to ADR reporting services. Perhaps this explains 
why some RMCs for pharmacovigilance in countries such as the UK and Canada have 
evolved out of hospital- or university-based based drug information services. (32) 
 
9.7 Quality and breadth of ADR Reporting to ADRAC 
The project team’s ability to assess the quality of all ADR reports was limited by the 
fact that 52 (50%) of the HP ADR reports were submitted to ADRAC independently 
of ADR hotline. In doing so, some of the ADR quality indices could not be obtained. 
 
 
9.7.1 Main symptom 
A diverse range of complaints from aplastic anaemia and sexual dysfunction to 
vomiting and saliva alteration were involved in HP calls. In general, specialists and 
GP’s more frequently reported complaints that would indicate the patient’s diagnosis 
than did non-medical professionals.  The fact that some reporters can only identify 
symptoms rather than the diagnosis is a complexity of ADR reporting that should not 
be overlooked. It can potentially diminish the value of an ADR as without a diagnosis, 
the full clinical picture cannot be appreciated and the evidence of drug-induced 
pathology cannot be consulted. But it also highlights the potential value of a learned 
intermediary via a telephone helpline, whose can assist in converting the perceived 
clinical symptoms into a potential diagnosis, and argues for the inclusion of a medical 
professional in the helpline team.  
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9.7.2 Drugs involved  
A broad range of medicines were involved in HP reports to ADRAC, but there was a 
clear trend for reports to involve recently marketed drugs (celecoxib, rofecoxib, 
tramadol, bupropion), drugs in the media (bupropion, celecoxib) or those subject to 
adverse reaction warnings during 2001-2002. (141) This finding is consistent with 
other studies wherein HPs have been motivated to report reactions to new drugs or 
those popular in the media. (51, 58, 72, 73, 125) Indeed, ADRAC has reported that 
ADR reporting by HPs increases exponentially whenever there’s a drug scare in the 
media.  
 
 
9.7.3 Probability (possible, probable, certain) 
The majority of reactions reported by HPs to ADRAC were possible (49.1%) or 
probable (42.3%) respectively. Only three of the 52 reports submitted via the helpline 
were certain, and a specialist, a GP and a pharmacist submitted these. This is 
consistent with the literature that says that ADRs reported to regulatory agencies are 
mostly possible or probable and rarely certain. (29, 31) Pharmacovigilance agencies 
support this approach, as they prefer HPs to register their medication safety concerns 
by reporting suspicions rather than waiting to be certain, and perhaps never submitting 
the report. (142) 
 
 
9.7.4 Novelty of the reaction 
 
In our study, novelty of the perceived ADR was a strong motivator for HPs to report. 
Approximately 90% of the ADRs reported (via the hotline) were infrequently or not 
mentioned in the PI, involved an ADRAC DOCI, a new drug or CAM. This agrees 
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with Biriell’s (72) findings that the three top reasons given by HPs for reporting 
ADRs were to contribute (new data) to medical knowledge; to report reactions 
previously unknown to the reporter; and to report reactions to new drugs. In addition, 
Boyd (34) has stated that HPs are sometimes in doubt as to what should be reported. 
ADRAC attempts to provide some direction with a list entitled “ What to Report” on 
the back page of every ADRAC bulletin, and this list in some respects prompts 
reporting of reactions to new drugs and DOCIs, by listing out the individual drug 
names. 
 
 
9.7.5 Impact on QOL 
 
This parameter is not often considered in the ADR literature, but the QOL impact of 
ADRs is important to consider so that the reaction’s seriousness is judged from the 
patient’s perspective. (143) Medical seriousness loses its relevance if the patient feels 
that the ADR is sufficiently disturbing to warrant discontinuation of the medication. 
For example, a drug-induced taste disturbance may not be medically serious but may 
make the patient miserable and prompt medication non-compliance.  
 
In our study ADR reports with a major or moderate impact on QOL comprised 73.1% 
of those submitted to ADRAC. It is encouraging that QOL impact was considered to 
this extent, even though almost half of the ADRs were classified as only possible 
(49.1%) rather than probable or certain. This potentially represents an important trend 
towards “patient-centred care” as it suggests that HPs in the study were vigilant to 
report patient complaints that impacted negatively on patients’ lives, even though the 
causal link with their medication was uncertain.  
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9.7.6 Intervention required 
 
Treatment intervention was required for the majority (88.5%) of all ADRs reported 
submitted via the HP hotline. Almost one in five (19.2%) were ADRs that involved 
hospitalisation. These data suggest that the  “visit to the hospital/ doctor” was an 
indicator to HPs either of the validity or the seriousness of the ADR , both of which 
would encourage reporting. However, some studies suggest that HPs are simply made 
more aware of an ADR when the outcome has involved hospitalisation, doctor 
consultation or medication change. (94)  
 
 
9.7.7 Predictability -TYPE A/B  
 
Type B reactions (59%) were slightly more likely to be reported than type A reactions 
(41%). This is not a surprising result given that, during the study, HPs often stated 
that they are not inclined to report well-known, type A side effects e.g. ACE inhibitor-
induced cough and our results have shown a tendency for HPs to focus on new and 
novel reactions, which are likely to be categorised as Type B. This is in contrast 
however, to some studies where HPs have been educated to report more Type A 
reactions related the pharmacology of the drug, in order to train them away from 
reporting more easily identified allergic, type B reactions.(86) 
 
It is reassuring, however, that the data also suggests that triaging pharmacists 
remained open-minded and did not shy away from reporting type B effects, as our 
study protocol gave them the power not to report ADRs they judged unlikely, which 
would more likely be type B reactions. It should be noted that the high number of 
“rashes” (x9) reported by pharmacists inflates the type B data somewhat.  
108 
 
 
9.7.8 Seriousness of ADRAC reports 
 
HPs claim there is a strong correlation between the seriousness of an ADR and the 
chance of it being reported by HPs. (46, 57) (144) However, only eighteen (17.3%) of 
the 104 ADRs reported by HPs in the study were classified as serious. This can partly 
be explained by the fact that 60% of the ADRs reported via the hotline were from 
community pharmacists and, in attitudinal surveys, this profession has claimed that 
they are generally not involved in or able to witness serious ADRs. (145) In contrast, 
hospital based pharmacists (who were not included in our study) are often the 
designated officer responsible for reporting serious ADRs in a hospital setting. (144) 
The serious ADRs reported in our study are valuable and clearly important to be 
captured, but our results suggest gross under-reporting of serious ADRs in our 
community and this is supported by the literature. (45, 46, 48, 53, 146, 147) 
 
9.8 Frequency of ADR reporting  
 
ADR reporting increased by a factor of four in each of the three HP groups as a result 
of the study interventions. These results were significant (p<0.05) both in terms of 
increasing from baseline within each group, as well as increasing greater than 
members of the control group. Although the absolute numbers of ADRAC reports are 
small (less than 40 reports per group over a two year period), the differences in ADR 
reporting from before and after the intervention were statistically significant (p<0.05). 
Therefore education and access to a reporting helpline can be viewed as effective 
strategies for improving ADR reporting by HPs. In terms of the educational 
intervention, this is consistent with the literature, as education in various forms has 
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been shown to be an effective strategy for improving ADR reporting (85, 116) (51, 
86) However, our study is likely to be the first published study to demonstrate that a 
pharmacist-operated, ADR reporting helpline is also an effective strategy for 
increasing HP reporting.  
 
The fact that we did not acknowledge the receipt of ADR reports from HPs with thank 
you notes or feedback letters is an important limitation of our study results. In 
retrospect, this oversight would have reduced ADR reporting by busy HPs, who have 
adequately expressed in the literature that feedback and correspondence from central 
agency is a strong motivator for further ADR reporting (29, 58, 142, 145). Many 
similar studies have successfully communication tools to encourage ADR 
reporting.(79, 94, 116) 
 
Another limitation of this study is that the long-term impact of the reporting 
interventions study is likely to return to zero without repetition. Feedback from 
ADRAC however, stated that ADR reports from HPs in our study (either by the 
Hotline or individual practitioners) were submitted regularly throughout the two years 
of the study, implying that interventional effect on behaviour was sustained for at 
least the study period of 1-2 years. However, the literature suggests that the effect of 
most interventions on ADR reporting wears off over time and therefore ADR 
reporting needs to be prompted by repeated reminders over time (76) (148) 
 
9.9 Conclusion 
In the short term, access to the ADR Reporting hotline increase the frequency, breadth 
and quality of post-marketing reporting to ADRAC by HPs and acted as a conduit for 
the longer term strategies.  
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10. Consumer study: results 
10.1 Number of calls and mode of contact 
In the 22 months of the study the SER Line received 972 calls from consumers. 
Following is a breakdown of the results of these calls. The telephone proved to be the 
most popular mode of contact. (Table 29) 
 
Table 29:  Number of calls and mode of contacts 
Mode of contact No. of calls Percentage 
 
Telephone 969 99.7 
Fax  0 - 
Email 0 - 
Mail 3 0.3 
TOTAL 972 100% 
 
 
10.2 Call duration 
Calls from consumers took an average of 24.3 minutes (+/- 13.5 min). As expected, 
general and side effect enquiries were of shorter duration than calls relating to ADRs, 
whether reported to ADRAC or not, as outlined in table 30. Calls resulting in a report 
to ADRAC took the longest (average 26.7 minutes), as more background information 
was required from the caller, including:  
 
 a full list of the medications taken by the consumer, their dose and duration, both 
prescribed and self-medicated;  
 a comprehensive description of the adverse symptoms being experienced; and  
 the temporal relationship between the medication and the adverse event. 
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Table 30: Average call duration 
Call type % of all calls Average call duration (mins) 
 
General enquiry  12.4 % 18.8 
Side effect enquiry 18.0 % 19.2 
ADR - not for ADRAC 35.1 24.0 
ADR - for ADRAC 336 29.4 
 972 Mean (SD) = 24.3  (+/- 13.5) mins 
 
 
10.3 Caller Location 
SER Line callers were located by their postcode, which have been collated into the 34 
Queensland Health Districts. Calls from outside Queensland were described by state 
(Table 31). The majority (82.8%) of calls emanated from southeast Queensland, 
which parallelled the geographical reach of SER Line marketing.   
 
 
10.4 Source of SER Line number  
Electronic media (radio and television) were the primary sources for the SER Line 
number in 48.5% of cases. The Queensland Medication Helpline, a companion drug 
information service run by Mater Pharmacy Service, referred 12.1% of calls. Previous 
callers and word of mouth constituted 11% and 9.4% of calls respectively. Health 
professionals infrequently referred callers to the SER line (Table 32).  
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Table 31: Caller location by postcode 
Caller location (by postcode) No. of calls Percentage 
(%) 
Prince Charles Hospital & District 248 26.0 
Queen Elizabeth II Hospital & District 149 15.6 
Bayside 82 8.6 
Sunshine Coast 81 8.5 
Gold Coast 76 8.0 
Logan-Beaudesert 61 6.5 
Redcliffe-Caboolture 55 5.8 
West Moreton 36 3.8 
New South Wales 27 2.8 
Mackay 21 2.3 
Toowoomba 17 1.8 
Bundaberg 17 1.8 
Fraser Coast 17 1.8 
Gympie 10 1.0 
Victoria 10 1.0 
South Burnett 8 0.8 
Townsville 7 0.7 
Southern Downs 5 0.5 
Gladstone 4 0.4 
Roma 4 0.4 
Cairns 3 0.3 
Northern Downs 3 0.3 
Rockhampton 3 0.3 
Tablelands 3 0.3 
Mt Isa 2 0.2 
Innisfail 1 0.1 
Central West 2 0.1 
South Australia 1 0.1 
Tasmania 1 0.1 
Western Australia 1 0.1 
Banana 0 0.0 
TOTAL 954 100% 
 
 
 
 
 
 
82.8%
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Table 32: Source of SER Line telephone number 
Source of SER Line Number Number of calls Percentage 
(%) 
Television 308 31.7 
Radio 163 16.8 
Queensland Medication Helpline 118 12.1 
Previous caller 107 11.0 
Word of Mouth 91 9.4 
Print media 72 7.4 
Support Service 57 5.9 
Lecture 25 2.6 
Doctor/Pharmacist 17 1.7 
Other HP 9 0.9 
Queensland Health 3 0.3 
Telstra 2 0.2 
TOTAL 972 100% 
 
10.5 Gender and Age of Caller 
SER Line callers were predominantly female. More specifically, the ratio of female to 
male callers was approximately 4:1 (Table 33).  
Table 33: Gender of caller 
Caller Gender Number of Calls Percentage 
(%) 
Ratio 
 
Female 773 79.5 
Male 199 20.5 
4:1 
TOTAL 972 100%  
 
 
Grouping caller age into decades demonstrates that service uptake was generally by 
adults in their middle to later years, peaking at 61-70 years (Figure 3). Almost half the 
users (49.4%) were between the ages of 51 and 70 years, and 72.9% were aged 51 
years or more. Average age was 59 +/- 12.02 years. 
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Figure 4.  Range of caller age (yrs) 
 
10.6 Call for self or ‘other’ 
In 15.4 % of calls, the enquiry was made on behalf of someone other than the caller. 
In other words, the caller was not the medication-user (Table 34). The patient’s 
relationship to the caller in these situations was as partner (44%), child (27.3%), 
parent (14%), family member (7.3%), friend (5.3%) or client (1.3%). Two 
complementary medicine practitioners made calls to this consumer-oriented service 
for their clients.  
 
Table 34: Calls for significant others 
Patient’s relationship to caller 
 
No. of calls 
 
Percentage of calls 
(%) 
Spouse 66 44.0 
Child 41 27.3 
Parent 21 14.0 
Other family member 11  7.3 
Friend 9  5.3 
Client/patient 2   1.3 
TOTAL 150 100%  
(=15.4% of total calls)  
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10.7 Gender and age of patient  
In the calls where the patient was a “significant other”, the gender ratio was virtually 
1:1. (Table 35) 
 
Table 35: Patient gender 
Patient Gender Number of Calls Percentage 
(%) 
Ratio 
 
Female 77 51.3 1.05 
Male 73 48.7 1 
TOTAL 150 100%  
 
 
Table 36 shows that patient age varied from the very young to the very old. The two 
peaks in this age range were 0-20yrs and the later years 61-80 yrs. One-fifth of these 
calls (30 calls) were regarding a person 20 years or younger, usually a child whose 
parent was concerned about their medication. The high percentage of calls regarding 
persons aged 61-80 years corresponded with high medicine use in the community at 
this age group.  
Table 36: Age of patient 
Age of patient No. of calls Percentage 
(%) 
0-10 17 11.3 
11-20 13 8.7 
21-30 9 6.0 
31-40 11 7.3 
41-50 8 5.3 
51-60 11 7.3 
61-70 30 20.0 
71-80 34 22.7 
81-90 16 10.7 
91-100 1 0.7 
TOTAL 150 100% 
 Average age = 52.2 +/- 27.36 
 
20% 
42.7% 
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10.8 Enquiry Type 
10.8.1 Adverse Drug Event classification of enquiries 
Streamlining of SER Line calls was achieved by determining whether each call 
related to an actual adverse drug event (ADE) or not, as per the ADE decision matrix. 
(Table 37) These data show that approximately one third of consumers’ calls (31.7%) 
did not relate to an ADE.  Either the consumer knew that already (No ADE/ No ADE) 
or the helpline pharmacist explained to the consumer that their perception was 
different, and why an ADE was unlikely to be the cause of their worrying symptom 
(ADE/ No ADE). The 8.9% of the latter type represents the frequency of consumers’ 
opinion of an ADE differing from “expert opinion”. Conversely, the reliability of 
consumers’ attribution of adverse events as being medication-related was correct in 
91.1% (22.8% + 68.3%) of cases. 
Table 37: Collaborative ADE (potential ADR) decision matrix 
Consumer 
perception 
SER line 
perception 
No. of calls 
(%) 
Possible 
outcome 
Decision 
No ADE No ADE 222  
(22.8%) 
No ADE 
(222) 
ADE No ADE 86  
(8.9%) 
No ADE 
(308)  
31.7% 
No ADE ADE 
 
0  
 
ADE ADE 664 
 (68.3%) 
 
 
Possible 
ADEs 
(750) 
ADEs 
(664) 
68.3% 
 
TOTAL  972 972 972 
 
 
10.8.2 Call classification and signal to noise ratio 
Table 38 shows that approximately one third of calls were general and side effect 
enquiries (represented largely by non-ADE calls) while ADRs not for- and for-
ADRAC were the remaining two thirds of calls (largely representing ADEs).  
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Drug interactions were the suspected mechanism of 64 potential ADRs, 51 of which 
were reported to ADRAC. The total number of consumer ADR reports submitted to 
ADRAC during the study period was 336. This number expressed as a fraction of the 
total number of calls received from consumers represents the signal to noise ratio 
(SNR). The SNR for CAR was 34.5%, 1: 2.  In other words, for every three consumer 
calls, one resulted in an ADRAC report.  
 
Table 38: Call classification 
Type of Call 
 
No. of calls Percentage 
(%) 
Overall Signal-to-
noise ratio 
General enquiry  
 
121 12.4 - 
Side effect enquiry 
 
174 17.9 
30.3% 
- 
ADR - not for ADRAC 
 
341 35.1 - 
ADR - for ADRAC 336 34.6 
69.7% 
1:2 or 
1 in 3 
TOTAL 972 100%   
 
 
10.8.3 Potential ADRs  
According to the SER Line protocol, once a suspected ADR was identified, it was 
further subdivided into three possible types: ADR only, drug interaction or birth 
defect. As more than one ADR could be reported in a call (e.g. an ADR and a drug 
interaction could BOTH be reported) the number of ADRs reported exceeded the total 
number of calls. Thus 677 potential ADRs were recorded from the total of 664 calls, 
90.5% of which were assessed as an ADR only and 9.5% involving a potential drug 
interaction. No ADRs causing birth defects were reported during the study. 
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Table 39: ADR type 
ADR type No. of calls 
  
Percentage 
(%) 
ADR only 613 90.5 
ADR = drug interaction 64  9.5 
ADR = birth defect 0 0 
TOTAL potential ADRs 677 100% 
 
 
10.8.4  Primary complaint 
In each call, a “primary complaint” was documented as the main symptom or adverse 
event causing the caller’s concern. Where consumers rang with a general or side 
effect question, the primary complaint was recorded as “no complaint”. Table 40 lists 
the primary complaints involved in four or more calls, regardless of whether the calls 
resulted in an ADRAC report or not. Most of these complaints were symptoms rather 
than diagnoses. In addition, based on the definition of a serious reaction, these 
symptoms tended to be less serious.  
 
Table 40: Primary complaint in 4 or more calls 
Primary Complaint 
(>/= 4 calls) 
No. of Calls 
Weight Increase 20 
Rash 15 
Nausea 11 
Taste Perversion 9 
Diarrhoea 8 
Vomiting 8 
Depression 8 
Insomnia 7 
Sexual Function Abnormal 6 
Convulsions 6 
Myalgia 6 
Pruritus 6 
Constipation 5 
Fatigue 5 
Menstrual Bleeding 5 
Withdrawal Symptoms 5 
Headache 4 
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Aggressive Reaction 4 
Amnesia 4 
Coughing 4 
Leg Cramps  4 
Dizziness 4 
Drug Level Decreased 4 
Flushing 4 
Photo-sensitivity Reaction 4 
 
 
10.8.5 Drugs in each call type 
Table 41 highlights the drugs mentioned most frequently by call type. Bupropion, 
celecoxib, rofecoxib, sertraline and tramadol were the top five drugs that generated 
consumer ADRAC reports. Four of these five drugs are also the main drugs in all SER 
line enquiries. 
 
Table 41: Frequent drugs in CONSUMER calls (rank order) 
No. of calls  
 
Main drug in consumer calls 
General & 
side effect 
enquiries  
 
ADR- not 
for 
ADRAC 
ADR for 
ADRAC 
All SER 
Line  
enquiries  
 (Rank) 
Bupropion* 8 12 34 54 
Celecoxib* 17 11 17 45 
Rofecoxib* 13 9 11 33 
Irbesartan 9 6 5 20 
Sertraline 4 4 11 19 
Atorvastatin 4 6 7 17 
Herbal (misc) 3 7 4 14 
Alendronate 6 5 6 15 
Paroxetine 2 4 8 14 
Tramadol* 1 1 11 13 
Prednisone/olone 4 7 1 12 
Venlafaxine 2 5 5 12 
Oestradiol/iol/conjug.oestrogens 5 2 5 12 
Zolpidem* 3 1 7 11 
Warfarin 2 7 2 11 
Telmisartan 3 5 3 11 
Omeprazole 2 4 4 10 
Atenolol  2 6 2 10 
Fluoxetine 1 5 3 9 
Olanzapine 1 5 2 8 
Diltiazem 1 6 1 8 
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Cephalexin  3 1 4 8 
Amitriptyline 6 2 - 8 
Tibolone* - - 7 7 
Thyroxine 3 2 2 7 
St John’s Wort 2 1 4 7 
Mirtazapine 2 - 5 7 
Glucosamine 3 2 2 7 
OCP/ ethinyloestradiol 1 3 3 7 
Alprazolam 3 - 4 7 
Cerivastatin 0 1 3 4 
* New drugs during 2001-2 
 
Herbals, prednisone, oestrogens, diltiazem and warfarin were drugs that generated 
high call frequency, but few ADRAC reports. Indeed out of 12 calls regarding 
prednisone/olone, only one valid ADRAC report was generated. Only two ADRAC 
reports resulted from the 11 calls about warfarin. Typical comments made by anxious 
consumers about such drugs on the SER Line have included:  
“……I’ve been feeling funny lately and it must be due to the warfarin because my 
friends all say it’s related to rat poison.” 
……Prednisone must be dangerous for me because it’s a steroid, and they are 
banned in athletes”. 
 
The drug which generated most calls on the SER Line was Buproprion (Zyban®), 
which generated a total of 54 calls from consumers, 34 of which resulted in ADRs for 
ADRAC, 12 were ADRs not for ADRAC, and 8 were side effect or general enquiries.  
 
Zyban® was marketed for the first time in Australia in early 2001 and enjoyed a high 
level of community awareness as it was frequently portrayed in the media as an 
“easy” method for smoking cessation. When reports began to emerge associating 
Zyban ® with serious, unexpected adverse reactions including death, the SER Line 
was inundated with calls from consumers wishing to either enquire about the safety of 
Zyban or to report their own adverse events. The QUIT Line, a national telephone 
helpline for quitting smoking, referred many of these calls. Staff of the SER line had 
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to keep abreast of the rapidly changing evidence on morbidity and mortality of 
buproprion that was appearing daily in the media as well as the medical press. 
 
Celecoxib (Celebrex®), Rofecoxib (Vioxx ®), Tramadol (Tramal ®), Tibolone 
(Livial®) and Zolpidem (Stilnox®) were also newly marketed in Australia during the 
study period, and ranked highly in all three types of calls on the SER Line both in 
terms of general questions as well as generating ADRAC reports.  
 
Cerivastatin (LipoBay ®) was withdrawn from the Australian market during the study 
period (August 2001) due to the high risk of myopathy, rhabdomyolysis and renal 
failure associated with the use of this HMGCo-A reductase inhibitor, especially in 
combination with gemfibrozil. Cerivastatin was the subject of only four calls during 
the project, however one of those calls was quite significant. (Table 42) 
 
Table 42: Cerivastatin case study 
Case study: Mr AW 61 years old. 
Four months prior to the world-wide withdrawal of cerivastatin, the SER line received 
a call (#437) from the wife of Mr AW, a 61 year-old gentleman who had had just been 
admitted to a private hospital in acute renal failure and put on dialysis. She said he 
experienced the rapid onset of “ all over muscle pain, nausea and vomiting” a few 
days after the dose of his cerivastatin was increased from 0.4mg to 0.8mg. The patient 
was also taking gemfibrozil, as well as a range of medicines for type I diabetes, all in 
high doses. She stated that the medical team, which included an endocrinologist, renal 
physician and haematologist, blamed the episode on Mr AW’s worsening diabetes, 
however she and her husband felt strongly that the medication was the cause. 
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Amongst many interventions, the cerivastatin and gemfibrozil were both ceased in 
hospital, and the patient recovered and was discharged within 10 days. The wife was 
able to obtain pathology reports that included a statement that rhabdomyolysis was the 
mechanism for the renal failure. Once sufficient details were obtained, the SER Line 
submitted an ADRAC report about this case. When the Lipobay ® withdrawal was 
later announced, the SER Line was pleased to have contributed one of the eighteen 
reports that ADRAC quoted as having on record associating rhabdomyolysis with 
cerivastatin  +/- gemfibrozil. 
 
 
10.8.6 Signal-to-noise ratio for specific drugs 
In table 43 the SNR for specific drug is for a range of drugs frequently cited in SER 
Line calls, to determine whether individual drugs were associated with a certain level 
of SNR. Results range from 1:1 (high SNR) to 1: 12 (low SNR). These data suggest 
that tibolone, tramadol, bupropion and a range of drugs used in psychiatry including 
St Johns Wort, yielded a high SNR less than or equal to than 1:2. In contrast, drugs 
such as the corticosteroids, antibiotics and antihypertensives generated low SNRs.   
 
Table 43: Signal-to-noise ratio’ for specific drugs 
Main drug Total no. 
consumer calls 
No ADR’s 
reported  
to ADRAC 
Signal to noise ratio 
(No. reports / No. 
calls) 
Tibolone* 7 7 1 / 1.0 
Tramadol* 13 11 1 / 1.2 
Mirtazapine 7 5 1 / 1.4 
Bupropion* 54 34 1 / 1.6 
Zolpidem* 11 7 1 / 1.6 
Sertraline 19 11 1 / 1.7 
Alprazolam 7 4   1 / 1.75 
Paroxetine 14 8   1 / 1.75 
St John’s Wort 7 4   1 / 1.75 
Contraception, oral 7 3 1 / 2.3 
Oestradiol/oestrogens 12 5 1 / 2.4 
Atorvastatin 17 7 1 / 2.4 
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Venlafaxine 12 5 1 / 2.4 
Alendronate 15 6  1 / 2.5 
Omeprazole 10 4 1 / 2.5 
Celecoxib 45 17 1 / 2.6 
Fluoxetine 9 3 1/ 3.0 
Rofecoxib 33 11  1 / 3.0 
Herbal Misc,. 14 4 1 / 3.5 
Thyroxine 7 2 1 / 3.5 
Glucosamine 7 2 1 / 3.5 
Telmisartan 11 3 1 / 3.6 
Warfarin 11 2 1 / 5.5 
Olanzapine 8 2 1 / 4.0 
Irbesartan 20 5 1 / 4.0 
Atenolol  10 2 1 / 5.0 
Cephalexin  8 1 1/  8.0 
Diltiazem 8 1 1 / 8.0 
Prednisone/olone 12 1 1 / 12.0 
   Range = 1.0 - 12.0 
Average SNR =  3.3 
 
 
10.9 ADRs for ADRAC 
 
A total of 336 ADRAC reports resulted from consumer calls on the SER Line during 
the study. Given that ADRAC reported that I the years 2001-2003, the average 
number of reports submitted by consumers was 309 (120), it is fair to say that the SER 
Line doubled ADRAC consumer reports in those years. 
 
 
10.9.1 Drug and primary complaint in ADRAC reports 
In table 44 describes the 38 scheduled medicines involved in 205 consumer ADRAC 
reports, and their associated primary complaints. Atypical (type B) reactions are 
bolded and represent a considerable proportion of primary complaints.  
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Table 44: ADRAC reports from certain medicines and the primary complaint 
ADRAC primary 
drug 
No 
ADRAC 
reports 
Primary complaints (Type B in bold) 
Alendronate 6 Dysphagia, Dyspepsia, myalgia, oesophageal ulcer, 
peptic ulcer, ankle oedema 
Alprazolam 4 Taste perversion, amnesia, withdrawal syndrome, 
depression 
Atenolol 2 Bronchospasm, sexual dysfunction 
 
Atorvastatin 7 Myalgia (x3), insomnia, headache, abdomen 
enlarged, neuropathy  
Buproprion 34 Convulsions, agitation (2x), tremor (x2), dizziness, 
Anxiety, Headache, Neuralgia,  Aggressive 
Reaction (2) Insomnia (x2) Withdrawal Syndrome 
Nausea (x6) Anorexia (2), Taste Loss, Diarrhoea 
Gastritis, (x3), Rash (x4), Pruritus (x2), 
Sexual Function Abnormal, Chest Pain, Weight 
Decrease 
Celecoxib* 17 Thinking Abnormal, Migraine, Deafness 
Depression, Vaginal Discomfort, Photosensitivity, 
Pruritus, Oliguria, Face oedema, Hypertension 
Dyspnoea, pulmonary Oedema, Vomiting, Gastritis, 
Melaena (x2) 
Cephalexin 1 Arrhythmia 
Cerivastatin 3 Rhabdomyolysis with renal failure, 
Rash, insomnia 
Clarithromycin 4 Bronchospasm, palpitation, nausea, 
hypersensitivity reaction 
Diltiazem 1 Fatigue 
Domperidone 3 Gynecomastia (2), somnolence,  
Dothiepin 3 Hyperglycaemia, palpitation, xerophthalmia 
Ethinyloestradiol 
Oral contraception  
3 Cervical dysplasia, rash, weight increase. 
Fluoxetine 3 Sexual dysfunction (x2), leg cramp 
Gabapentin 2 Constipation, weight gain 
Haloperidol 2 Hyperprolactinemia, weight gain. 
Irbesartan 5 Depression, taste perversion, fatigue, weight 
increase, cough. 
Isotretinoin 2 Alopecia, migraine. 
Mirtazapine 5 Dreaming abnormal (x2), weight increase, appetite 
increase, cough. 
Moclobemide 3 Confusion (x2), dizziness 
Oestradiol/Oestriol 
Oestrogens conjug. 
 
5 Gall bladder dysfunction, menorrhagia, thrombo-
embolism, skin discolouration, withdrawal 
syndrome.  
Olanzapine 2 Weight gain, sexual dysfunction 
Omeprazole 4 Renal function abnormal, taste perversion, Taste 
loss, agitation. 
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Paroxetine 8 Weight gain (x5), ejaculation disorder, dyskinesia, 
confusion, 
Piroxicam 3 Headache, haematemesis, cough 
Pravastatin 3 Myopathy, myalgia, constipation 
Raloxifene 5 Oedema, breast pain, xerophthalmia, eructation, 
pruritus 
Risperidone 3 Coordination abnormal, ejaculation disorder, bone 
disorder 
Rofecoxib* 11 Blood in stool, nausea, oedema, ankle oedema, 
pulmonary oedema, coughing, urinary retention, 
parasthesia, diarrhoea (2x), rash, 
Sertraline 11 Bruxism, dreaming abnormal (x2), speech disorder, 
sexual dysfunction, vomiting weight gain (x3), 
manic reaction (x2) 
Telmisartan* 3 Gastritis, ejaculation disorder, depression. 
Terbinafine 3 Taste perversion, taste loss, rash. 
Thyroxine 2 Hyperthyroidism , Drug level decrease. 
Tibolone* 7 Weight increase, allergic reaction, hair growth 
enhanced, leg cramp, therapeutic response 
decrease, vaginal discomfort, hypertension. 
Tramadol* 11 Aggressive reaction, convulsions (x3), tremor, 
parasthaesia, hallucination, vomiting (x2), fatigue, 
gait abnormal. 
Venlafaxine 
 
5 Constipation, dizziness, headache, hyponatremia, 
appetite increase. 
Warfarin 2 Weight increase, taste perversion.  
Zolpidem* 7 Amnesia (x2), hallucination, chest pain, 
consciousness fluctuating, nausea, vomiting. 
TOTAL 205  
*new drugs in 2000-01 
  
10.9.2 CAM and primary complaint in ADRAC report.  
Table 45 provides a list of 24 CAMs and the primary complaints involved in the 45 
ADRAC reports that were submitted. ADRs associated with CAM drug interactions, 
are listed separately in Table 46. 
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Table 45: ADRAC reports to herbal and complementary medicines  
ADRAC primary 
drug 
No 
ADRAC 
reports 
Primary complaints * 
(* Type B in bold)) 
Beta carotene 1 Chest pain 
Bee pollen extract 
“Nature Bee” 
1 Arthralgia 
 
Black cohosh 1 Diarrhoea 
Calcium 1 Neuralgia 
Chamomile 1 Hepatic function abnormal 
Echinacea 5 Rhinitis, abdominal pain, cystitis, irritable 
bowel syndrome, depression 
Evening Primrose Oil 3 Menstrual disorder, aggressive reaction, 
convulsions 
Fish Oil capsules 1 Vasculitis 
Garlic 1 Anaemia 
Gingko biloba 2 Cerebral haemorrhage, gastric ulcer 
haemorrhage 
Ginseng 1 Depression 
Glucosamine 2 Malaise, flatulence 
Green-lipped mussel  1 Lymphadenopathy 
Guarana 2 Dizziness, flushing 
Hawthorn 1 ECG abnormality 
Herbal misc. 6 Peritonitis, weight increase, bronchospasm, 
menstrual disorder, flushing, 
hyperthyroidism 
Kava Kava 2 Urticaria, depression 
Liver Tonic AUSTL 
61625 Nutralife 10000 
1 Taste perversion 
Noni juice 2 Diarrhoea, rash. 
Phytoestrogen formula 1 Nausea 
Soya formulation 1 Taste perversion 
St Johns’ Wort 6 Menstrual disorder (x2), vomiting, 
xerophthalmia, dizziness, decreased drug levels 
Vitamin C 1 Weight increase 
Vitamins, Multi 1 Consciousness impaired. 
TOTAL 45  
(* type B in bold) 
 
 
 
 
128 
Table 46: Suspected CAM drug interactions reported to ADRAC 
Main CAM Other medicine ADR (type B) 
 
Evening Primrose Oil Sod.valproate Convulsions 
Garlic Celecoxib Anaemia 
Ginkgo biloba Warfarin Gastric ulcer haemorrhage 
Ginseng Phenelzine Depression 
Glucosamine Magnesium Flatulence 
Guarana Irbesartan Dizziness 
Herbal misc. Clarithromycin Bronchospasm 
Herbal misc. Methotrexate Mucosal ulceration 
Herbal misc. Thyroxine Hyperthyroidism 
St John’s Wort Tibolone Decr. Therapeutic response 
St John’s wort Oral contraceptive Menstrual disorder 
St John’s wort Venlafaxine Dizziness 
St John’s wort Oral contraceptive Menstrual Disorder 
St John’s Wort Sertraline Vomiting 
St Johns’ wort Thyroxine Decreased drug levels 
Vitamin C Oral contraceptive Weight increase 
 
10.9.4 Probability 
 
The 336 ADRAC reports submitted by the SER Line were sub-classified according to 
their probability, novelty, predictability and impact on quality of life (QOL). These 
aspects can be used as a measure of reliability and quality of consumer ADR 
reporting. Table 47 shows the high level of reliability of consumer ADRAC reports 
submitted in this study, as their probability was graded as 14.9% certain and 47.3% as 
probable. 
Table 47: Probability of Consumer ADRAC reports 
Probability Percentage (%) 
n = 336 
TOTAL 
Certain 14.9 
Probable 47.3 
62.2% 
Possible 37.5 
Unlikely 0.3 
37.8% 
TOTAL 100%  
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10.9.5 Novelty 
Table 48 outlines the novelty of the content of the consume ADRAC reports. Over 
13% of ADRAC reports submitted involved a CAM, 42% involved newly marketed 
drugs and 2% were associated with an ADRAC DOCI. The fact that 15.6% of 
suspected ADR’s reported by consumers were not yet documented in the registered PI 
demonstrates possible generation of new ADR signals.  
 
Table 48: Novelty of the potential ADR 
Novelty Percentage (%) 
n = 336 
In PI <5% 29.8 
In PI >5% 27.2 
NOT in PI 15.6 
New Drug 12.0 
CAM 13.4 
ADRAC DOCI  2.0 
TOTAL 100%  
 
 
10.9.5 Quality of Life impact 
Table 49 demonstrates that over 76% of ADRAC reports related to ADRs were 
associated with a moderate to major impact on QOL, which is defined in appendix 7.  
 Table 49: Impact of potential ADR on Quality of Life 
 Percentage (%) 
n = 336 
Major  25.7 
Moderate 50.6 
Minor 23.7 
TOTAL 100%  
 
10.9.6 Intervention required 
Consumer reports to ADRAC involved considerable intervention, with just over 73% 
of ADRs to ADRAC requiring a hospital visit or doctor consultation. 
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Table 49. Intervention required in ADRAC reports 
 Percentage 
n = 336 
Doctor consultation 59.9 
Self treatment 17.1 
Hospital, not life threatening 10.5 
No treatment  7.1 
Hospital, life threatening 3.0 
Visit pharmacy  1.5 
CAM practitioner 0.9 
TOTAL 100%  
 
10.9.7 Predictability 
Study results in table 50 show that consumers were able to report both type A and 
type B in a ratio of 1:1.  
 
Table 50: Predictability of consumer reports to ADRAC 
Predictability 
 
Percentage  
Type A 47.3 
Type B 52.0 
Unknown   0.7 
TOTAL 100% 
 
 
10.9.8 Serious ADRs to ADRAC 
Table 51 outlines the nature of the 44 serious ADRAC reports generated by 
consumers in this study. There were ten (10) life-threatening ADRs, and 34 non-life 
threatening hospitalisations reported, which represents 13.1% of the total 336 
consumer reports submitted to ADRAC throughout the study. Two deaths were 
reported during the study, however both remain incomplete as they were required to 
call back with more information and never did. No birth defects were reported. 
73.4% 
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Table 51: Serious ADRS reported by HPs to ADRAC 
Call No.  ADR Main Drug Outcome 
280 Arrhythmia Cephalexin 
346 Menorrhagia Oestradiol 
390 Chest Pain Bupropion 
421 Hypersensitivity Clarithromycin 
437 Rhabdomyolysis Cerivastatin 
625 Blood in Stool Rofecoxib 
746 Pulmonary Oedema Rofecoxib 
759 Cerebral haemorrhage Gingko 
966 Hyponatraemia Venlafaxine 
1019 Anaphylactic Shock Flucloxacillin 
Hospitalised 
Life-threatening 
(10 reports)
    
36 Confusion Moclobemide 
196 Vomiting Bupropion 
202 Depression Ginseng 
223 Gastritis Celecoxib 
275 Cataract Lamotrigine 
328 Bronchospasm Atenolol 
343 Constipation Ferrous Sulphate 
356 Cervical dysplasia Ethinyloestradiol 
394 Palpitation Dothiepin 
408 Blood in Stool Celecoxib 
446 Convulsions Bupropion 
449 Anaemia Sulfasalazine 
465 Depression Bupropion 
469 Coordination Abnormal Risperidone 
502 Manic Reaction Sertraline 
529 Serum Sickness Nitrofurantoin 
573 Gall Bladder Disorder Oestradiol 
594 Convulsions Sodium Valproate 
620 Vasculitis Fish Oil/Warfarin 
632 Abdominal Pain Echinacea 
681 Uterine Fibroid Tamoxifen 
742 Peritonitis Herbal 
800 Dyspnoea Oxaliplatin 
841 Menstrual Disorder Evening Primrose Oil 
852 Convulsions Tramadol 
863 Allergic Reaction Ceftriaxone 
873 Ototoxicity Gentamicin 
921 Diarrhoea Meloxicam 
927 Psychosis Dexamethasone 
984 Withdrawal Syndrome Alprazolam 
1163 Convulsions Tramadol 
1167 Nausea Bupropion 
1023 Convulsions Pseudoephedrine 
1146 Hepatitis Flucloxacillin 
Hospitalised - non-
life threatening 
(34 reports)
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11. Discussion 
 
11.1 Introduction 
Consumer ADR reporting may have much to offer the science of pharmacovigilance 
by partly addressing the problem of under-reporting by HPs. However little is known 
about the quality and quantity of CAR via spontaneous ADR reporting.  In the 
following chapter, the results of the Consumer ADR Reporting Project will be 
discussed and future directions proposed.  
 
11.2 Study design and recruitment 
This study represented a prospective case series analysis of consumers who called the 
SER Line. (102-105) The design of this study was significantly different from the 
bulk of previous CAR research, which has mostly been based on patient event report 
monitoring systems (PERMS).  This is a pro-active and somewhat deliberate model of 
ADR reporting whereby consumers from specific populations or on specific 
medicines are recruited, usually by their physician or pharmacy, to identify possible 
ADEs and ADRs experienced retrospectively or prospectively, over a specific period, 
and reported them via a questionnaire, diary or telephone interview 
 
Our model, based on a pharmacist-operated telephone helpline, was chosen in order to 
give consumers the opportunity to report ADRs voluntarily and spontaneously in 
much the same way as health professionals and manufacturers currently do, without 
restricting the types of drugs and patients in any way. In so doing, the results could be 
compared with the HP ADR reporting arm of the study, as well as informing the 
current debate of whether consumers should be included in current spontaneous ADR 
reporting systems.  
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An extensive literature review revealed only one other published study where 
consumers have used a telephone helpline model for ADR reporting,. In that study, by 
Egberts et al (107), ADR reports were derived from calls made to the Dutch national 
drug information centre for consumers and the ADRs also were also compared with 
those reported by HPs to the Dutch ADR reporting agency, Lareb. Extensive 
comparisons cannot be made with this study, however, as the ADR reports were 
obtained from a retrospective analysis of the call data. Consumers were using this 
service for drug information, not to make a contribution to pharmacovigilance.  
 
The helpline model for ADR reporting in our study was popular with consumers, as 
evidenced by the large number of calls received.  In contrast to PERMS where a low 
response rate (30-40%) is a often a limitation. (111) However the helpline model 
carries a number of limitations. Firstly, it requires the expertise of trained clinical 
pharmacists to be able to triage the calls effectively, and identify eligible ADRs for 
reporting.   
 
Secondly, like most telephone helplines, the SER Line relied heavily on continuous 
awareness campaigns to maintain reasonable numbers of incoming calls. We have 
shown in previous work (135, 149) that regardless of the benefits of a service, few 
calls will be received if the service is not well publicised. This agrees with the 
findings of Strutton and Lumpkin (150) who investigated information-seeking 
behaviours of elderly consumers of health care innovation. They found that adoption 
of new health care services by the elderly (which could include adopting use of a 
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telephone helpline) relied more on marketing and media as a source of information 
than recommendation by medical experts. 
 
Many more calls could have been generated during the study had there been more 
publicity of the service. Unfortunately, there was no funding in the project’s budget 
for a structured marketing campaign, thus awareness activities were limited to those 
generated at no cost.  It was interesting that electronic media usually provided a 
significant, instant response from consumers, whereas the response prompted by print 
media was usually delayed, sometimes up to months later. The reluctance of HPs to 
refer calls to the SER Line reflects the importance of a widespread and comprehensive 
awareness campaign, which is aimed not just to consumers but to HPs as well, in 
order to engender confidence in the professionalism, ability and confidentiality of the 
service, which respects the doctor-patient relationship.  
 
Another limitation of the helpline model is that data handling can be a significant 
challenge, specifically because the number of in-coming calls is unpredictable and can 
increase exponentially with only a moment’s notice. SER Line phone calls were 
recorded manually and entered into an ACCESS database separately, but we 
sometimes found ourselves with an intimidating backlog of data entry when incoming 
calls were in high volume.  
 
Manual data entry was cost-effective for this project, however in retrospect it was too 
labour intensive.  Each form took 5-10 minutes to input, which meant data-entry was 
often deferred to a less busy time, creating a delay sometime up to weeks. This also 
meant that some ADR were not reported to ADRAC until weeks to months after they 
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were reported, thereby losing the advantage of consumers reporting directly.  If an on-
going CAR service were to be officially established, it is recommended that manual 
systems be avoided, and either an electronic “scan form” system be used to capture 
call data or an on-line system of data management be developed to instantaneously 
capture data electronically. 
 
Finally, ensuring that all SER Line pharmacists handled calls in the same way over 
the long term was a challenge. Although we had developed specific protocols for call-
handling and data entry, it was found that unless strict quality assurance procedures 
were performed on a regular basis, especially when new staff was employed, 
individual bias and variability would creep in and alter interpretation of the consumer 
reports. Therefore, it is recommended that regular quality assurance processes be an 
essential part of any future CAR service.   
  
11.3 Demographic of consumer response 
Callers were predominantly female, aged on average 59 years, located in southeast 
Queensland, and rang on behalf of themselves. Calls made on behalf of a significant 
other were predominantly made for a spouse or a child, with an average age of 52 
years. 
 
Our results suggest a potential gender (F>M) and age bias (older persons) on the SER 
Line, which may limit the applicability of the data obtained, but it is also possibly an 
unavoidable bias, as it is a well-recognised utilization pattern of many health-related 
services, including general practice itself. (151) The ratio of female to male callers 
(4:1) in this study also concurs with the work of international (125, 133, 134) and 
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Australian consumer medicines-information services (135, 149, 151) where, over 
several years, female callers have outnumbered male callers by a factor of three.  
 
Use of the SER line by older persons is consistent with their greater medication use as 
a result of age-related disease and generally being more actively concerned about their 
health needs. (152) However, we found that it is possibly also a reflection on older 
persons’ availability, as this age group is more likely than younger people to be 
available during working hours to be: 
• exposed to marketing activities broadcast on television or radio during the day, 
which were the most effective forms of publicity; 
• a member of a consumer health support groups or community service 
organisations, where much SER Line awareness was also generated; and  
• able to consult the SER Line, which was only open during business hours. 
 
11.4 Frequency, duration and SNR of calls 
The SER Line received 972 calls from consumers over 22 months. Calls were 24.3 
minutes in duration on average, however this varied from 18.8 minutes for general 
enquiries to 29.4 minutes for ADRs reported to ADRAC. Regarding call content, one 
third of calls did not relate to an ADE, but involved general and side effect enquiries. 
Two thirds of calls involved potential ADRs, half of which (336 reports) resulted in 
an ADR for ADRAC. Drug interactions were the suspected mechanism of 64 potential 
ADRs, 51 of which were reported to ADRAC. Overall, one ADRAC report was 
generated from every third call on the SER Line, resulting in an SNR of 1:2 or 1 in 3.  
 
138 
11.5 Quality and breadth of consumer ADR reporting to ADRAC 
11.5.1 Primary complaint 
 
A wide range of complaints prompted SER Line calls, ranging from relatively benign 
(weight gain, hair growth and pruritus) to serious events such as cerebral haemorrhage 
and seizures. The primary complaint in consumer ADRAC reports congregated 
around gastrointestinal, urogenital, musculoskeletal and CNS symptoms. This partly 
agrees with Mitchell et al (111) who, in their multidisciplinary ADE reporting survey, 
found that HPs tended to report disorders of critical body systems such as liver, blood 
and skin whereas consumers more often reported common, symptomatic complaints, 
particularly of the lower urinary tract and CNS.  Mitchell and his colleagues 
concluded that consumer ADRs cover such a broad range of medicines and organ 
systems, that data collected is different from, and complementary to reports from HPs.  
 
A limitation of this finding is that the data collation software used in this study could 
accommodate only one complaint per call. Situations where consumers suffered two 
or more symptoms or complaints could therefore not be represented.  
 
 
11.5.2 Drugs involved.  
 
There was a clear trend in our study for consumers to be concerned about three groups 
of drugs: new drugs (celecoxib, rofecoxib, tramadol), those subject to media attention 
due to safety concerns (e.g. bupropion, hormone replacement therapy, herbal 
medicines) and medicines carrying social stigma (antidepressants, corticosteroids, 
warfarin). It is interesting how similar this range of medicines was to that found in the 
Egberts study (125), where consumers focussed on antidepressants, corticosteroids, 
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antithrombotics, hormonal therapy and antipsychotics in their ADR questions and 
reports. In our study, the drugs carrying social stigma also generated a low signal to 
noise ratio e.g. prednisolone was 1 in 12. 
 
Consumers in our study reported a significant number of ADRs involving over-the-
counter, supermarket and complementary medicines (13.4%), and the reactions 
involved were frequently serious. The value of these reports is that they were unlikely 
to be reported by HPs given that these remedies are usually self-prescribed and their 
use is often not disclosed to HPs. (112) This benefit of CAR concurs with Charles 
Medawar’s (39) famous statement that 
 ‘…… patients can report- in their own words- essential information which 
professional reporters can never be expected to provide”. 
 
 
11.5.3 Probability (possible, probable, certain) 
 
The ADRAC reports from consumer in our study showed a high level of reliability, 
with 14.9% being rated as certain, and 84.8% rated as probable (47.3%) or possible 
(37.5%). Although this probability assessment is open to some bias by the helpline 
pharmacists, the results compare favourably with consumer reporting reliability in 
other studies. For example, in the study by Jarernsiripornkul et al (108) researchers 
classified 71% of the ADR reported by patients as being probably or possibly related 
to the drugs studied, and concluded that their ability to identify drug-induced effects 
was acceptable. 
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11.5.4 Novelty 
 
Novelty was a strong feature of the ADRs reported by consumers in our study, as 
15.6% of complaints were not yet documented in the registered PI, 13.4% of ADRAC 
reports involved a CAM, 12% were associated with newly marketed drugs, and 2% 
were associated with an ADRAC DOCI. All of these aspects demonstrate the ability 
of consumers to report on new and emerging aspects of drug therapy, some of which 
will point validly to new and hitherto overlooked reactions, which is CAR is seen by 
some authors as an essential part of signal generation.  (67, 69, 113).  
 
11.5.5 Impact on QOL 
 
The majority (76.3%) of ADRs from consumers related to a moderate to major impact 
on QOL, which suggests that this parameter is a motivator for reporting. As 
previously mentioned, this parameter is not often considered in the ADR literature, 
but it is particularly with respect to CAR, in order to judge the reaction’s seriousness 
from the consumer’s perspective. An extensive literature search was unable to find 
other CAR studies that had measured impact on QOL, which is a limitation to the 
interpretation of our results in that they cannot be benchmarked. However, the results 
are surprisingly similar to those from the HP arm of our study. (Table 23)  
 
 
11.5.6 Intervention required 
 
The intervention required in ADRAC reports can imply a level of validation of 
consumer concerns. The fact that 73.4% of ADRAC reports required hospitalisation 
or doctor consultation implies that consumer concerns were not trivial or misguided. 
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However, the fact that 17.1% of ADRs only required self-treatment did not prevent 
them from being reported.  
 
 
11.5.7 Predictability- type A/B 
 
It is apparent that consumers were not driven by the known pharmacology of a drug to 
report an ADR, as approximately 52% of symptoms reported were classified as type 
B, and only 47.3% as type A. However, a significant proportion of these Type B 
reactions are allergic skin reactions that contribute to CAR as much as they do to HP 
reporting.  
 
 
11.5.8 Seriousness of ADRAC reports 
 
There is an argument that consumers report less serious complaints than health 
professionals, and therefore their reports are less valuable.(27) Despite 73.4% of 
consumer ADRAC reports warranting a doctor consultation or hospitalisation the 
majority of adverse effects reported by consumers in our study do not, at first glance, 
appear very serious. However, this does not render them worthless.  
 
As mentioned earlier, QOL impact assists in judging the seriousness of an adverse 
drug event from the perspective of the consumer who, after all, has to live with the 
consequences of the ADR. (113) Symptoms such as insomnia, weight gain, muscle 
pain and sexual dysfunction may not medically “serious” however, these symptoms 
can dominate a patient’s life if they remain unrelieved. 
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Secondly, less serious ADEs may herald the onset of more serious problems. 
McKewen (60) has defended the reporting of apparently trivial or well-known adverse 
effects for this reason as, for example, dizziness and confusion may indicate 
hyponatraemia caused by thiazide diuretics or selective-serotonin reuptake inhibitors. 
Persistent dry cough, often associated with ACE inhibitors, was long overlooked as a 
common finding in older patients before spontaneous ADR reporting demonstrated 
the causal link with the medication. Reporting of less serious or presumed common 
reactions can highlight problems by increasing the amplitude of existing signals. 
Hence ADRAC’s regular bulletin carries a section entitled, “What to report?”  that 
states “……seemingly insignificant or common adverse effects should be reported, as 
they may highlight a widespread prescribing problem.” (141)  
 
 
11.6 Further limitations of the study and the results 
11.6.1 Interpreting consumer language  
A demanding task for the SER-line pharmacists was ensuring that consumers’ 
worrying symptoms were understood correctly and translated appropriately into an 
appropriate medical term. Clearly some of the potential miscommunication may have 
been created by the limitations of telephone communication (no eye contact etc), but 
errors also arose in comprehending lay language. For example, one man complained 
of feeling “lousy” whilst taking bupropion, which was initially interpreted as 
“malaise”. However later in the conversation it was realized he meant “infested with 
lice” or “itchy” and thus pruritus was the correct term. Consumers often struggle to 
find a word to describe their worrying symptoms , so they resort to non-specific and 
even nonsensical terms such as “My head feels sloppy” or  “ I’m off my feet”. Much 
time and patience was required by SER Line staff to translate these expressions into 
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meaningful medical language for ADRAC purposes and our study.  Excellent 
communication skills were required to be sure that one had understood exactly what 
the consumer was trying to say. 
 
11.6.2 ADRs reported already 
The ADR Study protocol included an assumption that ADRs reported by consumers 
had not already been reported to ADRAC. Clearly there was a possibility that this 
assumption was false, but in some cases we did not report to ADRAC because the 
patient strongly felt that their doctor had already submitted a report. However, most 
consumers did not know about ADRAC reporting at all, and asking them about prior 
reporting was less than fruitful. Given the evidence in the literature of widespread 
under-reporting of ADRS by all parties, we operated on the assumption that it was 
unlikely that many ADRAC reports would be duplicated. Moreover, ADRAC can 
often detect double reporting and allowances are made for this in their data 
management. 
 
11.6.3 Consumer reported symptoms not diagnoses 
Another important limitation of the CAR study was that consumers reported 
symptoms not diagnoses. For example, a consumer may report leg pain not myopathy, 
numbness not neuropathy. This phenomenon limited the certainty with which SER 
Line pharmacist could assume that a specific pathology was being described and 
whether that pathology was drug-induced. Therefore, a significant proportion of calls 
classified as “ADR-not for ADRAC” involved patients with non-specific symptoms 
that had to be referred back to health professionals for diagnosis of their symptoms. 
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Our experience agrees with Mitchell et al (111) who expressed concerns that 
consumer ADR reports suffer from a lack of detail.  
 
This lack of diagnostic clarity however makes it all the more important that a CAR 
service is manned by health professionals with a reasonable background in pathology 
and disease processes, to act as a “learned intermediary”, who can interpret symptoms 
reported by consumers, translate them into potential diagnoses and judge their 
relationship with medicines and their clinical significance. 
 
11.6.4 Lack of consumer ADR validation 
Another problem associated with CAR is a lack of objective validation of the event, 
and it has been suggested that, without it, CAR is not worth pursuing. (47) SER Line 
pharmacists were able to validate complaints to some extent by asking consumers 
searching questions, correlating complaints with the literature, making associations 
from an extensive knowledge of drugs, and making follow-up calls with consumers’ 
HPs to seek outcome data of the ADR. However, not every call could be followed up 
for outcomes, not all consumers were contactable, issues of privacy and 
confidentiality were sometimes raised, and some consumers would not give contact 
details of their doctor, lest they “get them into trouble”. 
 
11. 7 Future directions 
11.7.1 Algorithms 
If an on-going consumer ADR reporting service were to eventuate, a symptom-related 
algorithm that assists the health professional intermediary to synthesise the clinical 
picture would need to be developed. Health call centres, such as NHS Direct in the 
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UK, use such algorithms for disease state management and it would overcome some 
of the problems of case management mentioned above. 
 
11.7.2 Publicity 
Consumer ADR services in future must consider the vital nature of publicity to 
consumer-awareness and ensure the following are in place: 
• A marketing plan. This helps map out the target audience for the service, and 
directs advertising activities to specific consumer populations.  
• A ‘catchy’ name.  The service’s name should be brief and imaginative, whilst 
giving consumers a reasonable idea of the services aims and characteristics. 
The SER Line worked well, but without the word “drug” in it, it was 
considered by consumers to be a little vague. 
• Listing in the telephone book. This would have been ideal to direct 
consumers already looking for a telephone-based drug information service. 
Unfortunately, but this is an expensive measure and as phonebooks are not 
printed simultaneously, there is a time lag to national coverage. Free listings in 
community-based publications can be a big help. 
• A website. Many consumers today seek drug information independently on 
the Internet and therefore a web-presence is vital to capture as broad an 
audience as possible. 
• Merchandise such as stickers, fridge magnets and posters for repeated 
reminders of the helpline’s presence. 
• Pro-active marketing. When new drugs are released or old drugs withdrawn 
from the market, these are times of peek activity for the SER Line. At these 
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times proactive awareness campaigns would ensure greater accessibility and 
higher call numbers.  
 
 
11.8 Conclusion 
The results of this study show that consumers were keen to report ADRs via a 
telephone helpline and the SNR for consumer calls was acceptable at one in three. 
Consumer ADR reports submitted to ADRAC in this study were of high probability, 
quality and novelty. Given that 336 Consumer ADRAC reports were generated by this 
study, it is not unreasonable to say that the SER Line effectively doubled ADRAC 
reporting by consumers (120). 
 
Overall, these data suggest that consumers can reliably identify and report suspected 
ADRs and thus should be given the opportunity to report them on a long term basis 
directly to ADRAC via a clinical pharmacist intermediary such as the service 
described. By improving post-marketing pharmacovigilance, benefits to public health 
may be realised. 
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12. OVERALL DISCUSSION 
12.1 Introduction 
ADRs are a major cause of patient morbidity and mortality, half of which is thought 
to be preventable. (12, 14, 15, 23) Spontaneous ADR reporting (SAR) systems 
operate worldwide to collect information on ADRs to identify early signals of drug 
toxicity and ultimately prevent drug-associated harm. (89) SAR systems rely heavily 
on case reports submitted by HPs for their data, but studies suggest that HP reporting 
rates rarely exceed 10% of serious ADRs and 2-4% of non-serious ADRs. (144) 
Therefore, methods to enhance ADR reporting rates have been keenly sought. (60) 
 
In the literature, much research preceded the ADR study on ways to improve HP 
reporting, and evaluations were made of the value of consumer ADR reporting. 
Egberts (125) was the only study retrieved that compared ADR reporting by HPs and 
consumers and suggested that both populations provide useful yet different and 
complementary ADR information. The ADR study aimed to involve HPs and 
consumers in SAR to improve pharmacovigilance, but also to ultimately compare 
their performance.  
 
Therefore, the ADR reporting study was essentially a tale of two projects aimed at 
increasing the frequency, quality and breadth of ADR reporting by HPs and 
consumers, and ultimately to compare the results. Both projects relied on the 
intervention of a pharmacist-operated telephone helpline to report ADRs, but the HP 
study also involved an educational intervention.  
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The results of the health professional study showed that health professionals given 
access to an ADR hotline and /or ADR educational interventions significantly 
improved the frequency, breadth and quality of their ADR reporting. The results of 
the consumer ADR reporting study demonstrated that consumers were able to reliably 
detect and report ADRs with the assistance of a pharmacist intermediary on a 
telephone helpline, and were eager to do so. The ADR reports from consumers were 
valid, reliable and informative. 
 
12.2 Combining the results 
Combining the HP and consumer study results together, as outlined in Table 52, has 
allowed comparisons of ADR reporting by each group to be made. 
 
12.2.1 Number of calls 
The consumer SER Line was utilised much more frequently than the HP ADR hotline, 
with nine times more calls being received (972 calls versus 108 calls) over the 22-
month study period. This suggests that consumers are more motivated than HPs to 
report ADRS, which is understandable given that they probably have a personal, 
vested interest in the outcome. This enthusiasm is an important aspect of CAR 
overcoming under-reporting by HPs. 
 
12.2.2 Gender and age 
Consumers using the SER Line were, on average, a decade older than the HPs using 
the ADR hotline, but both groups were predominantly female. Female gender of 
health information-seeking clients is a constant finding, especially in health call 
centres. (125) However, the age difference between the two groups is useful and as 
they complement each other well.  
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12.2.3 Call duration 
The average duration of consumer calls (24.3 +/- 13.5 mins) is only slightly longer 
than the average duration of HP calls (21.3 +/- 12.8 mins). These data argue against 
the speculation that consumer calls would occupy considerably more time than calls 
from HPs. (27) 
 
12.2.4 Call type 
One third (30.3%) of consumer calls related to general or side effect enquiries (no 
ADR) however one-fifth (19.5%) of HP calls related to enquiries. It was expected that 
consumers would be interested in using the helpline for drug information and advice 
as well as reporting, but these results show that HPs were also using the service for 
information and advice. It was our experience that offering an ancillary advisory 
service alongside the ADR reporting service in the study, attracted more callers ( both 
HP and consumer) and allowed for the capture of more ADRs by casting a broader 
net. 
 
 
12.2.5 Number of ADRAC reports 
The HP reporting hotline yielded 52 reports over 22 months, whereas the consumer 
helpline yielded 336 reports. Even if the 52 reports submitted independently to 
ADRAC by HPs are also included, to give a total of 104 reports, it is clear that 
consumers reported three times as many ADR as HPs. This is a significant 
contribution to pharmacovigilance and again supports the argument that CAR can 
compensate for under-reporting by HPs. 
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12.2.6 SNR 
Based on the number of ADRAC reports submitted via the helplines, the SNR for 
consumers and HPs was not vastly different, at 1:2 and 1:1 respectively. This result is 
contrary to expectations, where commentators were concerned that consumer 
reporting would be from an high SNR, yielding few signals from a lot of “noise” and 
preoccupy an already stretched pharmacovigilance system.  (27) 
 
12.2.7 Primary complaint 
The nature of symptoms involved in ADRs from HPs tends to be more serious and 
governing different body systems than those that concern consumers. This difference 
is ultimately useful, as the consumer focus provides a useful complement of 
information to that provided by HPs. A disadvantage of CAR however, is that the 
primary complaint is often expressed as a cluster of symptoms rather than a diagnosis, 
which is prone to misunderstanding and misinterpretation, thereby lessening the 
potential impact on the ADR. (39) 
 
 
12.2.8 Drugs involved 
Newly marketed drugs and drugs in the media were the focus of ADRs from both HPs 
and consumers. In both groups approximately 13% of calls involved CAMS. In 
contrast to HPs, consumer focus on drugs carrying social stigma, such as 
antidepressants, corticosteroids and warfarin, and these calls carried a low SNR. 
Consumers’ calls are more likely to involve OTC and non-prescription drugs. 
Together, consumers and HPs can cover a much broader range of drugs than either 
group alone. 
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12.2.9 Probability 
A higher percentage of consumer ADRs was classed as certain (14.9%) than in the 
ADRs from HPs (8.6%). Some of this difference would be due to the influence of 
ADRAC on the assessment of HP 52 ADRS that were independently submitted.  A 
higher percentage of “possible” ADRs were reported from HPs than had been 
reported from consumers. This could reflect either that HPs sensitised to the study 
were more willing to report to ADRAC perceived adverse drug events, or hotline 
pharmacists felt more compelled to submit “possible” reports from a colleague. 
 
12.2.10 Novelty 
The study data suggest that both HPs and consumers are motivated by novelty of the 
drug or reaction to report an ADR, as concerns with new drugs, CAMs and symptoms 
not in the PI were reported in 46.2% of HP reports and 41% of consumer reports 
respectively. Since the aim of SAR is to identify early signals of potential drug 
toxicity, then reporting on novel drugs and reactions provides a path towards 
achieving this goal. It is reassuring that both HPs and consumers report this concern 
with approximately the same frequency.  
 
12.2.11 Impact on QOL 
Approximately three quarters of the ADRs reported by HPs (73.1%) and consumers 
(76.3%) had a major or moderate impact on QOL. These results confirm that 
consumer ADRs are as valuable to pharmacovigilance in terms of patient care impact 
as those submitted by HPs. 
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12.2.12 Intervention required 
Hospitalisation or doctor consultation was involved in the majority of ADRs reported 
by both HPs (88.5%) and consumers (73.4%). These data suggest that both groups 
used the “visit to the hospital/ doctor” as an indicator of the validity of the ADR and 
as a prompt for reporting, which again suggests that consumer ADRs are as valuable 
as those form HPs. 
 
12.2.13 Predictability (Type A/B) 
Approximately half of the ADRs reported to ADRAC by HPs and consumers were 
type A and Type B reactions. HPs reported slightly more Type B reactions (59%) than 
consumers (52%), and slightly less type A (41%) than consumers (47%) but the 
differences are unlikely to be meaningful.  
 
12.12.14 Seriousness 
Over the 22-month study period, consumers reported more serious reactions (44) than 
HPs (21). However, in terms of percentages, HP reports were more likely to involve 
serious reactions (20%) than reports from consumers (13%).  
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Table 52: Comparison of HP and Consumer ADR reporting 
 HP ADR hotline Consumer SER Line 
Number of calls 
 108 972 
Gender 
Age 
Female 
30-40 years 
Female 
50-60 years 
Call duration 
(Range) 
21.3 mins (+/- 12.8) 
(12.2- 37.1 mins) 
24.3 mins (+/- 13.5) 
(18.8 – 29.4 mins) 
Call type 
Gen and S/E enquiries 
ADRs for ADRAC 
 
19.5% 
48.5% 
 
30.3% 
34.6% 
ADRAC reports 
 52 336 
SNR 
 1: 1 1:2 
Primary complaint Diagnoses > symptoms 
Emphasis on seriousness 
Critical body systems such 
as liver, blood and skin 
Symptoms > diagnoses 
Emphasis on QOL impact 
Gastrointestinal, 
urogenital, musculoskeletal 
and CNS 
Drugs involved Newly marketed drugs, drugs in media, DOCIs. 
New drugs, drugs in 
media, drugs with social 
stigma (corticosteroids, 
antidepressants, warfarin.) 
Probability 
Certain 
Probable 
Possible 
 
8.6% 
42.3% 
49.1% 
 
14.9% 
47.3% 
37.5% 
Novelty 
In PI <5% 
New drug 
Not in PI 
CAM 
ADRAC DOCI 
- 
44.2% 
13.5% 
19.2% 
13.5% 
- 
- 
29.8% 
12.0% 
15.6% 
13.4% 
2.0% 
Impact on QOL 
Major 
Moderate 
Minor 
- 
25.0% 
48.1% 
26.9% 
- 
25.7% 
50.6% 
23.7% 
Intervention required 
Hospital, life threatening 
Hospital, not life threat 
Doctor consultation 
Pharmacist consultation 
Self treatment 
- 
1.9% 
17.3% 
69.3% 
9.6% 
0% 
- 
3.0% 
10.5% 
59.9% 
1.5% 
17.1% 
Predictability 
Type A 
Type B 
- 
41% 
59% 
-  
47.3% 
52.0% 
Serious ADRAC reports 21 of 104 (20.2%) 44 of 336 (13.1%) 
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12.13 Conclusion and future directions 
The quality of CAR compares favourably with ADR reporting by HPs, the data 
provided is different from, but complementary to the information in HP ADRs, and 
the SNR from CAR is tolerable. These results, therefore, suggest that consumers 
should be given the opportunity to report ADRs via a pharmacist –operated telephone 
helpline, as this would provide valuable and complementary data to existing HP-
oriented ADR reporting 
 
The helpline model has been demonstrated in this study in both the consumer and HP 
settings as a conduit for quality ADR reporting. In the interests of QUM, a permanent, 
national, consumer ADR reporting hotline, similar to the SER Line should be 
developed. It should have close links with ADRAC.  Similarly, Australian health 
professionals should be given access to a national ADR reporting hotline. Although an 
independent service is required, it could be linked with the existing National 
Prescribing Service Therapeutic Advice and Information Service to improve cost-
effectiveness of the strategy.  
 
The utility of the ADR workshop produced by the project team as an HP educational 
intervention warrants that funding be sought from government to produce a similar 
educational package to be implemented nationally. This educational package should 
be incorporated into all Australian health professional academic courses, ideally at 
undergraduate level. The course materials and competencies should be profession 
independent. 
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Appendix 1  Mater Ethics Approval 
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Appendix 2  How to handle consumer ADR call 
 
Is there a defined Adverse Event? 
NO - > General enquiry – refer to Medicines Line 
YES -> Describe the Adverse Event 
 
COMPLAINT: Tease out the adverse event in terms of the worrying symptoms 
Location 
Intensity 
Nature 
Duration 
Onset 
Cessation 
Aggravation 
Relief 
Frequency 
 
DRUGS: Record details of the patient’s current and recent medications 
Prescribed, herbal, recreational  and OTC 
Dose 
Duration - date started and ceased. 
Has drug been associated with observed complaint before?   
If YES -> increase likelihood of ADR 
If NO -> decrease likelihood of ADR 
Is a drug interaction suspected? 
Was the drug RECHALLENGED? 
If YES -> did the adverse event recur?  
-> YES= certain ADR  -> NO = possible AE 
If NO -> Possible ADR      
 
PATIENT : Outline details of patient’s medical history 
Age 
Gender 
Ethnicity 
Medical Diagnoses- history 
Risk factors eg renal function, hepatic function 
Has the patient had this or similar adverse events before? 
if YES -> decrease likelihood of ADR 
if NO -> increase likelihood of ADR  
 
TIME : Is there a plausible temporal relationship between the medication and the adverse event? 
No -> unlikely ADR 
Yes -> possible ADR  
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Appendix 3  How to diagnose an ADR  
 
“CD PT DR”= mnemonic 
Complaint : - Tease out the adverse event in terms of the worrying symptoms 
Location,Intensity,Nature,Duration,Onset,Cessation,Aggravation,Relief,Frequency 
 
Drugs: Record details of the patient’s current and recent medications 
Has the suspect drug been associated with observed complaint before?   
Is a drug interaction suspected? 
Was the drug RECHALLENGED? 
 
 
Patient: Outline details of patient’s medical history 
Risk factors eg renal function, hepatic function 
Has the patient had this or similar adverse events before? 
 
 
Time : Is there a plausible temporal relationship between the medication and adverse event? 
 
 
Dechallenge: What happened when the medication was ceased? 
 
 
Rechallenge: what happened when the medication was taken again?  Did the ADR 
recur?
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Appendix 4  Rash Description for Consumers 
 
SYSTEMIC INVOLVEMENT?  
Eg temperature, breathing difficulties, dizziness, nausea, muscle aches etc 
 
REGION INVOLVED?  
 Generalised 
 
DURATION?  
 When start? Permanent or comes and goes? 
Worse, Better, Same?  
 
 Side – left, right or both? 
 By region: 
 Trunk 
 Back 
 Limbs 
 Arms 
 Upper legs 
 Lower legs 
 Extensor (knee, elbow) 
                      Flexor (behind knee, elbow) 
 Face 
 Butterfly 
 Eyelids 
 Other description 
 Neck 
 Scalp 
 Hairline 
 Any hair loss? 
 
 Hands 
 Palms 
 Back of hand 
 Feet 
 Sole 
 Sides 
 Top 
 Nails 
 Finger 
 Toe 
 All or some 
 Specific areas 
 Underarm (axillae) 
 Under breast (submammary) 
 Tummy button (natal cleft) 
 Groin (inguinal) 
 Genitalia 
 Buttock 
 
LESION NUMBER?  
 Single 
 Multiple 
 
 
LESION DISTRIBUTION?  
 Close together / Clustered 
 Far apart / scattered / isolated 
 Join together / overlap 
 
FLAT or RAISED? 
• Flat (macule) 
• Solid elevation (papule if <0.5cm) 
• Liquid filled blister (vesicle if <0.5cm, 
bulla if >0.5cm) 
• Swelling / oedema (wheal if transient) 
• Pus (pustule) 
• Whitehead / Blackhead (comedo) 
• Flat, solid and raised (plaque if >2cm) 
• Visible blood vessels (telangiectasis) 
 
COLOUR? 
 Red (erythema) 
 Purple - bleeding under skin, bruising 
(purpura or petechiae if pinpoint) 
 Pigmented / tanned 
 Skin / flesh coloured 
 
EVEN COLOUR?. 
 Stronger in middle 
 Stronger at edge 
 Even 
 
SURFACE?  
 Smooth 
 Rough / warty (verucous) 
 Broken 
 Skin peeling (exfoliation) 
 
SENSATION?  
 Itch 
 Pain 
 Burning 
 Stinging 
        Hot 
ON PRESSURE? .. 
 Tender? 
 Change of colour? 
 
AGGRAVATING / RELIEVING FACTORS? 
 Heat 
 Sunlight 
 Trigger factors eg repeat drug exposure  
 
 
RESULT OF TREATMENT?  
If so, what does rash look like now? 
 What tried? 
 Relieved rash? 
 Aggravated rash? 
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Appendix 5  Definitions for Impact on Quality of Life 
 
Mild:  Self-limiting, causing mild discomfort, no loss of appetite, maintaining activity 
and productivity, symptoms able to resolve over time without treatment.  
 
Moderate:  Those causing moderate discomfort, temporary immobilization, unable to 
maintain activity, but still able to work, required therapeutic intervention and/or 
hospitalisation prolonged by one day. 
 
Severe:  Major disturbance, immobilization, unable to eat, unable to work, severe 
pain or discomfort, life-threatening, carcinogenic or permanently disabling or fatal, 
and prolonged hospitalisation by > 1 day. 
 
 
. 
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Appendix 6  ADRAC definition of SERIOUS ADRs  
 
A serious ADR is generally defined as one that requires hospital admission, prolongs 
hospital stay, is permanently disabling or results in death. (4, 153) However, 
ADRAC(154) employs a slightly expanded definition of serious reactions as follows: 
 
Serious reactions are those that are suspected of significantly affecting a patient’s 
management, including reactions suspected of causing: 
• Death 
• Danger to life 
• Admission to hospital 
• Prolongation of hospitalisation 
• Absence from productive activity 
• Increased investigational or treatment costs 
• Birth defects. 
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Appendix 7  Definitions of ADR probability  
The probability of the medicine causing a suspected ADR is often referred to as the 
“degree of causality”.  Pharmacovigilance centres commonly employ four levels of 
probability when assigning causality to ADR reports. These four levels of probability 
are defined in the table below. (5, 142) To some extent, the degree of causality can be 
used as a measure of reliability of ADR reports, as probable reports are more 
“convincing” than possible reports.  
 
CERTAIN • Plausible time scale,  
• Cannot be explained otherwise,  
• Response to withdrawal definitive 
• Response to rechallenge definitive 
• Supporting documentation in the literature 
 
PROBABLE 
 
• Reasonable time scale,  
• Alternative explanation less plausible 
• Rechallenge not required 
• Some documentation in literature 
 
POSSIBLE • Reasonable time scale, but could be explained by 
concurrent illness, other drugs or agents 
• Info on other drug withdrawal lacking or unclear 
• may not have been reported before 
 
UNLIKELY • improbable time scale, 
• other explanation more plausible 
•  
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Appendix 8  When to report to ADRAC 
 
Submission of a blue card to ADRAC should be considered for ADRs with the 
following characteristics: 
 
 
♦ All suspected ADRs with validity of possible, probable or certain 
♦ In PI <5%, or suspect incidence may differ from that in PI, 
♦  
Or  
♦ ALL reactions to  
♦ New drugs 
♦ Drug interactions 
♦ Birth defects 
♦ Drugs of current interest 
♦  
Or  
♦ Reactions suspected of significantly affecting a patient’s management, including 
those resulting in  
♦ Death 
♦ Danger to life 
♦ Admission to hospital / prolongation of stay 
♦ Absence from productive activity 
♦ Increased investigation or treatment costs 
♦ Significant impact on QOL 
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Appendix 9  Data collection form 
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Appendix 10 Modified (blue) ADRAC reporting form 
 
Report Of Suspected Adverse Reaction To Drugs And Vaccines 
Report to ADRAC all suspected reactions relating to: 
• New Drugs 
• Drugs of current Interest  
• Drug interactions 
• Impact on patient management 
• Novel reactions (in PI <5%) 
 
Patient Details: (Initials or UR No.)   Date of birth …./…./…. or Age ..……yrs 
       Sex:  M   /   F           Weight……….kg  
 
Adverse Reaction Description:  Date of onset …/…/….  Date reported …/…/… 
 
 
 
 
All Drug therapy prior to reaction 
 
Please (use trade names) 
Daily Dose Date 
Begun 
Date 
Stopped 
Reason for use 
     
     
     
     
     
     
     
     
     
     
 
Treatment of reaction:     Sequalae: 
 
Severity:   Life threatening  Hospitalised / Prolong  Visit to GP    Visit Specialist 
 
Outcome: 
   Ceased Drug      Continued Drug    Rechallenged drug   Unknown 
   Recovered  (date .. /.../ ...)     Not yet recov’d   Fatal (date …/…/…)   Unknown  
 
Comments:_____________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________ 
Reported on behalf of (name-optional) :……………………Medical specialist / GP / Hosp ph’cist / 
Community ph’cist/ Consumer / Nurse / Dentist / Other specify)………………………………… 
 
Submitted by:  The Qld ADR Reporting Hotline Study,  
 C/o Mater Pharmacy Services, Mater Misericordiae Hospitals, SouthBrisbane. 4101 
Name:…………………………….   Signature ……………………………… 
Date………./………./………… 
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Appendix 11 Health professional informed consent document 
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Appendix 12 Letter recruiting control HPs 
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Appendix 13 ADR hotline poster for HPs 
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Appendix 14 ADR Hotline – Guidelines and FAQs 
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Appendix 15 Examples of ad hoc Marketing Activities 
 
Date Activity 
01/02/01 ABC talkback Radio – Medication Safety 
04/02/01 4BC talkback radio- Medication Safety 
05/02/01 Brisbane Extra- Launch of SER Line 
13/02/01 Talk at Family Planning Qld 
22/02/01 ABC Radio- Zyban ADRs 
10/03/01 IBS Support group- talk 
19/03/01 SER Line Press release sent out 
29/03/01 Courier Mail article on SER Line (Healthwatch column) 
19/04/01 Channel 7 news – SER Line 
09/05/01 Women’s Health Qld Wide talk 
19/05/01 Brisbane City Inner Wheel (Rotary) Club 
20/05/01 SER Line article in Quest Newspapers e.g. Bayside Bulletin 
28/06/01 ABC Radio- Safety of Off-beat cure alls 
04/07/01 Kedron Wavell Service Club- talk on CAM Interactions 
07/07/01 North Qld Pharmacy Expo- talk 
21/07/01 Pharmacy Expo in Brisbane- ADRs and CAMs 
09/08/01 Ch 7 news - Lipobay withdrawal 
18/08/01 Qld Coeliac society – SER Line 
20/08/01 Postgraduate Pharmacy education- ADRs in the elderly 
22/08/01 Ch 7 Today Tonight- Blood clots and The Pill. 
29/08/01 National Seniors Week- three talks on Ser Line 
02/10/01 Ch 9 Brisbane Extra- Safe medication disposal. 
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Appendix 16 Consumer flyer 
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Appendix 17 CHOICE article 
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Appendix 18 Evaluation results of ADR Workshop  
Issue Percentage 
(n = 81) 
 
Subject matter 
 
Very Good 97.3% 
      Good 0.7% 
Average 2.0 % 
 
Relevance to my practice 
 
Very Good 61.1% 
Good 33.8% 
Average 5.1%  
 
Value to me 
 
Very Good: 70.0% 
Good: 28.8 
Average 0.2% 
 
Would you recommend this course to others? 
 
 
Yes 98.7% 
No 0.3% 
 
What features did you find particularly good?  
 
Responses included: 
- clinical examples & case studies 
- understanding role of ADRAC 
- explanation of P450 interactions causing ADRs 
- descriptions of ADRs 
 
 
What features did you find of least value? 
 
Few responses, but included: 
- coverage too extensive 
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Appendix 19 Drugs in all HP calls 
Specialist GPs Pharmacist Nurse/other 
Warfarin 
Herbal 
Ramipril 
Naltrexone 
Diltiazem 
Amiodarone 
Rofecoxib 
 
Aspirin 
Atenolol 
Atorvastatin (2) 
Bupropion (2) 
Celecoxib 
Fenugreek 
Grapefruit 
Guarana 
Herbal (2) 
Ipratropium 
Irbesartan 
Medroxyprogesterone 
Methionine 
Nefazodone 
Orlistat 
Paroxetine 
Perindopril 
Phyto-Oestrogens 
Raloxifene 
Shark cartilage 
Sodium Acid Phosphate 
St John's Wort 
Vitamins 
Acyclovir 
Alcohol 
Alendronate (2) 
Amlodipine (2) 
Atorvastatin (3) 
Azathioprine 
Bupropion (8) 
Cefaclor 
Celecoxib (4) 
Cerivastatin 
Clarithromycin 
Diltiazem 
Doxycycline (2) 
Gabapentin 
Gemfibrozil 
Herbal (5) 
Homeopathic 
Interferon 
Oestradiol 
Omeprazole (2) 
Orlistat 
Paroxetine 
Pneumococcal Vaccine 
Quetiapine 
Rofecoxib (4) 
Sertraline 
Temazepam 
Tramadol (2) 
Venlafaxine (2) 
Vigabatrin 
Vitamins, Multi- 
Warfarin 
Zolpidem 
Methadone 
Venlafaxine 
Digoxin 
Loratadine 
Olanzapine 
Warfarin 
Thyroxine 
Nitrazepam 
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